Published in final edited form as:

Rep Prog Phys. 2010 July ; 73(7): . doi:10.1088/0034-4885/73/7/076701.

Diffuse Optics for Tissue Monitoring and Tomography

T Durduran¹, R Choe², W B Baker², and A G Yodh²

T Durduran: durduran@alumni.upenn.edu

¹ICFO- Institut de Ciències Fotòniques, Mediterranean Technology Park, 08860 Castelldefels (Barcelona), Spain

²Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104, USA

Abstract

This review describes the diffusion model for light transport in tissues and the medical applications of diffuse light. Diffuse optics is particularly useful for measurement of tissue hemodynamics, wherein quantitative assessment of oxy- and deoxy-hemoglobin concentrations and blood flow are desired. The theoretical basis for near-infrared or diffuse optical spectroscopy (NIRS or DOS, respectively) is developed, and the basic elements of diffuse optical tomography (DOT) are outlined. We also discuss diffuse correlation spectroscopy (DCS), a technique whereby temporal correlation functions of diffusing light are transported through tissue and are used to measure blood flow. Essential instrumentation is described, and representative brain and breast functional imaging and monitoring results illustrate the workings of these new tissue diagnostics.

1. Introduction

More than 80 years ago [1] light was employed to “see” tumors in thick tissues. Basic ideas from those measurements still survive today. Optical methods offer a range of sensitivities useful for characterization of a wide variety of samples. The simplest of these methods is light absorption, whereby attenuation in signal intensity occurs whenever the light wavelength coincides with a material resonance. This effect permits quantitative identification of the molecules present in a sample, their concentration, and their local environment. In a different vein, light scattering provides information about micron-size objects (e.g. molecular weight, particle diameter) that scatter light in the sample, and dynamic or quasi-elastic light scattering (DLS or QELS, respectively) provides information about the motions of those objects. Generally, these traditional optical techniques are rigorous and are well established in simple, homogeneous, optically thin samples.

In order to use these schemes to study biological tissues, however, a physical understanding of photon propagation in highly scattering media is required. Otherwise the traditional techniques remain qualitative (at best) or are fraught with systematic errors (at worst). A key contribution to optical studies of tissue was made by Jöbsis in the late 1970s [2–4]. Jöbsis observed a spectral window in the near-infrared (NIR, ~650–950 nm) wherein photons could travel deep in tissue, as a result of the relatively reduced absorption of water and

hemoglobin (see Figure 1). Of course this penetrating light was also scattered in tissue and more physics insight was required for better quantification of detected signals. Since the early work, arguably the most critical advance in the field was the recognition and widespread acceptance that light transport over long distances in tissues is well approximated as a diffusive process [5,6]. Using this physical model it is possible to quantitatively separate tissue scattering from tissue absorption, and to accurately incorporate the influence of boundaries and heterogeneities [5, 7–22]. These models for light propagation formalized the field and paved the way for a large variety of applications ranging from imaging breast tumors (“optical mammography”) to functional imaging of brain [23].

Generally, the propagation of light through tissues is profoundly affected by scattering. Two length scales are important in this context: a rather short “scattering length” which corresponds to the typical distance traveled by photons before they scatter, and a longer “transport mean-free path” or “random walk step” which corresponds to the typical distance traveled by photons before their direction is randomized. The reciprocal of the photon transport mean free path is called the reduced scattering coefficient; it is wavelength-dependent and is denoted by $\mu'_s(\lambda)$, where λ is the wavelength of light. Light transport in tissue is also affected by a relatively smaller absorption. The wavelength dependent absorption length in tissue corresponds to the typical distance traveled by a photon before it is absorbed; its reciprocal, the absorption coefficient, is denoted by $\mu_a(\lambda)$.

In order to sort scattering from absorption in tissue, a model that separates the effects of tissue scattering from tissue absorption is required. The diffusion model provides a formal mathematical basis for this separation, and as a result of this approximation, experimenters can directly measure oxy- and deoxy-hemoglobin (HbO_2 , Hbr/Hb), water, and lipid concentrations using the well known spectra (Figure 1) of these molecules in the inverse analysis [5, 23]. From the scattering coefficient, experimenters gain access to information about cells, cell nuclei, cell organelles and surrounding fluids as well. Herein, we will refer to this measurement technique which uses diffuse near-infrared light to infer scattering and absorption, as “diffuse optical spectroscopy” (DOS) or “near-infrared spectroscopy” (NIRS). The imaging analog of DOS is called diffuse optical tomography (DOT); DOT provides a means to assign tissue optical and physiological properties independently to many volume elements within the tissue sample. Here we use “tomography” to refer to both “topographic” (2D) and “tomographic” (3D) approaches because they share similar formalism.

The diffusion approach is quite versatile and can be adapted to measure the concentrations and lifetimes of exogenous contrast agents such as dyes which may improve tumor contrast or specificity [24, 25]. A recent example of this application is fluorescence diffuse optical tomography wherein the fluorescent emission of a FDA approved contrast agent, Indocyanine Green (ICG), was used to identify breast cancer [26]. Other uses include the measurement of the concentration of oxidized cytochrome c-oxidase [2, 27] and the measurement of very fast changes in scattering related to neuronal swelling during neuronal activity [28, 29]. To learn more about these and other applications, readers can consult other recent reviews [23, 24, 30–35].

More information is available from diffusing light in tissues. Speckle fluctuations of light scattered by tissues are sensitive to the motions of scatterers such as red blood cells (RBCs). The traditional, single-scattering version of this optical technique is well known and has appeared with numerous names [36–50] over the years. In most of these experiments the temporal auto-correlation function of the scattered electric field (or its Fourier Transform) is measured and is explicitly related to the motions of scatterers within the samples. *The most significant tissue signal derived from the temporal auto-correlation function is from blood flow.* Early physiological work utilized single-scattering theory to analyze data derived from pairs of very closely separated (~ 0.25 mm) optodes, e.g. Laser Doppler and CCD-based speckle devices [41–43, 50–59]. Therefore, most of these early methods probed superficial tissue (< 1 mm). In the low signal limit, the photon correlation technique has an advantage over its Fourier counterpart because photon correlation instruments are essentially single photon counting devices. This advantage enables experimenters to probe more deeply into tissue samples, and begs for theoretical models to understand similar signals from deep tissues.

The multiple scattering analog of these dynamic light scattering measurements is called “diffuse correlation spectroscopy” (DCS) [60, 61] (Note, the technique called “diffusing wave spectroscopy” (DWS) [62–64] was introduced before DCS. DWS is essentially an integral formulation of DCS; the name DCS, however, has been adopted in the biomedical optics field because “DWS” had connotations for both absorption spectroscopy and fluctuation spectroscopy). Formally, DCS relies on the fact that diffusing temporal correlation also obeys a diffusion equation, albeit a slightly different one than is used for absorption spectroscopy. It shares the light penetration advantages of NIRS/DOS, but, since DCS explicitly measures cell movement, it provides a direct measure of quantities such as cerebral blood flow (CBF) [65–67]. Compared to NIRS/DOS and DOT, DCS is a relatively new methodology. DCS has been extensively validated *in vivo* in tissues, including comparisons with laser Doppler flowmetry (LDF) [65], Doppler ultrasound (DU) [65, 68–71], arterial-spin labeled MRI (ASL-MRI) [65,66,72,73], Xenon-CT [74], fluorescent microsphere measurement of CBF [75], and against expectations from invasive and non-invasive measures of tissue physiology [65–67,76–78]. In total, these and other [65,66,68–71,73–90] studies have shown that DCS can reliably provide a blood flow index (BFI) proportional to relative changes of tissue blood flow, and that the combination of DCS and DOS/DOT hold potential for continuous non-invasive estimation of metabolic rate of oxygen extraction that relies on fewer approximations than DOS/DOT alone, hence improving the quality of the estimates [71].

The remainder of this review outlines the fundamentals of diffuse optics in tutorial fashion. Towards the end of this review we illustrate the utility of diffuse optics with recent examples from optical mammography and cerebral monitoring. A glossary of terms and symbols is provided at the end of this document.

2. Theoretical Background

2.1. Photon Diffusion Formalism

Transport theory is the starting point for most theoretical formulations of diffuse optics. The key quantity in this formulation is the light radiance, $L(\mathbf{r}, \hat{\Omega}, t)$ (W/cm²sr), defined as the light power per unit area traveling in the $\hat{\Omega}$ direction at position $\mathbf{r}$ and time t . The light radiance is related to the light electric field; $L \sim |\mathbf{E}(\mathbf{r}, \hat{\Omega}, t)|^2$, where $\mathbf{E}(\mathbf{r}, \hat{\Omega}, t)$ is the electric field at $(\mathbf{r}, t)$ traveling in the $\hat{\Omega}$ direction. $L(\mathbf{r}, \hat{\Omega}, t)$ is governed by the radiation transport equation (RTE), which is a conservation equation for the radiance in each infinitesimal volume element within the sample [91–93], i.e.,

$$\frac{1}{v} \frac{\partial L(\mathbf{r}, \hat{\Omega}, t)}{\partial t} + \hat{\Omega} \cdot \nabla L(\mathbf{r}, \hat{\Omega}, t) = -\mu_t L(\mathbf{r}, \hat{\Omega}, t) + Q(\mathbf{r}, \hat{\Omega}, t) + \mu_s \int_{4\pi} L(\mathbf{r}, \hat{\Omega}', t) f(\hat{\Omega}, \hat{\Omega}') d\Omega'. \quad (1)$$

$f(\hat{\Omega}, \hat{\Omega}')$ is the normalized differential cross-section for single light scattering events in the medium; it essentially gives the probability that scattered light is scattered into the direction $\hat{\Omega}'$, given its incident direction was $\hat{\Omega}$. $Q(\mathbf{r}, \hat{\Omega}, t)$ (W/cm³sr) is the power per volume emitted by sources at position $\mathbf{r}$ and time t in the $\hat{\Omega}$ direction. The loss of radiance out of each infinitesimal volume element depends on the absorption and scattering coefficients in the volume and is formally characterized by the coefficient $\mu_t = \mu_a + \mu_s$. Here μ_s (cm⁻¹) is the light scattering coefficient, i.e., the reciprocal of the ‘scattering length’ (note, μ_s is different from μ_s'), and μ_a (cm⁻¹) is the light absorption coefficient, i.e., the reciprocal of the ‘absorption length’. v is the speed of light in the medium. The left-hand side of Equation (1) is a convective time derivative of the radiance in the infinitesimal volume element about $\mathbf{r}$ at time t travelling in direction $\hat{\Omega}$. This convective derivative of the radiance must equal the losses due to absorption and scattering (first term, right-hand side) plus the gains from radiance scattered into $\hat{\Omega}$ (third term, right-hand side), and gains from sources (second term, right-hand side). In most cases of interest, the RTE must be solved numerically.

To reduce the complexity of the RTE, we employ a standard method for approximating Equation (1) called the P_N approximation. In this method, L is written as a series expansion of spherical harmonics, $Y_{\ell m}$ (with coefficients $\phi_{\ell m}$), truncated at $\ell = N$ [91–94]:

$$L(\mathbf{r}, \hat{\Omega}, t) = \sum_{\ell=0}^N \sum_{m=-\ell}^{\ell} \sqrt{\frac{2\ell+1}{4\pi}} \phi_{\ell m}(\mathbf{r}, t) Y_{\ell m}(\hat{\Omega}). \quad (2)$$

We also assume that the normalized differential scattering cross-section, f , depends only on the angle between incident and outgoing scattering wavevectors, i.e., $f(\hat{\Omega}, \hat{\Omega}') = f(\hat{\Omega} \cdot \hat{\Omega}')$. When $L(\mathbf{r}, \hat{\Omega}, t)$ is nearly isotropic, the so-called P_1 approximation (wherein the series expansion in Equation (2) is truncated at $N = 1$) is valid, and we have [91–94]

$$L(\mathbf{r}, \hat{\Omega}, t) = \frac{1}{4\pi} \Phi(\mathbf{r}, t) + \frac{3}{4\pi} \mathbf{J}(\mathbf{r}, t) \cdot \hat{\Omega}. \quad (3)$$

Equation (3) introduces two important quantities. The photon fluence rate, $\Phi(\mathbf{r}, t)$ (W/cm^2), is defined as the total power per area moving radially outward from the infinitesimal volume element at position $\mathbf{r}$ and time t [‡]. More explicitly,

$$\Phi(\mathbf{r}, t) \equiv \int_{4\pi} L(\mathbf{r}, \hat{\Omega}, t) d\Omega = \phi_{00}. \quad (4)$$

The photon flux $\mathbf{J}(\mathbf{r}, t)$ (W/cm^2) is a vector sum of the radiance emerging from the infinitesimal volume, i.e.,

$$\mathbf{J}(\mathbf{r}, t) \equiv \int_{4\pi} L(\mathbf{r}, \hat{\Omega}, t) \hat{\Omega} d\Omega = \frac{1}{\sqrt{2}}(\phi_{1-1} - \phi_{11})\hat{x} - \frac{i}{\sqrt{2}}(\phi_{1-1} + \phi_{11})\hat{y} + \phi_{10}\hat{z}. \quad (5)$$

Thus, $\mathbf{J}(\mathbf{r}, t) \cdot \hat{\Omega}$ is the power per area travelling in the $\hat{\Omega}$ direction at position $\mathbf{r}$ and time t .

The photon fluence rate and flux are related by a continuity equation obtained from integrating Equation (1) over all solid angles:

$$\frac{1}{v} \frac{\partial \Phi(\mathbf{r}, t)}{\partial t} + \nabla \cdot \mathbf{J}(\mathbf{r}, t) + \mu_a \Phi(\mathbf{r}, t) = S(\mathbf{r}, t). \quad (6)$$

Here, $S(\mathbf{r}, t)$ (W/cm^3) is the total power per volume emitted radially outward from position $\mathbf{r}$ at time t , i.e., $S(\mathbf{r}, t) \equiv \int_{4\pi} Q(\mathbf{r}, \hat{\Omega}, t) d\Omega$.

In the P_1 approximation, another relation between Φ and $\mathbf{J}$ is obtained by substituting Equation (3) into Equation (1); we then multiply the resulting P_1 transport equation by $\hat{\Omega}$ and integrate over all solid angles to obtain §

$$\nabla \Phi(\mathbf{r}, t) = -\frac{3}{v} \frac{\partial \mathbf{J}(\mathbf{r}, t)}{\partial t} - 3\mu_t \mathbf{J}(\mathbf{r}, t) + 3 \int_{4\pi} Q(\mathbf{r}, \hat{\Omega}, t) \hat{\Omega} d\Omega + 3\mu_s g \mathbf{J}(\mathbf{r}, t). \quad (7)$$

The anisotropy factor g , which emerges from the differential scattering integral in Equation (1), is the ensemble average of the cosine of the scattering angle θ , i.e., $g \equiv \int_{4\pi} f(\hat{\Omega} \cdot \hat{\Omega}') \hat{\Omega} \cdot \hat{\Omega}' d\Omega' = \langle \cos \theta \rangle$. The closer g is to unity, the more probable it is for a photon to be scattered in the forward direction. In soft mammalian tissue, typical values for g range between 0.8 and 0.98 [95].

Assuming isotropic sources ($Q(\mathbf{r}, \hat{\Omega}, t) = Q(\mathbf{r}, t)$), the integral over Q in Equation (7) is zero. Furthermore, if we also assume slow temporal variations in the photon flux $\mathbf{J}$, then $(1/v) \mathbf{J}/t$ in Equation (7) can be neglected compared to $(\mu_t - \mu_s g) \mathbf{J}$. With these two assumptions, Equation (7) simplifies to Fick's law of diffusion, i.e.,

[‡]Some authors prefer to use the photon energy concentration, $\Gamma(\mathbf{r}, t)$ (J/cm^3), which is directly proportional to the fluence rate: $\Gamma = v\Phi$.

[§]For any vector $\mathbf{A}$, $\int_{4\pi} \hat{\Omega}(\hat{\Omega} \cdot \mathbf{A}) d\Omega = \frac{4\pi}{3} \mathbf{A}$, and $\int_{4\pi} \hat{\Omega}[\hat{\Omega} \cdot \nabla(\mathbf{A} \cdot \hat{\Omega})] d\Omega = 0$. Also, $\int_{4\pi} \frac{\partial \Phi}{\partial t} \hat{\Omega} d\Omega = \frac{\partial \Phi}{\partial t} \int_{4\pi} \hat{\Omega} d\Omega = 0$ and $\int_{4\pi} f(\hat{\Omega} \cdot \hat{\Omega}') \hat{\Omega} \cdot \hat{\Omega}' d\Omega' = \mathbf{J} \cdot \hat{\Omega} \int_{4\pi} f(\hat{\Omega} \cdot \hat{\Omega}') \hat{\Omega} d\Omega'$.

$$\nabla \Phi(\mathbf{r}, t) = -3(\mu'_s + \mu_a) \mathbf{J}(\mathbf{r}, t). \quad (8)$$

$\mu'_s \equiv (1 - g)\mu_s$ is called the reduced scattering coefficient.

Substituting Equation (8) into Equation (6) results in the *photon diffusion equation for the photon fluence rate* [20, 96, 97]:

$$\nabla \cdot (D(\mathbf{r}) \nabla \Phi(\mathbf{r}, t)) - v\mu_a(\mathbf{r})\Phi(\mathbf{r}, t) - \frac{\partial \Phi(\mathbf{r}, t)}{\partial t} = -vS(\mathbf{r}, t). \quad (9)$$

Here we have defined the photon diffusion coefficient $D(\mathbf{r}) \equiv v/3(\mu'_s(\mathbf{r}) + \mu_a(\mathbf{r}))$.

Microscopically, within this P_1 picture, photons travel through the medium along random walk pathways. Each photon is visualized to travel in straight-line segments with sudden interruptions wherein either the propagation direction is randomly changed or the photon is absorbed. The average length of the straight-line segments is the photon random walk step or the transport mean free path, ℓ_{tr} , which is approximately $1/\mu'_s$.

The validity of the photon diffusion model (Equation (9)) rests on the validity of the P_1 approximation (Equation (3)), which requires the radiance to be nearly isotropic ($\Phi \gg |\mathbf{J}|$).

This isotropy is achieved when $\mu'_s \gg \mu_a$, and when photon propagation distances within the medium are large relative to ℓ_{tr} . As a rough rule of thumb, μ'_s/μ_a should exceed 10 to accurately apply the diffusion model [98]. Additional assumptions, noted above, include source isotropy, slow temporal flux variations, and rotational symmetry (i.e., $f(\Omega, \hat{\Omega}') = f(\Omega \cdot \hat{\Omega}')$). Near a boundary such as an air-tissue interface, the radiance will no longer be nearly isotropic. In Section 2.5, we will show how the diffusion model can be applied near the surface with additional boundary conditions at the interface. For anisotropic tissues, such as axon fiber bundles where the rotational symmetry assumption may no longer be reasonable, slightly more complicated anisotropic diffusion models [99] are necessary for data fitting. For complex tissues that contain “non-diffusing” domains such as (arguably) cerebral spinal fluid inside the head [100, 101], or that contain very high concentrations of blood, as in the liver, optimal data analysis requires approximations beyond P_1 . In applications wherein photon propagation distances are comparable to ℓ_{tr} , the photon propagation directions do not fully randomize. Thus, approximations beyond the P_1 are needed here as well. We will discuss various schemes that extend beyond the diffusion (i.e. P_1) approximation in Section 2.10.

2.2. Source Types

To apply the diffusion model, one typically detects light at known distances from point sources. Figure 2 shows two source-detector pairs; one in the reflection geometry and the other in the transmission geometry. In the reflection geometry, light injected into the tissue by a source fiber (usually coupled to a laser) is detected a distance ρ away with another fiber (usually coupled to a photo-multiplier tube or avalanche photo-diode). In the transmission geometry, light detection is facilitated using either a fiber or a lens/CCD camera system. At

first glance, the directional light from a fiber violates the isotropic source assumption for the diffusion model. This light, however, can be very well approximated by an isotropic light source at depth ℓ_{tr} inside the tissue [97]. In practice, source-detector separation should exceed $3\ell_{tr}$ to apply the diffusion model and expect accurate ($\sim 5\%$) results [102].

Three types of light sources commonly used in diffuse optics are (see Figure 2): continuous wave (CW), intensity modulated (FD), and time pulsed (TRS). The simplest source type is CW light, where the intensity remains constant over time [103–106]. This enables fast data acquisition and the use of simple detectors and detection electronics, but as we will discuss further, μ_a and D cannot be determined simultaneously from a single measurement.

Intensity modulated sources (the frequency-domain technique, FD) are more complex but also give more information about the medium [9, 15, 107, 108]. Here, the light intensity of the source at position $\mathbf{r}_s$ is sinusoidally modulated with angular frequency ω (of order approximately 100 MHz or larger, up to ~ 1 GHz), producing a diffusive wave in the medium oscillating at the same frequency. At a given source-detector separation, both the amplitude and phase of the diffusing wave are measured. The additional information from the phase, in principle, permits simultaneous determination of μ_a and D .

Time pulsed light (the time-domain technique, TRS) is related to intensity modulated light via a Fourier transform, and it contains the same information content as intensity modulated sources scanned over the wide range of modulation frequencies present in the pulse [8, 12, 109–112]. Specifically, a short light pulse (< 100 ps) is delivered to the medium at position $\mathbf{r}_s$ and time t_s . The pulse temporally broadens as it propagates through the medium. At the detector, the pulse shape contains the necessary information to determine D and μ_a from a single source-detector pair. Also, by employing time-gating and moments analysis at the detection end, it is possible to pathlength resolve the detected light in order to reject contributions from superficial tissue layers [113, 114].

2.3. Diffuse Photon Density Waves

Most of the following theoretical discussion will be given in the frequency-domain, with the time-domain solution given for a common case. Frequency-domain sources induce fluence rate disturbances that behave in many ways like overdamped waves. To appreciate this point, we start with the diffusion equation for the fluence rate (Equation (9)) and assume the source term has DC and AC parts and can be written in the form $S(\mathbf{r}, t) = S_{DC}(\mathbf{r}) + S_{AC}(\mathbf{r})e^{-i\omega t}$. Then we look for the solutions that oscillate at the same angular frequency as the source. These AC solutions will have the following general form

$$\Phi_{AC}(\mathbf{r}, t) = U(\mathbf{r})e^{-i\omega t}. \quad (10)$$

Substituting Φ_{AC} into Equation (9), we see that $U(\mathbf{r})$ is described by

$$\nabla \cdot (D(\mathbf{r})\nabla U(\mathbf{r})) - (v\mu_a(\mathbf{r}) - i\omega)U(\mathbf{r}) = -vS_{AC}(\mathbf{r}), \quad (11)$$

which for homogeneous media gives

$$(\nabla^2 - k^2)U(\mathbf{r}) = \frac{-v}{D}S_{AC}(\mathbf{r}), \quad (12)$$

with $k^2 = (v\mu_a - i\omega)/D$. The general solution of Equation (12) is an overdamped wavelike fluence rate ‘disturbance’ in the turbid medium. Note, slightly different definitions for k^2 , e.g. $k^2 = (-v\mu_a + i\omega)/D$ or $k^2 = -(v\mu_a + i\omega)/D$ with $\Phi_{AC}(\mathbf{r}, t) = U(\mathbf{r})e^{i\omega t}$, enable us to write Equation (12) in a Helmholtz form. This approach was used early on and had the advantage of more obvious analogies with waves. Of course, regardless of the way terms are defined in Equation (12), the solutions are the same.

2.4. Solutions in Infinite, Homogeneous Turbid Media

The simplest geometry to consider is the infinite, homogeneous medium with a single intensity modulated point source at the origin ($S_{AC}(\mathbf{r}) = S_{AC}\delta(\mathbf{r})$). In this case, the main boundary condition is that the fluence rate falls to zero at infinity. The solution to Equation (12) in this geometry is well known. It has the form of a simple overdamped spherical wave with complex wave vector $k = k_r + ik_i$:

$$U(\mathbf{r}) = \frac{vS_{AC}}{4\pi Dr} \exp(-kr). \quad (13)$$

Here, $r = |\mathbf{r}|$,

$$k_r = \left(\frac{v\mu_a}{2D}\right)^{1/2} \left[\left(1 + \left[\frac{\omega}{v\mu_a}\right]^2\right)^{1/2} + 1 \right]^{1/2} \quad (14)$$

$$k_i = -\left(\frac{v\mu_a}{2D}\right)^{1/2} \left[\left(1 + \left[\frac{\omega}{v\mu_a}\right]^2\right)^{1/2} - 1 \right]^{1/2}. \quad (15)$$

Writing the fluence rate in the form $U(\mathbf{r}) = Ae^{i\theta}$, the determination of the change in wave amplitude, A , and wave phase, θ , with distance from the source enables experimenters to extract the absorption and reduced scattering factors of the turbid medium. In Figure 3 we show a measurement [13] of the amplitude and phase of such a diffuse photon density wave (DPDW).

In tissue measurements, a typical set of parameters are $\mu'_s = 10\text{cm}^{-1}$, $\mu_a = 0.025\text{cm}^{-1}$, $\omega = 2\pi \times (70\text{ MHz})$, and an index of refraction $n = 1.4$. In this case the DPDW wavelength ($2\pi/k_i \sim 19\text{ cm}$) is roughly a factor of 20 greater than the attenuation length ($1/k_r \sim 1\text{ cm}$). In the near-field, DPDWs have been demonstrated to exhibit several familiar wave-like properties including diffraction [14], refraction [13], interference [16], and dispersion [17].

The time-domain and frequency-domain solutions to Equation (9) are Fourier transform pairs. Therefore, if the solution in one domain is known, then it is straightforward to determine the solution in the other domain. The Fourier transform of Equation (13) gives the

fluence rate solution in the presence of a pulsed point source of the form, $S(\mathbf{r}, t) = S_0 \delta(\mathbf{r}) \delta(t)$, in the homogeneous infinite medium. The resulting fluence rate is

$$\Phi(\mathbf{r}, t) = \frac{v S_0}{(4\pi D t)^{3/2}} \exp \left[-\frac{r^2}{4Dt} - \mu_a v t \right]. \quad (16)$$

Here, to derive optical properties, one performs a nonlinear fit comparing Equation (16) to the measured fluence rate temporal arrival distribution at the detector (using only a single source-detector separation). The fitting determines D and μ_a . Alternatively, if it is only necessary to determine μ_a , the nonlinear fit can be avoided by noting that $\ln \Phi(\mathbf{r}, t) / t \rightarrow -\mu_a v$ as $t \rightarrow \infty$. Thus, μ_a is given by the slope of the natural log of the fluence rate at long times (i.e. typically only a few nanoseconds).

2.5. Boundary Conditions

While conceptually useful, the infinite homogeneous medium is not a good approximation for practical tissue geometries. Most realistic geometries have interfaces. A particularly useful geometry is the planar interface wherein a semi-infinite turbid tissue is bounded in the other half-space by air. To derive boundary conditions for the light diffusion problem, it is necessary to consider the radiance again. Typically, photons escaping from the tissue into air will never re-enter the tissue medium. Thus, the incoming irradiance (i.e., total light power per area traveling into the diffuse medium at the boundary), J_{in} , is due to Fresnel reflections of the radiance in the diffuse medium that travels out towards the interface (see Figure 4):

$$J_{in} \equiv \int_{\hat{\Omega} \cdot \hat{n} < 0} L(\hat{\Omega}) \hat{\Omega} \cdot (-\hat{n}) d\Omega = \int_{\hat{\Omega} \cdot \hat{n} > 0} R_{Fresnel}(\hat{\Omega}) L(\hat{\Omega}) \hat{\Omega} \cdot \hat{n} d\Omega. \quad (17)$$

$R_{Fresnel}(\hat{\Omega})$ is the familiar Fresnel reflection coefficient for light incident upon the boundary in a direction $\hat{\Omega}$ from within the medium.

Using the diffusion model, i.e., substituting the P_1 approximation (Equation (3)) in for L , and an appropriate form for $R_{Fresnel}(\hat{\Omega})$, one readily obtains the so-called partial-flux boundary condition (also known as the Robin boundary condition) which relates the fluence rate to its gradient at the boundary [115, 116]:

$$\Phi = z_b \hat{n} \cdot \nabla \Phi \text{ on the interface.} \quad (18)$$

Here, $z_b = 2\ell_{tr}(1+R_{eff})/3(1-R_{eff})$, where R_{eff} is the effective reflection coefficient to account for the index mismatch between tissue and air: $R_{eff} \approx -1.440n^{-2} + 0.710n^{-1} + 0.668 + 0.0636n$ (R_{eff} is defined exactly in Table 1). $n = n_{in}/n_{out}$ is the ratio of the index of refraction “inside” and “outside” the diffusing medium.

The partial-flux boundary condition is exact, but it is relatively difficult to use, especially if analytical solutions to the diffusion equation with interfaces are desired. In this case, a simpler boundary condition is usually made as an approximation to the more fundamental result. In particular, the fluence rate is Taylor expanded to first order around the boundary,

with the first-derivative term taken from the partial-flux boundary condition. The treatment gives a zero-crossing point for the fluence rate at a distance, z_b , outside (i.e. on the air-side) of the tissue (Figure 5):

$$\Phi(z = -z_b) = 0. \quad (19)$$

Equation (19) is called the extrapolated zero boundary condition. It approximates the exact partial-flux boundary condition quite well (see [115, 116] for details). With this ‘new’ zero fluence rate interface, it is readily possible to use the method of images to obtain analytic solutions in a variety of geometries. Many researchers employ numerical methods to solve these and other problems; in such cases the partial-flux boundary condition is often directly incorporated into the numerical codes rather than the extrapolated zero boundary condition (for example, see [117]).

2.6. Green’s Function Solutions

An age old strategy [118, 119] employed to solve the time-domain and frequency-domain diffusion equations (Equation (9) and Equation (11)) is to first find their respective Green’s functions, and then to use these Green’s functions to construct more general solutions. In diffuse optical spectroscopy, the usual assumption is to treat tissues as homogeneous media. For homogeneous media, Equation (9) can be written in the form $\hat{A}\Phi(\mathbf{r}, t) = -\nu S(\mathbf{r}, t)/D$, where $\hat{A} \equiv \nabla^2 - \partial/\partial t - \nu\mu_a$. The time-domain Green’s function $G_0(\mathbf{r}, \mathbf{r}_s, t, t_s)$ then satisfies $\hat{A}G_0(\mathbf{r}, \mathbf{r}_s, t, t_s) = -\delta(\mathbf{r}-\mathbf{r}_s)\delta(t-t_s)$ and the boundary conditions for the geometry of interest. Similarly, Equation (12) can be written in the form $B\hat{U}(\mathbf{r}) = -\nu S_{AC}(\mathbf{r})/D$, where $B \equiv \nabla^2 - k^2$. The frequency domain Green’s function $G_0(\mathbf{r}, \mathbf{r}_s)$ then satisfies $B\hat{G}_0(\mathbf{r}, \mathbf{r}_s) = -\delta(\mathbf{r}-\mathbf{r}_s)$ and the relevant boundary conditions. The full fluence rate solution in homogeneous media will be the convolution of these Green’s functions with the source term $\nu S/D$.

2.7. Solutions for Semi-infinite Media and Other Simple Geometries

In NIRS/DOS, the most commonly used models approximate tissue either as a homogeneous semi-infinite medium or as a homogeneous infinite slab (Figure 4). In both geometries, the method of images can be employed to find the diffusion equation Green’s functions, subject to the extrapolated-zero boundary condition (Equation (19)) [120, 121]. For example, consider a single normalized isotropic point source at position (in cylindrical coordinates) $\mathbf{r}_s = (\rho_s = 0, z_s = \ell_{tr})$ in the semi-infinite geometry. Recall from Section 2.2 that this source is a good approximation for light injected into the tissue by a fiber at $\mathbf{r} = (\rho = 0, z = 0)$. The extrapolated zero boundary condition is satisfied by introducing a negative image point source at $z_s = -(2z_b + \ell_{tr})$ (Figure 5). Superposition of the infinite medium solutions (Equation (13)) from each (positive and negative) point source yields the homogeneous semi-infinite Green’s function. In the frequency domain,

$$G_0([\rho, z], [\rho_s=0, z_s=\ell_{tr}]) = \frac{1}{4\pi} \left[\frac{\exp(-kr_1)}{r_1} - \frac{\exp(-kr_b)}{r_b} \right], \quad (20)$$

where

$$r_1 = \sqrt{(z - \ell_{tr})^2 + \rho^2} \quad (21)$$

$$r_b = \sqrt{(z + 2z_b + \ell_{tr})^2 + \rho^2}. \quad (22)$$

Let us now consider a NIRS/DOS measurement in reflection on a tissue sample, using a frequency domain source (Figure 4). Assuming the tissue is well modeled by a homogeneous semi-infinite geometry, the fluence rate along the tissue surface is $S_0 \psi G_0([\rho, z = 0], [\rho_s = 0, z_s = \ell_{tr}])/D$, where G_0 is given by Equation (20) and S_0 is the strength of the source. This solution contains two independent equations: one for the fluence rate amplitude, $A(\rho)$, and the other for the phase, $\theta(\rho)$. Thus, as with the infinite medium (Section 2.4), by measuring $A(\rho)$ and $\theta(\rho)$, one can solve the system of equations from the semi-infinite solution for D and μ_a .

We note that the detected light signal is the radiance integrated over the collection solid angle, which in the diffusion model is proportional to the fluence rate near the detector [115, 122]. It is difficult to predict this proportionality constant theoretically. Thus, in practice additional amplitude and phase-shift unknowns are usually incorporated into the solutions. Multiple source-detector separations are preferred to minimize this uncertainty and enable calibration.

Equation (20) can be fit exactly, but in the limit, $\rho \gg (\ell_{tr} + 2z_b)$, the solution simplifies considerably to

$$U(\rho, z=0) \approx \frac{vS_0}{4\pi D} \frac{e^{-k_r\rho}}{\rho^2} (2k(\ell_{tr}z_b + z_b^2)) = \frac{A_0 e^{-k_r\rho}}{\rho^2} e^{i(-k_i\rho + \theta_0)} = A(\rho) e^{i\theta}(\rho). \quad (23)$$

Note that in this limit, $\ln[\rho^2 A(\rho)]$ and $\theta(\rho)$ depend linearly on ρ ,

$$\ln(\rho^2 A(\rho)) = -k_r\rho + \ln A_0 \quad (24)$$

$$\theta(\rho) = -k_i\rho + \theta_0, \quad (25)$$

making it particularly simple to fit for k_i and k_r , which in turn permits calculation of μ_a and D .

The method of images can also be used to compute the frequency domain Green's functions for a homogeneous turbid medium in other geometries [120, 121]. Table 1 shows the frequency-domain Green's functions subject to the extrapolated-zero boundary condition for several simple geometries. Similarly, analytic solutions exist for heterogeneities such as spherical [123] and cylindrical [124] inclusions in homogeneous media as well as for multi-layer media [125–129].

2.8. Spectroscopy for Determination of Tissue Chromophore Concentrations

The tissue absorption depends linearly on the concentrations of tissue chromophores. In particular, the wavelength-dependent absorption coefficient is given by

$$\mu_a(\lambda) = \sum_i \varepsilon_i(\lambda) c_i. \quad (26)$$

Here $\varepsilon_i(\lambda)$ is the wavelength-dependent extinction coefficient (usually known for typical tissue chromophores), and c_i represents the concentration of the i^{th} chromophore. We have seen above (Section 2.4 and Section 2.7) that the diffusion approximation enables us to separate the scattering and absorption contributions in the detected light signals. Thus, by measuring μ_a at multiple optical wavelengths, we generate a system of coupled equations (Equation (26)) that can be solved to yield the unknown chromophore concentrations. Generally, to estimate the concentrations of N chromophores, one must determine μ_a at N or more wavelengths.

NIRS/DOS is most typically employed to measure oxygenated and de-oxygenated hemoglobin; thus a bare minimum of phase and amplitude measurements at two wavelengths are required. Use of more wavelengths permits inclusion of other tissue chromophores such as water and lipid, and also improves the accuracy of the hemoglobin measurements because measurement redundancy reduces systematic errors. Of course, more wavelengths increase the cost and complexity of the instrument and require longer data acquisition times.

The most common NIRS/DOS configuration is the reflection geometry, which employs the homogeneous semi-infinite medium analysis described above (Section 2.7) to derive $\mu_a(\lambda)$. However, other geometries are sometimes used to obtain bulk tissue properties; in this case the derived phase-shift and amplitude as a function of source-detector separation are usually more complex than the simple linear functions outlined above, and the fitting is correspondingly more tricky (but still possible). Imaging schemes employ essentially the same ideas on a volume-element-by-volume-element basis to assign chromophore concentrations to particular voxels in the sample (see Section 2.10).

NIRS/DOS provides quick estimates of bulk chromophore concentrations in large tissue volumes. These estimates are often accurate enough to be useful in many monitoring applications (see Section 4).

One technical problem associated with the multi-source/detector, multi-wavelength approach arises because each source and each detector has a different light coupling coefficient to tissue. This “coupling coefficient” (generally, a complex number in the frequency domain) is a parameter that combines many factors such as the wavelength-dependent fiber transmission, different source and detector optics, differences in the physical properties of sources and detectors, electronics, and tissue-fiber interfaces. The measured fluence rate for a given source-detector pair is thus equal to a product of the true fluence rate with the pair’s coupling coefficients. The light coupling coefficients for each source-detector pair will be additional unknowns in the inverse problem. If the coupling coefficients for different source-detector pairs are significantly different, then the NIRS/DOS inverse

problem is harder with added variables [130]. Several methods are commonly employed to address this problem. One approach uses calibration phantoms with known optical properties to determine the coupling coefficients before and after each experiment (see [131]). A second approach employs self-calibrating probes (see [81]). The first method assumes the coupling will be the same for tissue and phantom; the second method assumes tissue homogeneity. In the case of tomography (Section 2.10), it is often assumed that the reference measurement cancels out these coupling coefficients [132]. A more rigorous approach is to consider the coupling coefficients as unknowns and explicitly reconstruct them [130].

2.8.1. Optimal Wavelengths—Determination of tissue chromophore concentrations requires the separation of tissue absorption from tissue scattering at more than one optical wavelength. The optimal choice of wavelengths for chromophore concentration determination is an important topic in its own right, with an interesting history that involved careful consideration of measurement type, i.e. frequency-, time-domain, CW, and measurement signal-to-noise. For simple, two-wavelength time- and frequency-domain instruments, early experimenters wondered about which wavelengths to choose to minimize cross-talk between chromophores when inverting Equation (26). Superficially, one might expect that at least one wavelength within the NIR window should be below the isosbestic point of hemoglobin and one should be above this isosbestic point. The isosbestic point is the wavelength wherein the extinction coefficients of oxygenated and de-oxygenated hemoglobin are the same (~800 nm, see Figure 1); wavelengths below the isosbestic point are thus more sensitive to deoxy-hemoglobin, while wavelengths above are more sensitive to oxy-hemoglobin. However, such wavelength selection processes are limited. Yamashita *et al* [133], Strangman *et al* [134], and Boas *et al* [135] have shown theoretically and experimentally that when using only two wavelengths, a pair at 660 – 760 nm and 830 nm provides superior oxy- and deoxy- hemoglobin separation by comparison to what was the more commonly used choice of 780 nm and 830 nm.

A formal evaluation of the optimum wavelength selection for an arbitrary number of wavelengths was carried out by Corlu *et al* [136, 137]; they introduced a general procedure for finding those wavelengths which best differentiate tissue chromophores using CW and frequency-domain light. These results built on a theoretical approach developed in a classic paper by Lionheart and Arridge [138]. That paper [138] theoretically proved that it is impossible to uniquely separate scattering from absorption in a diffuse optical imaging experiment employing CW light. In an attempt to circumvent this uniqueness problem for CW imaging, Corlu *et al* demonstrated that a multi-spectral approach can be employed to uniquely reconstruct the chromophore concentrations, c_i . In a key advance, Corlu *et al* [136,137] abandoned the two-step approach of determining μ_a at each wavelength first and then inverting Equation (26). Instead, they introduced a multi-spectral approach that exploits known spectral properties of the medium *a priori* to directly reconstruct chromophore concentrations with better fidelity than the traditional two-step method. Specifically, *a priori* assumptions about the form of the scattering (e.g., $\mu'_s(\lambda) = A\lambda^{-b}$) and wavelength-dependent absorption extinction factors (i.e., Equation (26)) are used, and the wavelength independent variables c_i , A , and b are reconstructed directly from all of the data simultaneously. Because

the data from all wavelengths are simultaneously used, the inverse problem is better-constrained than the traditional approach (see [137] for details). The multi-spectral technique is now commonly used, and has been extended for frequency domain sources [139], for including uncertainties in the hemoglobin extinction coefficients [140], and for spectral window optimization when using broadband sources [141].

2.8.2. The Differential Pathlength (DPF) Approach—In many situations, we are interested in the temporal variation of quantities such as hemoglobin concentration or oxygenation with respect to some perturbation. In such cases, one need only measure ‘changes’ in tissue optical properties, i.e., μ_a and $\Delta\mu_s'$. If μ_a and $\Delta\mu_s'$ are small relative to their baseline values, $\mu_a^{(0)}$ and $\mu_s'^{(0)}$, respectively, and if they are homogeneously distributed across the sample, then a much simpler differential pathlength method can be employed using only the intensity of the detected light. Specifically, this method relates temporal changes in the optical density, $OD \equiv -\ln(A(\mathbf{r}_d, t)/A(\mathbf{r}_s))$, to changes in chromophore concentrations [10,120,134,142–146]. Here $A(\mathbf{r}, t)$ is the fluence rate amplitude. Furthermore, only one source-detector separation is needed to estimate these concentration changes.

The differential pathlength method is derived by truncating the Taylor series expansion of the optical density for a given source-detector separation ρ to first order in μ_a and μ_s' :

$$OD(\mu_a^{(0)} + \Delta\mu_a, \mu_s'^{(0)} + \Delta\mu_s', \rho) \approx OD(\mu_a^{(0)}, \mu_s'^{(0)}, \rho) + \frac{\partial OD(\mu_a^{(0)}, \mu_s'^{(0)}, \rho)}{\partial \mu_a} \Delta\mu_a + \frac{\partial OD(\mu_a^{(0)}, \mu_s'^{(0)}, \rho)}{\partial \mu_s'} \Delta\mu_s'. \quad (27)$$

Substituting Equation (26) into Equation (27), we see that temporal changes in the detected optical density, i.e.,

$$\begin{aligned} \Delta OD(\lambda, t, \rho) &\equiv -\ln(A(\mathbf{r}_d, t)/A(\mathbf{r}_d, t=0)) \\ &= OD(\mu_a^{(0)}(\lambda) + \Delta\mu_a(\lambda, t), \mu_s'^{(0)}(\lambda) + \Delta\mu_s'(\lambda, t), \rho) \\ &\quad - OD(\mu_a^{(0)}(\lambda), \mu_s'^{(0)}(\lambda), \rho), \end{aligned} \quad (28)$$

may be related to changes in tissue chromophore concentrations and scattering through a modified Beer-Lambert law:

$$\Delta OD(\lambda, t) \approx \sum_i (\varepsilon_i(\lambda) \Delta c_i(t)) d_a(\rho, \lambda) + \Delta\mu_s'(\lambda, t) d_s(\rho, \lambda) \sim \sum_i (\varepsilon_i(\lambda) \Delta c_i(t)) DPF(\lambda) \rho. \quad (29)$$

Here, $d_a \equiv OD(\lambda, t=0, \rho)/\mu_a$ and $d_s \equiv \partial OD(\lambda, t=0, \rho)/\partial \mu_s'$ are called the differential absorption and scattering pathlengths respectively for wavelength λ (or baseline values $\mu_a^{(0)}(\lambda) = \mu_a(\lambda, t=0)$ and $\mu_s'^{(0)}(\lambda) = \mu_s'(\lambda, t=0)$) and source-detector separation ρ [120]. The last step in Equation (29) is an approximation that is utilized widely in studies of brain hemodynamics (see Section 4). This approximation assumes that scattering is unchanged (i.e., $\Delta\mu_s' = 0$) and that $d_a(\rho, \lambda) = DPF(\lambda)\rho$, where DPF is a ‘normalized’ ρ -independent differential pathlength factor usually obtained from the literature.

Thus, by measuring OD at multiple wavelengths, we can invert Equation (29) to determine the changes in chromophore concentrations c_i . Again, in addition to assuming small absorption and scattering changes, Equation (29) assumes homogeneously distributed changes for μ_a and $\Delta\mu_s'$. If the changes are localized, the modified Beer Lambert law leads to systematic underestimations of the chromophore concentration changes (i.e., the partial volume effect) [145].

The parameters d_a and d_s depend on source-detector separation, tissue geometry, and the baseline optical properties of the underlying tissue, which in turn depend on the wavelength used. The parameters can be estimated analytically with a diffusion model, numerically using the Monte Carlo method [146], or measured using pulse-time methods in a sample of statistically similar tissue-types [10]. Pulse-time methods are relevant for a differential pathlength analysis involving light intensity only, because here the differential pathlength factors are related to the photon mean time of flight in tissue, $\langle t \rangle$, determined by pulse-time methods [120], i.e.,

$$d_a = \left[1 + \frac{\mu_a}{\mu_a + \mu_s'} \right] v \langle t \rangle, \quad (30)$$

$$d_s = \frac{\mu_a v}{\mu_a + \mu_s'} \langle t \rangle. \quad (31)$$

The differential pathlength approach essentially makes a best estimate for the actual light pathlength in the tissue. Although it is clearly a very approximate method, it has been employed extensively in the biomedical optics community (see [35,147–150], and many others).

2.9. Diffuse Correlation Spectroscopy

2.9.1. Dynamic Light Scattering in the Single-scattering Limit—The Dynamic Light Scattering (DLS) (sometimes called Quasi-elastic Light Scattering (QELS)) technique is a well known optical method for measuring the motions of scatterers such as particles in suspension [45,46,151]. In the experiment (Figure 6(Top)), a light beam illuminates a sample. To be concrete, let us assume that the sample is composed of a dilute solution of particles or macro-molecules; dilute in the sense that light is scattered once or not at all as it traverses the sample. Each of the particles develops an induced dipole moment in the presence of the incident light, and these oscillating dipoles, in turn, emit scattered light fields into all directions. The scattered light electric field at the detector, $\mathbf{E}(t)$, is thus built from a superposition of these dipole contributions. Because the particles move, the relative phases of the scattered dipole fields change and the light field (and light intensity) at the detector fluctuates in time.

It is straightforward to show [45, 46, 151] that for independent particles with isotropic dynamics, the normalized electric field temporal auto-correlation function (g_1) at the detector is

$$g_1(\tau) = \frac{\langle \mathbf{E}^*(t) \cdot \mathbf{E}(t+\tau) \rangle}{\langle |\mathbf{E}(t)|^2 \rangle} = e^{i2\pi f\tau} e^{-q^2 \langle \Delta r^2(\tau) \rangle / 6}. \quad (32)$$

Here, f is the frequency of the incident light, $\mathbf{q}$ is the scattered wave-vector representing the difference between output and input beam wave-vectors, and $\langle \Delta r^2(\tau) \rangle$ is the mean-square particle displacement in time τ . The brackets $\langle \rangle$ represent time-averages (for experiments) or ensemble averages (for calculations). Thus by measuring the temporal fluctuations of scattered light, one obtains quantitative information about the particle motions. For the case of Brownian motion, $\langle \Delta r^2(\tau) \rangle = 6D_b\tau$; for the case of random flow, $\langle \Delta r^2(\tau) \rangle = \langle V^2 \rangle \tau^2$. Here, D_b is the particle diffusion coefficient and $\langle V^2 \rangle$ is the second moment of the particle speed distribution. Of course there are other types of motions (e.g. rotation) which affect these signals, but we will restrict our discussion to these two types of particle motion.

In practice, experimenters often measure the scattered, normalized intensity temporal auto-correlation function (g_2); $g_2(\tau) \equiv \langle I(t)I(t+\tau) \rangle / \langle I(t) \rangle^2$, with the intensity $I(t) = |\mathbf{E}(t)|^2$. The Siegert relation [152],

$$g_2(\tau) = 1 + \beta |g_1(\tau)|^2, \quad (33)$$

is then used to extract the electric field auto-correlation function from the intensity data. β is a constant determined primarily by the collection optics of the experiment, and is equal to one for an ideal experiment setup.

2.9.2. Dynamic Light Scattering in the Multiple Light Scattering Limit—In

samples such as tissue or more concentrated colloidal suspensions, the incident light field is multiply scattered. As with light diffusion, one can envision the electric field temporal auto-correlation function propagating ballistically, then scattering from small volume elements within the sample, and then propagating ballistically again in a random manner as the light makes its way from one side of the sample to the other side. Each of these ‘single’ dynamic light scattering events, from a volume element within the sample, contributes to the detected correlation function. This is illustrated in Figure 6(Bottom). It is thus apparent that the detected field auto-correlation function is also related to motions of the scatterers within the medium, albeit in a more complex way. There has been elegant research on this multiple ‘dynamic light scattering’ problem over the years (for example, see [61–63, 153–155]). In the late 1980s the Diffusing Wave Spectroscopy (DWS) technique was formulated [62,63,156]. In DWS, the phase of the various photon random-walk paths through the sample is computed at time $\tau = 0$ and then recomputed at time τ . When the scattering events within each path are uncorrelated, and when the diffusion approximation is valid, one finds that the detected field autocorrelation function is then essentially equal to the angle-averaged DLS signal due to a typical single scattering event in the random walk sequence raised to the power N (where N is the number of random walk steps in the photon path). The detected signal is the integral of these single-path signals over all allowed photon paths. Another approach, which we will discuss in detail below, employs correlation transport theory to derive a diffusion equation for the field auto-correlation function. The correlation transport equation and the resultant correlation diffusion equation are particularly attractive in the

context of tissues, because they share a formal similarity with the results we have presented already about diffuse photon density waves.

2.9.3. Diffusion of Temporal Correlation Functions—Temporal fluctuations in the sample are characterized by an unnormalized electric field auto-correlation function,

$G_1^T(\mathbf{r}, \hat{\Omega}, \tau) = \langle \mathbf{E}^*(\mathbf{r}, \hat{\Omega}, t) \cdot \mathbf{E}(\mathbf{r}, \hat{\Omega}, t + \tau) \rangle$, where the brackets $\langle \rangle$ denote the usual time and/or ensemble averages, and as mentioned earlier, $\mathbf{E}(\mathbf{r}, \hat{\Omega}, t)$ is the electric field at position $\mathbf{r}$ and time t propagating in the $\hat{\Omega}$ direction. Ackerson and co-workers first suggested that G_1^T is analogous to the radiance L and should be governed by a correlation transport equation [154, 155]:

$$\nabla \cdot G_1^T(\mathbf{r}, \hat{\Omega}, \tau) \hat{\Omega} + \mu_t G_1^T(\mathbf{r}, \hat{\Omega}, \tau) = Q(\mathbf{r}, \hat{\Omega}) + \mu_s \int G_1^T(\mathbf{r}, \hat{\Omega}', \tau) g_1^s(\hat{\Omega}, \hat{\Omega}', \tau) f(\hat{\Omega}, \hat{\Omega}') d\Omega'. \quad (34)$$

Here $g_1^s(\hat{\Omega}, \hat{\Omega}', \tau)$ is the normalized temporal field auto-correlation function for single scattering (see Equation (32)), $f(\hat{\Omega}, \hat{\Omega}')$ is the normalized differential single scattering cross-section, $Q(\mathbf{r}, \hat{\Omega})$ is the light source distribution, and $\mu_t = \mu_a + \mu_s$. Equation (34) is a steady-state equation independent of time, meaning it is applicable for CW sources and systems in equilibrium.

Given Equation (34), one can implement a set of steps formally identical to the steps used to derive the diffusion equation for photon fluence rate from the radiative transport equation.

That is, using a P_1 approximation for G_1^T , the correlation transport equation reduces to the correlation diffusion equation for correlation ‘fluence rate’ [60, 61]:

$$\left[\nabla \cdot D(\mathbf{r}) \nabla - v\mu_a(\mathbf{r}) - \frac{\alpha}{3} v\mu_s' \kappa_0^2 \langle \Delta r^2(\tau) \rangle \right] G_1(\mathbf{r}, \tau) = -vS(\mathbf{r}). \quad (35)$$

Here, $G_1(\mathbf{r}, \tau)$ is the correlation fluence rate, i.e.,

$$G_1(\mathbf{r}, \tau) = \int_{4\pi} G_1^T(\mathbf{r}, \hat{\Omega}, \tau) d\Omega = \langle \mathbf{E}^*(\mathbf{r}, t) \cdot \mathbf{E}(\mathbf{r}, t + \tau) \rangle, \quad (36)$$

where $\mathbf{E}(\mathbf{r}, t)$ is the total light electric field at $(\mathbf{r}, t)$, and $S(\mathbf{r})$ is an isotropic source term:

$$S(\mathbf{r}) = \int_{4\pi} Q(\mathbf{r}, \hat{\Omega}) d\Omega. \quad (37)$$

α represents the fraction of photon scattering events that occur from moving particles in the medium, $\langle r^2(\tau) \rangle$ is the usual mean square displacement in time τ of the scattering particles (e.g., blood cells), $\kappa_0 = 2\pi/\lambda$ is the wavenumber of the CW light diffusing through the medium, and D , μ_a , and v are the same optical properties that arise in the photon diffusion equation (Equation (9)). Furthermore, a set of analogous correlation diffusion boundary conditions arise for $G_1(\mathbf{r}, \tau)$:

$$G_1(\mathbf{r}, \tau) = z_b \hat{n} \cdot \nabla G_1(\mathbf{r}, \tau) \text{ Partial - flux.} \quad (38)$$

$$G_1(z = -z_b, \tau) = 0. \text{ Extrapolated zero.} \quad (39)$$

Diffuse correlation spectroscopy (DCS) refers to the measurement of the temporal diffusing field auto-correlation function to obtain information about tissue dynamics. Equation (35) is essentially a differential equation formulation of diffusing wave spectroscopy (DWS). It is better suited than DWS for handling point sources, heterogeneous media, and tomography. Notice also that if we take the $\tau = 0$ limit of the correlation diffusion equation, then we obtain the CW diffusion equation for photon fluence rate.

Since Equation (35) with its boundary conditions has the same form as the photon diffusion equation (Equation (9)) for CW sources, the Green's function solutions of the correlation diffusion equation will also have the same form. For example, in a homogeneous semi-infinite medium, the solution to Equation (35) is (see Equation (20)),

$$G_1(\rho, z, \tau) = \frac{v}{4\pi D} \left[\frac{\exp(-K(\tau)r_1)}{r_1} - \frac{\exp(-K(\tau)r_b)}{r_b} \right], \quad (40)$$

where $K(\tau) = \sqrt{(\mu_a + \alpha\mu'_s\kappa_0^2\langle\Delta r^2(\tau)\rangle/3)v/D}$, and r_1 and r_b are given by Equation (21) and Equation (22), respectively. The new feature is that the decay constant, $K(\tau)$, also depends on the correlation time τ ; of course that is where the dynamical information resides.

As in the case of DLS, the quantity measured in practice is usually not G_1 , but is instead proportional to the intensity auto-correlation function $G_2(\mathbf{r}, \tau) = \langle I(\mathbf{r}, t)I(\mathbf{r}, t + \tau) \rangle$, where $I(\mathbf{r}, t) = |\mathbf{E}(\mathbf{r}, t)|^2$. Again, the Siegert relation (Equation (33)) may be used to relate the intensity and field auto-correlation functions.

Thus, G_1 is derived from the experimentally measured G_2 , and K^2 is determined by fitting to the temporal decay of G_1 (for a given source-detector separation). This information plus optical property information permit determination of $\alpha\langle r^2(\tau) \rangle$.

Strictly speaking, the Siegert relation is fully valid if the electric field, $\mathbf{E}(\mathbf{r}, t)$, is a Gaussian variable in time with zero mean [152]. For samples such as tissue, wherein some scatterers are static and some scatterers move, the total electric field will have static and dynamic components and can be written as $\mathbf{E}(\mathbf{r}, t) = \mathbf{E}_c(\mathbf{r}) + \mathbf{E}_f(\mathbf{r}, t)$. Here, $\mathbf{E}_c$ is a time-independent contribution to the total field from photons that have experienced only static scattering on their path from source to detector. $\mathbf{E}_f$ is the field due to photons that have experienced at least one dynamic scattering event between source and detector; this field will fluctuate in time. Application of the Siegert relation in such cases requires careful consideration of the interference terms involving $\mathbf{E}_c$ and $\mathbf{E}_f$. To date, a few methods for circumventing this problem have been developed [157–159], e.g., moving the sample (or detector) to induce fluctuations in $\mathbf{E}_c$ [157] or choosing speckles wherein $\mathbf{E}_c$ is small. We have conducted experiments in tissue phantoms and tissues to explore this further. In most practical tissue geometries we have found that the intensity auto-correlation functions decay to unity (typical field auto-correlation measurements are shown in Figure 8); collectively these measurements indicate that $\mathbf{E}_c$ is small, perhaps because most of the detected photon paths involve at least one moving red blood cell or another slow moving tissue scatterer (e.g., due to subtle vibrations or other effects). More work remains to clarify this observation.

Nevertheless, it appears that one can routinely employ the Siegert relation in most tissue dynamics experiments, except perhaps those wherein the subject is exercising.

2.9.4. Blood Flow Indices from Diffuse Correlation Spectroscopy—DCS is most sensitive to the motion of blood cells in the *microvasculature* (i.e. capillaries, arterioles, venules), since the diffusing light is mostly absorbed when traversing large arteries and veins. Typical detected photons experience scattering events from static (or very slow moving) scatterers in biological tissue (e.g. organelles and interfaces), in addition to the dynamic scattering from moving RBCs (see previous section for details) [153].

Since the microvasculature is convoluted, we may expect that the distribution of the directions of velocities of the sampled RBCs is more or less isotropic. Thus, the random ballistic flow model is sometimes a first “guess” as a choice for the dynamics of RBCs, where $\langle r^2(\tau) \rangle = \langle V^2 \rangle \tau^2$ (see Section 2.9.1). In practice, however, we and others [65, 66, 68–90] have found that the Brownian model, $\langle r^2(\tau) \rangle = 6D_b\tau$, fits the observed correlation decay curves better over a wide range of tissue types including rat brain [77, 78]; mouse tumors [68]; piglet brain [75]; and human skeletal muscle [81], tumors [83,84], and brain [66,69,71,74,80] (see Figure 8). In these cases, D_b is an effective diffusion coefficient obtained from fitting to correlation data; it is a few orders of magnitude larger than the traditional thermal Brownian diffusion coefficient of RBCs in the blood given by the Einstein-Smoluchowski relation [160]. Upon reflection, it should not be too surprising that the random flow model does not fit the data well. RBCs in the microvasculature do not move ballistically; they experience position-dependent shear stresses, they roll, they tumble, and they translate in the vasculature.

Clearly, the final cumulative effect of photon-RBC interactions on the measured auto-correlation function will depend on both the nature of the microscopic motions and on the spatial distribution of moving particles in tissue. In the vasculature, both of these factors can be quite complex [161, 162], and, in fact, their affects on light signals are not fully understood. The situation is further complicated by the nontrivial distribution of photon paths in tissue; for example, contributions from the largest vessels tend to be small, since photons that interact with RBCs in an artery are mostly absorbed and do not reach the detector.

Despite these apparent difficulties, we (and others) have worked to elucidate DCS measurement sensitivity. For example, we have carried out isolated limb perfusion measurements in rats (see Figure 7(Left)). The figure shows two correlation decay curves, one from the limb with normal circulation and the other due to controlled circulation (of roughly the same speed) of an external suspension of RBCs (with ~10 times reduced concentration) through the same vasculature. The measurement clearly demonstrates that our signal is due to RBC motion. Variation of RBC concentration in suspension decreased the measured αD_B in a proportional manner (~7.2 times). When healthy flow is compared to that from a dead limb the residual decay is < 3% of the baseline (see Figure 7(Right)). In the latter state, we altered and monitored the temperature of the limb while continuing to measure the correlation decay. Fitted αD_B was dependent linearly on the temperature, as

expected for true Brownian motion of the scatterers, which has a linear temperature dependence.

Furthermore, we (and others) have found that the fitted parameter αD_b (from the Brownian model) correlates well with other blood flow measurement modalities. As a result, it is natural to identify the αD_b parameter as a blood flow index (BFI). The BFI is not a measure of absolute blood flow in the strict sense (e.g., it has the wrong units), but the relative change in BFI has been repeatedly shown to be a quantitative measure of relative change in blood flow. In particular, it has been shown that under well controlled circumstances, αD_b is proportional to the absolute blood flow measured by ASL-MRI [73] and transcranial Doppler ultrasound [69,71]. Similar sorts of ambiguities are well known in the Laser Doppler literature, and in general, calibration and empirical modeling are used to estimate absolute values of blood flow velocity [43,153,163]. Calibration methods similar to those utilized by laser Doppler, e.g., to calibrate for “biological zero”, are also applicable for DCS [164–167]. We also note that it is possible (but difficult without constraints) to measure absorption and even scattering with DCS [168].

2.10. Tomography with Diffuse Photon Density Waves

Many of the simplifying assumptions used in spectroscopy, such as homogeneity and a semi-infinite or infinite slab geometry, are relaxed when imaging with diffusing waves. By using a more realistic model of tissue, diffuse optical tomography (DOT) improves the accuracy of the measured optical properties. Tomography is also critical for identification of localized heterogeneities such as tumors in tissue. The goal of DOT is to reconstruct the spatial distribution of optical/physiological properties at each point (or volume element) in the tissue from measurements of fluence rate on the tissue surface. This problem is typically called the ‘inverse problem’, whereas ‘forward problem’ refers to the calculation of the fluence rate on the tissue surface given a particular spatial distribution of optical/physiological properties. The transport/diffusion equations provide a tractable mathematical basis for tomographic image reconstruction [30].

Unfortunately, the dominance of scattering in light propagation makes each fluence rate measurement sensitive to a relatively large tissue volume compared, for example, to X-ray CT wherein scattering is minimal. The inverse problem in diffuse optical imaging is thus much more difficult than standard X-ray CT. The DOT inverse problem is also intrinsically nonlinear with respect to the tissue optical properties. As a result, it is computationally intensive to arrive at the inverse solutions, though as we will discuss, for some applications the problem can be linearized.

Despite these difficulties, several approaches have been developed and successfully applied for diffuse optical tomography (DOT) [30, 34, 169–171]. These include: backprojection methods [172, 173], diffraction tomography in k-space and variants [174–177], perturbation approaches [178–182], the Taylor series expansion approach [183–188], gradient based iterative techniques [189,190], elliptic systems methods [191, 192], truncated Newton schemes [193–196], multigrid inversion algorithms [197], and Bayesian conditioning [198–205]. Other important and related theoretical advances include the development of analytic inversion formalisms [206–209], development and clarification of differencing [210] and

differential [211] methodologies, and advances in the use of *a priori* information [212, 213]. Experimentally, different schemes such as the use of spatially structured/modulated illumination [214–216] and phased-arrays of sources [217, 218] were also considered to improve localization. For other recent reviews on image reconstruction, see [23, 30, 31, 98, 219–221].

As mentioned before, though the diffusion model is adequate for light transport in most tissues, many biomedical applications involve tissues with “non-diffusing domains” and/or tissue volumes which are smaller than a few scattering lengths. To handle these cases, more complex (and more computationally intensive) models are needed. These models are summarized in recent reviews [30, 220]. One approach consists of schemes based on the full radiative transport equation [30, 190, 222–224], which have recently been reviewed by Klose and Hielscher [225]. This approach has been especially successful for imaging small tissue volumes such as the finger [226]. Another approach is to use higher order P_N approximations of the transport equation [227–230]. If DOT is combined with an anatomical MRI, then it is possible to segment tissue into diffusive and non-diffusive regions. In this case, a hybrid model can be applied where light transport is modelled by diffusion in the diffusive regions and by radiosity theory [30, 231–233] or Monte Carlo [234] in the non-diffusive regions. The disadvantage of the hybrid model is that the boundaries between the diffusive and non-diffusive regions must be known. That said, many researchers are combining DOT with other imaging methods such as MRI in order to have more prior information to constrain the inverse problem. The incorporation of prior information improves the resolution and accuracy of the reconstructed images with DOT. A comprehensive review focusing on the incorporation of prior information into DOT has been recently published by Dehghani *et al* [235].

In the following sections, some common tomography approaches are outlined. Forward problem computations are an essential part of most of the methods used to solve the inverse problem. For simple geometries (e.g. Table 1), analytic solutions to the forward problem are quite useful. However, for complex geometries and/or heterogeneous optical property distributions, the forward problem is sometimes solved using numerical finite difference methods (FDM), finite element methods (FEM), boundary element methods (BEM), or Monte Carlo [30, 181, 182, 190, 236, 237]. Tomography approaches can be classified as linear or nonlinear. As mentioned above, the tomography inverse problem is nonlinear, but in the limit that the volume element optical properties are close to a specified background, the inverse problem is approximately linear (Section 2.10.1). This is usually the case for imaging differences in optical properties. For example, in a functional brain activation experiment, the perturbations in optical properties due to the brain stimulation are small compared with the background resting state of the brain (i.e., no stimulus). However, if the goal is to measure absolute optical properties, the full nonlinear problem should be tackled. Here, we focus the discussion on frequency-domain single-wavelength data; one can readily expand these ideas to continuous-wave and time-domain sources, as well as multi-spectral data (section 2.8.1).

2.10.1. Linear Numerical Inversion using the Perturbation Approach—To start, we write the optical properties at position $\mathbf{r}$ as

$$\mu_a(\mathbf{r}) = \mu_a^{(0)} + \delta\mu_a(\mathbf{r}), \quad (41)$$

$$D(\mathbf{r}) = D^{(0)} + \delta D(\mathbf{r}), \quad (42)$$

where $\delta\mu_a(\mathbf{r})$ and $\delta D(\mathbf{r})$ can be regarded as perturbations from a homogeneous “background” medium with optical properties $\mu_a^{(0)}$ and $D^{(0)}$. Here, $\mu_a^{(0)}$ and $D^{(0)}$ are estimated from a tissue spectroscopy measurement or from values reported in the literature for similar tissue samples. Thus, the inverse problem utilizes measurements of fluence rate on the tissue surface to determine $\delta\mu_a(\mathbf{r})$ and $\delta D(\mathbf{r})$, given some $\mu_a^{(0)}$ and $D^{(0)}$.

Two common forms are used for $U(\mathbf{r})$ to set up the inverse problem [238]. The Born approach writes $U(\mathbf{r}) = U_0(\mathbf{r}) + U_{sc}(\mathbf{r})$, while the Rytov approach writes $U(\mathbf{r}) = U_0(\mathbf{r}) \exp[U_{sc}^R(\mathbf{r})]$. In both cases, U_0 is the spatial part of the frequency-domain fluence rate in the homogeneous background medium, which can be calculated theoretically given $\mu_a^{(0)}$ and $D^{(0)}$, and $U_{sc}(\exp[U_{sc}^R])$ is the correction to U_0 as a result of the heterogeneities. Note that U_{sc} has units of power per area, but U_{sc}^R is dimensionless. For more detail on both approaches see [238].

Let us focus on the Born approach. Corresponding Rytov results will also be given. In the linear perturbative approach, $U(\mathbf{r})$ is set equal to its first-order Taylor series expansion about U_0 , i.e., $U = U_0 + (U_0/\mu_a)\delta\mu_a + (U_0/D)\delta D$. This defines a simple linear problem for $\delta\mu_a$ and δD :

$$[J_{a,ij}, J_{s,ij}]\{\delta\mu_a(\mathbf{r}_j), \delta D(\mathbf{r}_j)\}^T = \{U_{sc}(\mathbf{r}_d, \mathbf{r}_s)_i\}, \quad (43)$$

where $[J] = [J_{a,ij}, J_{s,ij}] = [U_0(\mathbf{r}_j)/\mu_a, U_0(\mathbf{r}_j)/D]$ is the Jacobian. The index i refers to the source-detector pair and the index j refers to the position within the sample. Equation (43) is derived from an expansion of U to first order, whose accuracy depends on $\delta\mu_a$ and δD being small. We note that the terminology weight matrix, sensitivity matrix, and Jacobian are often used interchangeably in the literature to refer to the matrix in Equation (43).

One could potentially calculate the Jacobian directly using numerical methods, but the perturbation approach lets one derive an analytic expression for the Jacobian. Substituting $U(\mathbf{r}) = U_0 + U_{sc}$, Equation (41), and Equation (42) into the heterogeneous diffusion equation (Equation (11)) gives a differential equation for U_{sc} :

$$[\nabla^2 - k^2]U_{sc}(\mathbf{r}) = \frac{v\delta\mu_a(\mathbf{r})}{D_0}U(\mathbf{r}) - \frac{\delta D(\mathbf{r})}{D_0}\nabla^2 U(\mathbf{r}) - \nabla \left(\frac{\delta D(\mathbf{r})}{D_0} \right) \cdot \nabla U(\mathbf{r}). \quad (44)$$

As before, $k^2 = (v\mu_a^{(0)} + i\omega)/D^{(0)}$. The integral solution for $U_{sc}(\mathbf{r}_d, \mathbf{r}_s)$, at detector position $\mathbf{r}_d$ given source position $\mathbf{r}_s$, is given by the convolution of the homogeneous Green's function $G_0(\mathbf{r}_d, \mathbf{r})$ (for the geometry of interest) with the right-hand side of Equation (44) (see Ch. 5 of [239]):

$$U_{sc}(\mathbf{r}_d, \mathbf{r}_s) = \int \left(\frac{-v\delta\mu_a(\mathbf{r})}{D_0} \right) G_0(\mathbf{r}_d, \mathbf{r}) U(\mathbf{r}, \mathbf{r}_s) d^3r + \int \left(\frac{\delta D(\mathbf{r})}{D_0} \right) \nabla G_0(\mathbf{r}_d, \mathbf{r}) \cdot \nabla U(\mathbf{r}, \mathbf{r}_s) d^3r. \quad (45)$$

Equation (45) is intrinsically nonlinear in $\delta\mu_a(\mathbf{r})$ and $\delta D(\mathbf{r})$ because $U(\mathbf{r}, \mathbf{r}_s)$ on the right-hand side also depends on $\delta\mu_a(\mathbf{r})$ and $\delta D(\mathbf{r})$.

If we assume that $U_0 \gg U_{sc}$, Equation (44) is readily linearized, i.e., U is replaced with U_0 in the integrals (U_0 is independent of the perturbations $\delta\mu_a$ and δD). Discretization of the integral in Equation (45) leads to a sum over NV elements (or voxels) of size V :

$$U_{sc}(\mathbf{r}_d, \mathbf{r}_s) = \sum_{j=1}^{NV} [W_{a,j} \delta\mu_a(\mathbf{r}_j) + W_{s,j} \delta D(\mathbf{r}_j)], \quad (46)$$

where $W_{a,j} = -v \nabla G_0(\mathbf{r}_d, \mathbf{r}_j) U_0(\mathbf{r}_j, \mathbf{r}_s) / D_0$ and $W_{s,j} = \nabla G_0(\mathbf{r}_d, \mathbf{r}_j) \cdot \nabla U_0(\mathbf{r}_j, \mathbf{r}_s) / D_0$.

In tomography problems, many source-detector pairs are typically spread out over the sample surface. Given NM source-detector pairs, Equation (46) is most easily expressed as a matrix equation that relates a vector of source-detector measurements to a vector of absorption and diffusion coefficient variations at voxels within the sample. Note that Equation (46) and Equation (43) are identical (i.e., $[J] = [W]$), so that

$$J_{a,ij} = \left[\frac{\partial U_0}{\partial \mu_a} \right]_{ij} = \frac{-v\Delta V}{D_0} G_0(\mathbf{r}_d^i, \mathbf{r}_j) U_0(\mathbf{r}_j, \mathbf{r}_s^i) \quad (47)$$

$$J_{s,ij} = \left[\frac{\partial U_0}{\partial D} \right]_{ij} = \frac{\Delta V}{D_0} \nabla G_0(\mathbf{r}_d^i, \mathbf{r}_j) \cdot \nabla U_0(\mathbf{r}_j, \mathbf{r}_s^i). \quad (48)$$

The matrix $[J]$ has dimensions $NM \times (2NV)$, the measurement vector $U_{sc} = U - U_0$ has length NM , and the perturbation vector $\{\delta\mu_a, \delta D\}$ has length $2NV$. Note, in most practical cases in the frequency domain, amplitude and phase data are further split in the matrix. Finally, the measurement vector U_{sc} is obtained from measurements of the fluence rate U ; but as we discussed in Section 2.7, the intensity measured in practice for a given source-detector pair, $I(\mathbf{r}_d, \mathbf{r}_s)$, is proportional to the fluence rate $U(\mathbf{r}_d, \mathbf{r}_s)$. Thus, as with spectroscopy (see earlier discussion on “coupling coefficients” in Section 2.8), a calibration scheme or explicit reconstruction of these unknowns should be employed [130].

The linearized Rytov approach (i.e., $U(\mathbf{r}) = U_0(\mathbf{r}) \exp[U_{sc}^R(\mathbf{r})]$) leads to a matrix equation of the same form as Equation (43), except that the measurement vector

$U_{sc}^R(\mathbf{r}_d, \mathbf{r}_s) = \ln[U(\mathbf{r}_d, \mathbf{r}_s) / U_0(\mathbf{r}_d, \mathbf{r}_s)]$ and the Jacobian terms are

$$J_{a,ij} = G_0(\mathbf{r}_d^i, \mathbf{r}_j) U_0(\mathbf{r}_j, \mathbf{r}_s^i) (-v\Delta V / U_0(\mathbf{r}_d^i, \mathbf{r}_s^i) D_0) \quad (49)$$

$$J_{s,ij} = \nabla G_0(\mathbf{r}_d^i, \mathbf{r}_j) \cdot \nabla U_0(\mathbf{r}_j, \mathbf{r}_s^i) (\Delta V / U_0(\mathbf{r}_d^i, \mathbf{r}_s^i) D_0). \quad (50)$$

Note, the Rytov approximation requires that the scattered field varies comparatively slowly (i.e. $(\nabla U_{sc}^R)^2$ is small relative to $v\delta\mu_a/D^{(0)}$ and $(\delta D/D^{(0)})(\nabla G_0/G_0)^2$).

The construction and the inversion of Equation (43) is generally the computationally most expensive step in the tomography problem. Because the Jacobian is almost always a nonsquare matrix ($NM \times 2NV$), one often multiplies Equation (43) by the transpose of the Jacobian to create a square matrix for the inversion, i.e.,

$$[J]^T [J] \{\delta\mu_a, \delta D\}^T = [J]^T \{U_{sc}\}. \quad (51)$$

$[J]^T [J]$ is usually singular, or close to singular, and is thus difficult to invert directly. Furthermore, experimental noise in the data tends to produce artifacts when explicitly solving Equation (51). To convert Equation (51) into a more readily solvable problem, a regularization parameter is usually introduced into the inverse problem. The regularization parameter is employed to suppress effects of measurement noise and model errors,

$$([J]^T [J] + R^g [C]^T [C]) \{\delta\mu_a, \delta D\}^T = [J]^T \{U_{sc}\}, \quad (52)$$

where R^g is a regularization scalar that weights a regularization operator $[C]$ [188, 240–243]. Regularization is a theoretical knob that can be adjusted to smooth image artifacts from experimental noise and other errors at the cost of decreasing the spatial resolution [244, 245].

Let us review the steps for this inversion approach. The linearized inversion problem constructs a suitable “perturbed” fluence rate, often within Born or Rytov approximations. The so-called “background”, “baseline,” or “homogeneous” field, U_0 , is either measured (e.g., using a homogeneous phantom before the breast scan, or during a “rest” period in case of functional studies of the brain) or calculated using a forward solver. The second step is the construction of the appropriate Jacobian (or weight matrix), which is derived from analytic solutions, numerical solutions (such as finite-element or finite-difference forward solutions of the photon diffusion equation), or a combination thereof. Then, typically, some sort of a regularization is applied to the Jacobian. Thus, up to this point, the steps are cumbersome but straightforward. The next step is to invert the often ill-posed Jacobian. Many strategies can be employed for this purpose, including “standard” singular value decomposition (SVD), algebraic reconstruction technique (ART) or simultaneous iterative reconstruction technique (SIRT), and k-space expansions [30, 170, 175, 179, 206, 208, 220, 239, 246, 247]. Despite the well known [30,170,220,239,246] limitations of linearized methods, these methods are employed for many applications including functional brain imaging, wherein well-defined and often localized optical property changes occur in response to neuronal stimulation (see Section 4), and optical mammography, wherein optical properties change in response to stimuli such as compression (see Section 3). Furthermore, in applications that involve many time points and near real-time feedback, such as the case of bed-side monitoring of brain function, the linearized inversion is attractive as a feasible option given the current state of portable computational power and speed.

2.10.2. Linear Analytical Inversion with Assumed Symmetry—For simple geometries such as semi-infinite, infinite slab, infinite cylindrical, and spherical, Schotland and colleagues have developed a fast alternative method for solving the inverse problem. Essentially, this method exploits the symmetry of the geometry to avoid constructing and inverting the entire weight matrix in Equation (43) [174, 206–208, 248]. Here, we will outline the method for the infinite-slab geometry using the Rytov approach.

The geometry is as defined in Figure 4 where $\mathbf{p}$ is the position vector on the plane where there is symmetry. By exploiting this symmetry, the Green's function (G_0) can be expanded in plane waves along $\mathbf{p}$ [175, 249], i.e.,

$$G_0(\mathbf{p}, z; \mathbf{p}_s, z_s) = \frac{1}{(2\pi)^2} \int d^2q \zeta(\mathbf{q}; z, z_s) e^{i\mathbf{q} \cdot (\mathbf{p} - \mathbf{p}_s)}, \quad (53)$$

where $\zeta(\mathbf{q}; z, z_s)$ gives the amplitude and phase of the plane wave with wave-vector $\mathbf{q} = (q_x, q_y)$ in the plane z due to a source in the plane z_s . Analytic expressions for $\zeta(\mathbf{q}; z, z_s)$ are given in [208].

Substituting Equation (53) into the linearized Rytov solution (Section 2.10.1) and then taking a four-dimensional (two each for the source and detector coordinates $\mathbf{p}_s$ and $\mathbf{p}_d$) spatial Fourier transform, we obtain

$$\tilde{u}(\mathbf{q}_d, \mathbf{q}_s) = \int_{z_s}^z \kappa_A(\mathbf{q}_s, \mathbf{q}_d; z) v \delta \tilde{\mu}_a(\mathbf{q}_s + \mathbf{q}_d, z) + \kappa_D(\mathbf{q}_s, \mathbf{q}_d; z) \delta \tilde{D}(\mathbf{q}_s + \mathbf{q}_d, z) dz. \quad (54)$$

Both κ_A and κ_D are known since we have analytic expressions for the coefficients defined in Equation (53) and are given by

$$\kappa_A(\mathbf{q}_s, \mathbf{q}_d; z) = \zeta(\mathbf{q}_s; z_s, z) \zeta(\mathbf{q}_d; z, z_d) \quad (55)$$

$$\kappa_D(\mathbf{q}_s, \mathbf{q}_d; z) = \frac{\partial \zeta(\mathbf{q}_s; z_s, z)}{\partial z} \frac{\partial \zeta(\mathbf{q}_d; z, z_d)}{\partial z} - \mathbf{q}_s \cdot \mathbf{q}_d g(\mathbf{q}_s; z_s, z) g(\mathbf{q}_d, z, z_d). \quad (56)$$

These steps, collectively, reduce the original inverse problem to a linear one-dimensional integral equation which can be inverted in a manner similar to those mentioned in Section 2.10.1 to obtain $\delta \tilde{\mu}_a(\mathbf{q}, z)$ and $\delta \tilde{D}(\mathbf{q}, z)$, which are the spatial Fourier transforms of the “images” we seek to reconstruct (see [208] for details). Performing an inverse Fourier transform on $\delta \tilde{\mu}_a(\mathbf{q}, z)$ and $\delta \tilde{D}(\mathbf{q}, z)$ gives the desired images. Exploiting the planar symmetry this way dramatically decreases the computation time relative to constructing the inverse for the entire Jacobian numerically (Equation (43)).

For example, Konecky *et al.* [250] used the Rytov linearized analytic inversion method to reconstruct objects of a complex structure (i.e. letters made from silicone rubber) with optical properties comparable to those of tissue embedded in an optically thick medium. In this study, reconstructions utilizing data sets of 10^7 source-detector pairs obtained with a CW instrument only required a minute of CPU time on a 1.3 GHz workstation. In addition to identifying the location and spatial extent of the heterogeneities, the resulting images

contained spatially-resolved features on the sub-centimeter scale at varying depths inside the optically thick medium (see Figure 9).

2.10.3. Nonlinear Numerical Inversion (Jacobian- and Gradient-based

Methods)—Linearized approaches are useful for generating images, but if the tissue optical properties are significantly different from those of a specified background, then the accuracy of the linear image reconstruction will be compromised. In Section 2.10.1, we showed that the linearized inverse problem in the Born approach ($U = U_0 + U_{sc}$) is valid if the magnitude of the fluence rate correction U_{sc} is small relative to the background U_0 . In the Rytov approach ($U = U_0 \exp[U_{sc}^R]$), the linearized inverse problem is valid if the fluence rate correction U_{sc}^R is slowly varying, i.e., $(\nabla U_{sc}^R)^2 \ll v\delta\mu_a/D$. In general, both of these linearized approaches break down when optical property perturbations are large. With the Born approach, this can easily be seen by noting that the derivation of Equation (43) assumed small optical property perturbations. [246]. When attempting to measure absolute optical properties of tissue, the specified background is an initial guess of these properties, which is often significantly different from the true properties. To improve image reconstruction, nonlinear approaches for the inverse problem are required. Jacobian-based nonlinear schemes in essence solve linear problems again and again, updating the perturbations $\delta\mu_a$ and δD iteratively, and then comparing calculated fluence rates with the measured fluence rates until they become sufficiently close.

Here, we will discuss a Born iterative method (BIM) and a Distorted Born iterative method (DBIM) presented by Yao *et al* [182]. Figure 10 is a schematic illustrating the steps for these two methods. First, μ_a and D are initialized, and the corresponding Green's function, G_0 , for the photon diffusion equation (Equation (44)) is determined. The forward problem is then solved; typically by using finite elements or finite difference numerical methods. To quantify the agreement between calculated fluence rate $U_c(\mathbf{r}_d)$ and the measured fluence rate $U_m(\mathbf{r}_d)$, an objective function χ^2 is constructed:

$$\chi^2 = \sum_{i=1}^{NM} \left| \frac{U_m(\mathbf{r}_d, \mathbf{r}_s)_i - U_c(\mathbf{r}_d, \mathbf{r}_s)_i}{\sigma^i} \right|^2. \quad (57)$$

Here NM is the number of measurements and σ^i is the measurement error for the i^{th} source-detector pair. When χ^2 falls below some pre-defined convergence criterion ϵ , the iteration procedure is stopped. If the iteration procedure is not stopped, then the optical properties are updated. Updated optical properties are derived via the solution to an inverse problem which has been outlined already for the linearized problem in Section 2.10.1 (i.e., Equation (52)).

The difference between the two methods is that the DBIM method calculates a new Green's function at every iteration, while the BIM method always uses the same Green's function (see Figure 10). The DBIM usually converges faster than the BIM, but it is also less robust to noise than the BIM [182]. Equivalent methods using the Rytov approach, i.e., Rytov iterative method and Distorted Rytov iterative method, are also utilized.

Another useful nonlinear reconstruction approach employs a gradient-based iterative scheme rather than explicitly building the Jacobian and solving Equation (52) [171, 189, 190]; in

this case, the gradient of the objective function χ^2 (Equation (57)) with respect to μ_a and D

(e.g. $\frac{\partial \chi^2}{\partial \mu_a}, \frac{\partial \chi^2}{\partial D}$) is determined to establish a search direction to minimize χ^2 directly. A line search is performed to find the optical properties that minimize χ^2 along this search direction, and these new optical properties are then used for the next iteration. The search direction is established using the nonlinear conjugate gradient method (see [171] for details). This process repeats until χ^2 has converged within a desired tolerance. Since the gradient-based approach does not involve direct inversion of the Jacobian matrix (time- and memory-consuming computational process), it is computationally less intensive than the Jacobian-based iterative methods under many conditions.

Public software packages are available that utilize the iterative methods described above for image reconstruction. Both the gradient-based and Jacobian-based approaches can be employed in the well known DOT reconstruction package Time-Resolved Optical Absorption and Scattering Tomography (TOAST) [171]. NIRFAST is another software package written in the MATLAB environment that uses the Jacobian-based approach [117].

2.10.4. Nonlinear Analytical Inversion—The exact fluence rate solution to Equation (11) can be written as an infinite series. For example, taking the Born approach, the series is generated by replacing U with $U_0 + U_{sc}$ in Equation (45) and then substituting Equation (45) in for U_{sc} in an iterative fashion:

$$U(\mathbf{r}_d, \mathbf{r}_s) = U_0(\mathbf{r}_d, \mathbf{r}_s) + \int G_0(\mathbf{r}_d, \mathbf{r}) F(\mathbf{r}) U_0(\mathbf{r}, \mathbf{r}_s) d^3r + \iint G_0(\mathbf{r}_d, \mathbf{r}) F(\mathbf{r}) G_0(\mathbf{r}, \mathbf{r}') F(\mathbf{r}') U_0(\mathbf{r}', \mathbf{r}_s) d^3r' d^3r + \dots \quad (58)$$

Here, $F(\mathbf{r}) \equiv (-\nu \delta \mu_a(\mathbf{r}) + \delta D(\mathbf{r}) \nabla_{\mathbf{r}} G_0(\mathbf{r}_d, \mathbf{r}) \cdot \nabla_{\mathbf{r}}) / D_0$.

Equation (58) truncated at first order is the Born approximation. Inclusion of higher order terms in the series leads to more accurate results, but numerically evaluating the higher order terms is more computationally expensive [246]. However, for special geometries, symmetry properties of the fluence rate can be exploited for all of the higher order terms in a similar manner to the method described for the linear term in Section 2.10.2. This scheme speeds up the reconstruction with higher order terms. Schotland and co-workers have derived an exact analytic inversion formula for the fluence rate written as an infinite series. For details about this approach, see references [209, 251].

2.11. Fluorescence Diffuse Optical Spectroscopy and Tomography

The use of extrinsic near-infrared fluorescent dyes has gained attention recently, in part because of their potential to target specific tissues and in part because of their potential to provide information about tissue type and tissue microenvironment. Some researchers in the biomedical optics field recognized the potential of fluorescence early on [14, 252–267] and set about developing theoretical formalisms to understand these fluorescence signals in the multiple scattering limit; these theories have provided a framework to quantitatively assess the potential of fluorescent contrast agents and to use fluorescence for diagnosis. Proper inversion of fluorescent data to derive contrast agent concentration (or fluorophore life time information), however, is more complication than DOS/DOT. It requires an understanding

of the transport of excitation light and the transport of fluorescent light. Thus, most generally, a set of coupled equations for both diffuse light waves must be set up and solved.

Fluorescence diffuse optical spectroscopy (FDOS) is a fluorescence analog of NIRS/DOS. Much of the theory for this relatively simple problem is fully developed (see, for example, references [254, 256, 260]), and these theories have been applied in contexts such as photodynamic therapy [268, 269]. Similarly, the potential for contrast agents has stimulated the development and use of fluorescence diffuse optical tomography (FDOT) for imaging molecular-targeting probes in small animals [270–272], for sentinel lymph node tracking in animals and humans [273, 274], for imaging tumors in human breast [26, 275, 276], and for monitoring blood flow in human brain [277–280]. The feasibility of FDOS and FDOT in humans has thus been demonstrated.

In a related vein, phosphorescence lifetime spectroscopy and tomography has been introduced as a unique means to measure tissue parameters such as the partial pressure of oxygen [281–283]. Bioluminescence tomography of tagged molecules has been utilized to track physiological processes such as gene expression [284], and the autofluorescence from various components of tissue components has been studied in oncological contexts [285–288] and in neuro-imaging [289]. All of these applications require knowledge of the diffuse light transport problem.

2.12. Diffuse Correlation Tomography

Image reconstruction with temporal correlation functions, i.e., diffuse correlation tomography (DCT), employs essentially the same theoretical techniques as DOT for CW light, because the underlying mathematical models are formally similar. In general, such reconstruction schemes permit imaging of spatially heterogeneous dynamics. The inverse problem, in this case, must reconstruct the homogeneous and spatially varying blood flow index, $BFI(\mathbf{r}) = BFI_0 + \delta BFI(\mathbf{r})$, absorption, $\mu_a(\mathbf{r}) = \mu_{a0} + \delta\mu_a(\mathbf{r})$, and scattering, $D(\mathbf{r}) = D_0 + \delta D(\mathbf{r})$. Quite often the changes in BFI dominate the problem, making it reasonable to assume that $\delta\mu_a(\mathbf{r}) = \delta D(\mathbf{r}) = 0$ or in case of hybrid instrumentation [76] to include them as inputs for the reconstructions.

The key difference between reconstruction with correlation functions versus reconstruction with the CW photon fluence rate is the correlation-time-dependence of G_1 . A simple practical approach selects a particular time $\tau = \tau^*$ for reconstruction of BFI from measured G_1 . Zhou *et al.* developed a model for estimating the reconstructed image noise in DCT from the DCS noise information at each source-detector pair; it was found that the time τ^* that minimizes the DCT noise satisfies the relation $G_1(\mathbf{r}, \tau^*) = G_1(\mathbf{r}, 0)e^{-1}$ [78]. This approach thus optimized data selection for DCT by considering both the experimental noise and ill-posedness of the tomographic problem.

2.13. Metabolic Rate of Oxygen Extraction

An important physiological parameter to monitor is the local metabolic rate of oxygen extraction. This quantity depends on the oxygen extraction fraction, i.e. the difference in oxygen saturation between the arterial and venous ends, and blood flow. The cerebral

metabolic rate of oxygen extraction ($CMRO_2$) has been studied extensively in the context of the brain and a wide range of models have been developed to estimate $CMRO_2$ from measurable quantities under different regimes [290–293].

A relatively simple model permits changes in $CMRO_2$ ($rCMRO_2$) to be calculated using a synthesis of $rCBF$, Hb and THC [76, 291–293]. In this case, a compartmentalized model of the vasculature is assumed and an equation that relates the measurable quantities is derived using Fick's law: $CMRO_2 = OEF \times CBF \times C_a$ [294]. OEF is the normalized oxygen extraction fraction, i.e. the difference between oxygen concentrations in arterial (C_a) and venous ends of the vasculature. Our goal is to estimate OEF (or changes thereof) with optical data. Since NIRS/DOS measures a mixture of arteriole, capillary and venule blood oxygen saturation and does not separate venous from arterial saturations, this task is non-trivial. We refer to this mixed signal as “tissue blood oxygen saturation” (StO_2).

A compartmental model relates microvascular blood oxygen saturation to the percentage of blood in the venous and arterial components of the vasculature [77, 295]. We write S_tO_2 as a mixture $S_tO_2 = k_1 \times S_aO_2 + k_2 \times S_cO_2 + k_3 \times S_vO_2$. Here, S_aO_2 , S_cO_2 , and S_vO_2 are the arteriolar, capillary, and venous saturations, respectively, and k_1 , k_2 , and k_3 are the respective weights of each compartment to the total blood volume ($k_1 + k_2 + k_3 = 1$). A standard simplification is to represent S_cO_2 as a weighted average of the arterial and venous saturations; $S_cO_2 = k_4 \times S_aO_2 + k_5 \times S_vO_2$ where $k_4 + k_5 = 1$. The system can then be reduced to a two-compartment model [65, 66, 76, 77, 296] to estimate $rCMRO_2$:

$$rCMRO_2 = rOEF \times rCBF = \left(\frac{S_aO_2 - S_tO_2}{S_aO_{2bl} - S_tO_{2bl}} \right) \left(\frac{\gamma_{bl} S_aO_{2bl}}{\gamma S_aO_2} \right) rCBF \approx \left(\frac{S_aO_2 - S_tO_2}{S_aO_{2bl} - S_tO_{2bl}} \right) \left(\frac{S_aO_{2bl}}{S_aO_2} \right) rCBF. \quad (59)$$

$S_tO_2 = HbO_2/(THC)$ is the microvascular blood oxygen saturation measured by NIRS/DOS. Sub-script “ bl ” ($_{bl}$) is used to indicate baseline values of a parameter. Baseline StO_2 (S_tO_{2bl}) and THC_{bl} are ideally measured but are often estimated from the literature values. Here γ is the percentage of blood in the venous compartment and if we assume that it remains constant over time, it divides out of our measures of $rOEF$. Thus, $rCMRO_2$ can be directly calculated from optical measurements of $rOEF$ and $rCBF$.

3. Breast Cancer Imaging & Spectroscopy

Approximately one in eight women in the United States will develop breast cancer, and, about 30% of these women will ultimately die of the disease [297]. Thus even modest improvements in breast cancer screening (detection), diagnosis, and therapy monitoring can have huge impact in women's health. While existing clinical modalities have reduced the morbidity and mortality rates of breast cancer, no single diagnostic modality is suitable for the plethora of management problems that arise in the clinic. For example, accurate detection and characterization of tumors is required for screening and diagnosis, whereas predictions about treatment efficacy are important for therapy monitoring. X-ray mammography, a routine screening modality, has high false negative rate (i.e. missing cancers) in women under 50 years of age [298] and cannot be used too frequently due to the ionizing nature of X-ray radiation. Techniques such as ultrasound and magnetic resonance imaging (MRI) are sometimes employed in addition to X-ray mammography, but they have

limitations such as high cost, low throughput, limited specificity (MRI) and low sensitivity (ultrasound). Most of these imaging modalities rely on the anatomical differences between cancer and healthy tissues. On the other hand, positron emission tomography (PET) relies on functional tumor contrast such as glucose metabolism and is recommended for assessing metastatic status. However, frequent measurements with PET pose problems due to its expense and the requirement of radioactive isotope injection. Thus new methods are needed to detect cancers earlier for treatment, to detect cancers missed by mammography [299–301], to reduce the false-positive rate [302,303], and to monitor tumor progression during cancer therapy.

Near-infrared diffuse optical tomography and spectroscopy are tools that rely on functional processes for contrast and therefore have potential to enhance sensitivity and specificity of breast cancer detection/diagnosis. Diffuse optical techniques are attractive, because they provide physiological information directly related to tumor vascularity and oxygenation, while utilizing inexpensive, non-ionizing, rapid, portable, and non-invasive instrumentation.

A variety of instrumentation and algorithmic strategies have been developed for optical mammography and tumor monitoring. Instruments range from handheld remission systems [304–309], to tandem-scanning systems [310–315] to full three-dimensional tomographic systems [106, 111, 316–321]. These instruments generally differ with respect to measurement geometry (e.g. remission, parallel-plate, ring/cone), detection type (e.g. CW, FD, TD), wavelength implementation (e.g. broadband vs discrete wavelengths), and source/detector numbers. Analysis algorithms vary too, ranging from analytic solutions in the homogeneous semi-infinite geometry to full fledged 3D tomographic reconstruction; algorithm choices must carefully consider clinical trade-offs in time and space against increased spectral- and spatial-content, and detection complexity for improved data fidelity.

3.1. Diffuse Optical Mammography Based on Endogenous Contrast

3.1.1. Endogenous Properties of Normal Breast Tissue—An understanding of normal breast optical properties is desirable, even if one's ultimate goal is to probe cancer. Recent diffuse optical spectroscopic research on normal tissues has demonstrated sensitivity to tissue composition [322–329], which can change significantly with age or hormonal status. The subcutaneous breast tissues consist of adipose, glandular and fibrous stroma, and the blood supply is typically richest in the glandular areas [330]. Total hemoglobin concentration is thus expected to be larger in breasts with high glandular content and smaller in breasts with high adipose content. Since verification of actual breast composition for individual subject is difficult, we rely on surrogate markers such as body mass index (BMI) or mammographic parenchymal patterns for consistency checks. A significant inverse correlation between THC and BMI has been found, wherein high BMI is an indication of high adipose tissue content [321,322,324,331]. Mammographic parenchymal patterns can be derived from the X-ray attenuation characteristics of fat (radiolucent) and epithelial and stromal tissues (radiodense) [332]. Cubeddu and co-workers have found that water and lipid content correlated well with the mammographic parenchymal pattern, which is an indicator of the composition of adipose and fibrous tissue content [331].

The observation that optical measurements of absorption and scattering can provide physiologically relevant information about breast tissue composition [324] has been extended in a new direction by Lilge and co-workers. Based on parenchymal pattern classification studies of X-ray mammography, it was found that women with dense tissue in more than 60–75% of the breast are at 4–6 times greater risk of breast cancer than others [332]. Using a principal components analysis of a broadband optical spectroscopy measurement, Lilge and co-workers have found agreement between the mammographic assessment of tissue density (high vs low) and optical measurements with 90% accuracy [333–335].

3.1.2. Breast Cancer Detection and Characterization—Tissue properties accessible to DOT and DOS techniques are demonstrably different in tumors compared to normal tissues [213,306,310,314,316,319,321,325,326,336–344]. Among various physiological parameters available to DOT and DOS, most groups have reported high *THC* contrast in malignant tumors [321, 325, 337, 338, 340, 344–348]. Since the malignant growth of tumors is often accompanied by sustained angiogenesis to supply oxygen and nutrient [349], *THC* might reasonably be expected to be higher in the cancers compared to normal tissues. Indeed, a positive correlation between microvessel density and *THC* has been found, providing further insight about the microscopic origin of *THC* contrast [337, 348, 350]. The rapid growth of many tumor cells can also give rise to an increase in number density of subcellular organelles (e.g. mitochondria, nucleolus), which in turn affect tissue light scattering coefficients. Mean size and volume fraction of the nucleus and nucleolus measured by microscopy have indeed been correlated with light scattering observations by DOT [351], and some groups have reported tumor-to-normal contrast in tissue scattering parameters [122, 342, 345, 346,348, 351].

Information about tumor oxygenation status is important, especially for predicting the efficacy of cancer therapies [352–354]. However, while it has been hypothesized that malignant cancer would exhibit low oxygenation due to hypermetabolism [306], its manifestation in macroscopic DOT measurements has not been apparent. Some groups have observed a decrease of StO_2 in the tumor [306, 344, 355–358], whereas others observed no difference [122, 321, 341–343, 359, 360] or even an increase [345]. This discrepancy may be due to dependency of cancer oxygen metabolism on the cancer stage, type, biochemical pathways, or differences in oxygenation accuracy sensitivity among systems.

The spatial locations of tumors based on optical contrast have been compared with X-ray mammograms/ultrasound [314, 321, 337, 351, 361, 362], and MRI [122, 363, 364]. Since optical and other imaging measurements were performed with different compression geometries, new image coregistration schemes [365] and algorithms [341, 366, 367] have been developed for quantitative comparisons between different imaging modalities. It was demonstrated that the spatial locations of optical tumor contrast agree with those identified by MRI and/or PET, and the extracted tumor physiological contrast parameters from optics have been shown to be correlated with PET parameters [367].

Ultimately, characterization of a new imaging modality can be established through computation of Receiver Operating Characteristic (ROC) curve [368, 369]. Let us suppose

that there is a parameter (X) from new imaging modality whose value seems to be higher for malignant lesions and lower for benign lesions. (Note: depending on the test, one can easily substitute 'healthy' or 'non-diseased' state to 'benign'.) For each value of the threshold value ($X_{threshold}$), all the lesions under consideration can be grouped into the following four categories. Some lesions are indeed malignant and correctly predicted to be malignant by the new modality (true positive; TP); some lesions are malignant, but incorrectly predicted to be healthy (false negative; FN); some lesions are benign, and correctly predicted to be benign (true negative, TN); and some lesions are benign, but incorrectly predicted to be malignant (false positive; FP). These quantities can be expressed as rates by dividing by the total number of true malignant lesions or true benign lesions: for example, true positive rate $TPR = TP/(TP+FN)$ and false positive rate $FPR = FP/(TN+FP)$. The ROC curve is constructed by plotting true positive rate on the horizontal axis and false positive rate on the vertical axis at different $X_{threshold}$. A perfect test establishes a threshold which separates diseased and non-diseased subjects completely, i.e. the true positive rate is 1 and the false positive rate is 0. A useless test is one in which diseased and non-diseased states have the same probability (i.e. 50/50 chance) regardless of the threshold; in this case the ROC curve has slope of unity. Thus, a larger 'Area under ROC curve' (AUC) implies a better test/method. AUC of 50% corresponds to an ROC slope of unity (i.e. a useless test). Chance *et al* [306] used a threshold based on a combination of relative THC and StO_2 (derived by DOS) of tumors compared to the tissue from the contralateral breast and obtained 95% AUC to discern cancer from normal tissue. Poplack *et al* [370] achieved 88% AUC for differentiating cancer from normal tissue, and 76% AUC for differentiating malignant cancer from benign lesions using $rTHC$ derived from 3D DOT images for a subset of subjects with lesions larger than 6 mm; their AUC decreased when smaller lesions were included in the data set. In recent work from our laboratory [122], we have extracted the optical parameters from 3D reconstructed images based on MRI-guided region-of-interest selection. As seen in Figure 11, there is a clear distinction between benign and malignant lesions in tumor-to-normal ratio of THC with AUC higher than 90%. Similar trends were seen in tumor-to-normal contrast of HbO_2 and the tissue scattering coefficient. While AUCs of DOS/DOT are relatively high, showing the potential of DOS/DOT for differentiating malignant tumors from healthy or even benign tumors, it needs more assessment since the number of subjects are still low compared to other imaging modalities.

At this point in time, these findings do not represent a final assessment of DOT performance. Most often, each study focused on demonstration of a particular methodology. Discrepancies among groups can be a function of method, subject groups (e.g. lesion size, percentage of benign and malignant lesions, etc) and lack of large-scale, blinded clinical trials. Clearly much work remains, but promise has been demonstrated.

3.2. Optical Mammography Based on Exogenous Contrast

DOT can be conducted concurrently with injection of exogenous contrast agents. With use of exogenous contrast dyes tumor contrast can be improved as a result of tissue-dependent spatial distributions of the dyes and dye lifetimes [24, 25]. Currently, ICG is the only FDA-approved compound suitable for DOT, having an absorption and fluorescence spectra in the

NIR window. ICG has been demonstrated to enhance absorption of human breast cancer *in vivo* [336, 371, 372].

In principle, fluorescence signals can provide greater detection sensitivity and specificity compared to absorption signals, as well as access to new information about tissue micro-environment, such as pO_2 , pH, and intracellular calcium concentration [373, 374].

Sevick-Muraca and co-workers have demonstrated fluorescence imaging using ICG in canine breast cancer [375] and in realistic breast phantoms [376]. In our laboratory, we have recently demonstrated the first 3D fluorescence diffuse optical tomography (FDOT) of *in vivo* human breasts and breast cancer [26]. In Figure 12, one example of FDOT is given. Endogenous optical signals and fluorescence signals from ICG injection were measured from a 46-year-old pre-menopausal female diagnosed with invasive ductal carcinoma. Selected slices from 3D DOT reconstructions of endogenous optical properties (i.e. THC , StO_2 , μ'_s) and 3D FDOT reconstruction of ICG concentration exhibit large contrast. In a volume that was confirmed to be the tumor region by Gd uptake and radiology reports, the reconstructed THC , μ'_s and ICG concentrations were higher and StO_2 somewhat lower than the surrounding tissue. When we take 3D iso-surface images of THC , μ'_s and ICG concentration contrast with iso-values set to three standard deviations above their means. The iso-surfaces of the three contrasts overlay quite well, and the volumetric differences may be due to real tissue physiology variation. Other groups have now started to report more cases of *in vivo* FDOT in human patients with enhancement of tumor contrast [275, 276].

3.3. Therapy Monitoring

Neoadjuvant (i.e. pre-surgical) chemotherapy is an important therapeutic approach for women with locally advanced breast cancer that can increase long-term survival. Typically, such breast cancers are large (e.g. larger than 5 cm) and many anticipated responses to drugs are vascular in nature. For treatment optimization, it is desirable to monitor tumor responses during this process. For example, alterations in tumor biology and physiology can be seen early following cytotoxic chemotherapy and can be a marker of tumor response. Dynamic contrast enhanced MRI (DCE-MRI) has been used to monitor the change in both tumor size and vascularity following preoperative (neoadjuvant) chemotherapy in patients with locally advanced breast cancer [377–379]. Results demonstrate that even before clinical or imaging evidence of tumor shrinkage are measurable, changes in tumor vascularity can be seen through blunting of the dynamic enhancement curve following intravenous administration of gadolinium contrast agents. Furthermore, Positron Emission Tomography (PET) has found that metabolic changes of cancer due to cancer therapy can precede morphological changes by up to eight days [380, 381]. DCE-MRI and PET, however, are expensive and are not practical for frequent monitoring.

The feasibility of applying diffuse optical techniques in the context of cancer therapy monitoring has been demonstrated successfully in imaging instruments [341, 350, 382, 383] and with hand-held probes [84, 325, 384]. Thus far, tumor size and/or properties (e.g. THC , HbO_2 , water) detected by diffuse optical methods have correlated well with patient response to chemotherapy (i.e. complete, partial or none) [382–384].

3.4. Outlook: Optical Mammography

The field of diffuse optics, as applied to breast cancer imaging and monitoring, is rapidly evolving. Innovative instrumentation and reconstruction algorithms have been developed and combined to improve image fidelity, and these factors continue to improve over time. In addition, more statistics from *in vivo* breast cancer data provide insight into the biological issues and guidance for more directed instrumentation and algorithm development.

Spatial resolution and detectability are two major concerns about optical mammography. In general, these factors depend on the size and contrast of the heterogeneities we investigate. To date, a few groups have demonstrated that the tumors of order 1 cm are readily detectable with excellent sensitivity and specificity based on, for example, total hemoglobin concentration contrast [122,306,370]. Tumor sensitivity and specificity decreases as the lesion size becomes smaller [370], with 4–7 mm being the state-of-the art resolution demonstrated in tissue phantoms at tumor-to-normal ratios of 2× to 4× [250]. The resolution of a DOT system depends on the many factors, such as the number of sources and detectors, the field of view covered by the optodes and optode spacings, the tissue volume to be reconstructed, the depth of target (e.g. tumor), the target-to-background contrast, the presence of *a priori* spatial or spectral information, and fundamentally on the physics of photon propagation in tissues [229]. While the current level of DOT resolution poses some barriers for its use as a stand-alone imaging modality for cancer screening, cancer detectability is not necessarily limited by resolution and can be utilized in complementary fashion with other imaging modalities in tumor detection and diagnosis. Strategies to further improve detectability and/or resolution are (1) to find other optical contrast related to tumoral physiological changes, (which may even occur before angiogenic changes) (2) to use anatomical constraints given by other imaging modalities to improve DOT resolution, and (3) to enhance tumor-to-normal contrast based on molecular-targeted (fluorescent/absorption) probes.

In the search for optical contrast to enhance differentiation between tumor and normal tissues, research groups are employing broader wavelength ranges to explore water, lipid and collagen concentrations, bound water fraction, and refractive index [312, 313, 348, 358, 360, 385–387]. Some of the most recent investigations have found that water concentration is higher in tumors compared to normal tissues [312,313,348,358,360], that lipid concentration is lower in tumors compared to normal tissues [312, 360], that the bound water fraction [385] and refractive indices [387] may provide novel tumor contrast as well. In addition, using diffuse correlation spectroscopy, experimenters have found that blood flow in breast cancer is larger than in normal breast tissues [84, 86].

Several groups have incorporated concurrent optical measurements with other imaging modalities. The multi-modal approach can potentially overcome structural resolution limitations of DOT, using the spatial information provided by other imaging modalities to constrain the DOT inverse problem. This multi-modal approach also provides extra physiological information for the other imaging modalities. Thus far advances have been made in three fronts: concurrent measurements with MRI [336, 371, 388–392], 3D X-ray mammography [213, 393, 394], and ultrasound [340, 347, 350, 383, 395–397].

The most effective clinical role for diffuse optical tomography in the screening, diagnosis, and treatment monitoring of breast cancer has yet to be determined. It is clear, however, that DOT and DOS provide exquisite functional information directly related to tumor pathophysiology (e.g. metabolic activity, angiogenesis, and blood flow/concentration), and complementary to structural and functional information provided by conventional imaging. Furthermore, advances in diffuse optical tomography of breast are critical for exploitation of the advances of *molecular imaging* [24, 270, 398], an emerging field of medicine with promise of new generation optical contrast agents. Photo-acoustic, optical mammography was also recently reported [399].

4. Optical Monitoring of Cerebral Hemodynamics

4.1. Clinical Relevance of Diffuse Optics for Cerebral Hemodynamics

The ability to measure cerebral hemodynamic responses to stimuli has important implications in fundamental neuroscience, clinical modeling and the clinic. A key concept in the field concerns the coupling between functional stimulation and regional changes in cerebral blood flow (CBF). This phenomenon is often referred to as activation flow coupling (AFC). AFC has been known for over a century but is still poorly understood [400–403]. Since most neuroimaging methods rely on AFC as an indicator of neuronal activity, a detailed characterization of AFC under normal conditions improves understanding of normal as well as pathological brain physiology, and it permits us to relate hemodynamic quantities to neuronal activity.

Hemodynamics play other crucial roles in the brain. Cerebral well-being is dependent on adequate and continuous delivery of oxygen and on the clearance of the by-products of oxygen consumption, e.g. carbon dioxide. In a simplistic picture, oxygen-saturated red blood cells (RBCs) are pumped through the arterial network to smaller vessels and into the microvasculature. Tissues are perfused by the microvasculature. Oxygen exchange occurs by diffusion at the microvascular level and the by-products are cleared, along with oxygen depleted RBCs, on the venous side (see Section 2.13). In general, this phenomena is tightly autoregulated by a variety of processes, including changes in the vascular resistance [404], to maintain constant blood perfusion in spite of changes in local pressures and other factors (see Figure 15 inset). In brain, local perfusion pressure (i.e. “cerebral perfusion pressure” (CPP)) is defined as the difference between the mean-arterial pressure (MAP) and the intracranial pressure (ICP). It is very difficult to monitor cerebral autoregulation in clinical settings. ICP can be monitored by invasive probes [405], but in many populations, clinicians prefer *not* to accept the risks of invasive probes; in this case MAP and neurologic signs are utilized as surrogate markers for ICP.

Microvascular CBF is particularly difficult to measure at the bed-side. To date many attempts have been made to measure CBF, all with unique advantages and disadvantages. Below, we list some of the major modalities employed *in the clinic; research only* modalities, which are very promising but not yet widely utilized are not included in the list [406]:

- i. *Laser speckle* techniques such as *Laser Doppler Flowmetry (LDF)* rely on physical principles similar to those of DCS [50]. These techniques can measure *microvascular* CBF. However, practical problems in detection and overly simplified modeling largely restrict the use of LDF to the single scattering and limit its uses to about ~ 0.5 mm below the tissue surface (see Section 1). Therefore, the skull must be removed to access the brain, and clinical applications are limited to intraoperative measurements [407–409]. Recent, developments now permit penetration up to ~ 5 mm in skeletal muscles [410], but the technology is not yet useful for non-invasive, transcranial monitoring. Another variant of the method, *laser speckle flowmetry (LSF)* using a CCD camera, has recently been introduced to examine cerebral hemodynamics in rodents [411, 412]. It has not yet been widely commercialized, however, and its application in humans is limited to measurements during open-skull surgery [409].
- ii. *Doppler ultrasound* uses the frequency shifts in an ultrasound beam to image blood flow. However, due to technical issues only the proximal portions of the intracranial arteries can be insonated. Thus far the ultrasound method has only been used to measure blood flow velocity through large vessels, i.e. *macrovascular blood flow velocity* [413, 414]. Furthermore, since velocity changes predict CBF variation only if vessel diameters do not change, transcranial Doppler ultrasound (TCD) has limited utility in important clinical applications such as stroke evaluation [415], with its success arising in patients with proximal arterial occlusions [416]. Nevertheless, TCD remains a primary clinical modality for serial monitoring of CBF at the bedside.
- iii. *Arterial Spin Labeling MRI (ASL)* [417–419] and *Flow-Sensitive Alternating Inversion Recovery MRI (FAIR)* [420, 421] are two modalities of magnetic resonance imaging (MRI) sensitive to perfusion/flow that have been used extensively in the brain. Additional MRI modalities are available for perfusion measurements, but they require bolus injections. Although these MRI methods offer a “full-head” imaging capability and can readily be co-registered with the high-resolution anatomical information of MRI and other functional MRI modalities (e.g blood oxygen level dependent, BOLD), their use in clinical settings is limited. For example, the presence of strong magnetic fields makes them difficult to use in intensive care units, and their low through-put relegates their use to a single-shot measurement where the patients are transferred into the magnet for one ~ 30 – 60 minute observation. Furthermore, the instruments and instrument-time are expensive. Some difficulties also arise from patient specific problems; for example, it is sometimes difficult to hold infants still, and some patients are claustrophobic.
- iv. *Xenon Computed Tomography (Xenon CT)* is used in the clinic for measurements of “full-head” maps of cerebral blood flow [422, 423]. The modality dynamically scans the head using a CT system while the patient inhales Xenon gas. The method is gaining acceptance as a complementary modality in some intensive care units, i.e., in preference over MRI and PET modalities. As in the case of MRI, however, the use of Xenon-CT is limited to few time-points, even though quasi-portable

variants are available to reduce patient transport issues. Finally, the instrument and the xenon gas are quite expensive, and xenon gas is also known to alter CBF which makes quantification more difficult.

- v. *Positron Emission Tomography (PET)* is a diagnostic modality that offers direct measurements of a variety of physiological parameters including blood flow [424], glucose metabolism [425] and oxygen metabolism [424]. However, use of radioactive materials limits its applicability in many clinical settings such as the intensive care unit [426]. PET shares problems with MRI and Xenon CT as per expense, availability, patient discomfort and limitations for long-term monitoring. Finally, PET requires injection and/or inhalation of chemicals and uses radioactive materials.

Clearly, an optimal method for hemodynamic monitoring has yet to be developed. A strong need exists for an inexpensive, continuous, non-invasive instrument for measurement of CBF, and the technologies described in this review offer a great deal of promise along these lines. Diffuse optical tomographic and spectroscopy (i.e. DOT and DOS) methods have been demonstrated to measure blood volume, blood oxygenation and changes thereof, in research and clinical settings; in addition, through some maneuvers, it is also possible to employ DOS/DOT for the measurement of blood flow. DOS/DOT have been particularly successful in infants [144, 427–433]. The development of DCS has had even more impact, however, because it permits clinicians to measure several hemodynamic parameters independently with non-invasive probes (i.e. the hemoglobin concentrations and the blood flow), thus permitting estimation of changes in oxygen metabolism.

The primary advantages of diffuse optics for monitoring cerebral hemodynamics in the clinic are as follows:

- i. The technique is non-invasive and involves no risk to the patient (e.g. no ionizing radiation, no gases to be inhaled or drugs to be injected).
- ii. The technique samples and reports results in real-time.
- iii. The technique can track changes over long periods (hours to days), in contrast to single-time-point modalities (e.g MRI, PET, Xenon-CT).
- iv. The technique can sample more than one spatial location, permitting examination of regional differences in the brain.
- v. The technique can be employed at the bedside; critically ill patients need not be moved.
- vi. The technique is applicable to measurements patients of all ages, from pre-mature born infants to adults.
- vii. The instrumentation is relatively inexpensive and the per-measurement costs are minimal.

Diffuse optical measurements also have limitations: relatively short penetration beyond the skull/scalp, relatively coarse spatial resolution, limited structural/morphological information which makes partial volume effects more difficult to account for, and difficulties with the

assignment of absolute optical properties. Furthermore, as with any new modality proposed for clinical use, diffuse optical monitors must demonstrate clinical utility in large, controlled trials before mainstream acceptance is assured. For applications in neurology, portable devices that monitor hemodynamics in large tissue volumes are popular due to the relative simplicity of the instrumentation and analysis algorithms, and due to simple, comfortable probe-heads. Several topographic (2D) and tomographic (3D) imagers are used now to map hemodynamic changes locally or globally [434, 435], and various approaches ranging from dense probe designs to utilization of secondary data have been considered to optimize the spatial resolution [135, 436]. Given these pros and cons, we now consider *clinical* applications at the present state of diffuse optics technology.

4.2. Selected Translational Results

Optical imaging – ranging from microscopy methods to diffuse optics – has found a myriad of applications in brain imaging [434,435]. It is beyond the scope of this review to describe this wide-ranging field. Here we limit our discussion to those translational applications wherein diffuse optical methods are used in the clinic.

Broadly speaking, two groups of studies have been employed: (1) Those using commercial devices [435], and (2) those using state-of-the-art research devices and algorithms [435].

Thousands of commercial instruments are currently in use with a rapidly increasing number of studies being published as a result [435]. Unfortunately, some of these studies have been done without state-of-the-art instrumentation and/or algorithms, and over the years, the lack of optimized methodology has led to some debate over the utility of (particularly) NIRS/DOS [437–439]. We believe that NIRS/DOS and related techniques offer a great deal of promise and with improvements in technology and improvements in physical understanding about photon propagation through tissues and its modeling, the utility of NIRS/DOS will rapidly become more apparent. Commercial systems are, indeed, crucial for the clinical penetration of the technology, but until large-scale clinical trials have been performed, instrumentation needs to be handled as research tools. At this point, at least three [435] devices have the USA Food and Drug Administration’s approval for use in patient populations.

Amongst many potential applications, NIRS/DOS has been utilized for cerebral monitoring of adults with traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) [440–445], ischemic stroke [80, 277–280, 446–453], sleep apnea and other sleep disorders [454–457], intraoperative brain monitoring [458, 459] and in neonates and children [433, 460–462]. This list is not exhaustive; it is meant to give a “flavor” of the field. Over the years, NIRS/DOS has been utilized for a very wide-range of applications, but unfortunately largely for feasibility demonstrations.

4.2.1. Hemodynamics of Healthy Brain—Figure 13(a) shows a schematic and data from two studies conducted in our laboratory [65, 66]. Here we have combined NIRS/DOS and DCS methods in a hybrid instrument [65, 77]. For NIRS/DOS, three, amplitude modulated (70 MHz, “frequency-domain”) lasers operating at 690nm, 785nm and 830nm were employed as light sources. A photomultiplier tube (PMT) was used as a detector and

its output was fed to a radio-frequency, homodyne, I&Q demodulation electronics box which calculated the relative amplitude and phase [463]. NIRS/DOS data was analyzed using the “differential pathlength factor” (DPF, see Section 2.8.2) formulation [143]. For DCS, a long coherence length, continuous wave laser was used as a source. Eight photon-counting, fast avalanche-photodiodes (APDs) and a multi-channel autocorrelator board was used. DCS data was analyzed using a semi-infinite medium solution (see Section 2.9.3) [65,76,77]. The fiber optics from the two devices were mounted on the same probe and were time shared; data was acquired in an interlaced sequence by utilizing optical switches.

Figure 13(b) shows data from a hypercapnia experiment wherein we have measured the CBF response to increased carbon dioxide (CO₂) breathing. We measured CBF in five subjects at rest, and during 4–6 minute periods of increased cerebral carbon dioxide induced by breathing a 6% CO₂ gas mixture. In healthy subjects, hypercapnia causes a well-defined increases in CBF [464]. We observed a sustained increase of mean CBF of $35.4 \pm 9.6\%$, and an accompanying increase in EtCO₂ of 14.7 ± 4.7 mmHg. This relative rate corresponds to a $2.4 \pm 0.4\%$ CBF increase per mmHg of EtCO₂, a number well within the literature values (i.e. 2–3.6%/mmHg). During this investigation we also placed a laser Doppler probe on the scalps of a subset of volunteers. The probe enabled us to directly compare CBF measured by DCS to scalp flow measured by laser Doppler flowmetry (LDF) during activation. Figure 13(b) shows these measurements for one subject, along with measured EtCO₂. Notice the scalp flow signal is small compared to CBF measured by DCS and largely unchanged with changes in EtCO₂ (right vertical axis). These studies demonstrate the DCS signal *does not* arise from changes in scalp blood flow, but some contamination is inevitable.

Figure 13(c–d) show data from an experiment where the subject was asked to carry out a task that would stimulate the sensorimotor cortex [66]. First, we localized the hand sensorimotor cortical area contralateral to the dominant hand according to the 10–20 system [465]. The probe (Figure 13(a)) was placed and secured over this region. For the activation period, the subject was instructed to tap index and middle fingers against the thumb at 3 Hz. A blocked design of fifteen such stimuli was used. In order to illustrate the local nature of the observed response, we have also taken data where the whole process was repeated with probe placed ~2 cm frontal to the sensorimotor cortex. Figure 13(c) shows the results of one such study. None of the observed quantities show any changes that are correlated with the stimuli despite the fact that stimuli were presented during the time period shown by vertical bars. Figure 13(d) shows the population averaged results from seven subjects; a robust change correlated with the activation was observed in all quantities. Mean changes observed were $39 \pm 10\%$ for rCBF, $12.5 \pm 2.8 \mu\text{M}$ for HbO₂, $-3.8 \pm 0.8 \mu\text{M}$ for Hb, $8.3 \pm 2.3 \mu\text{M}$ for

THC and $10.1 \pm 4.4\%$ for rCMRO₂. rCBF changes are well within the range of values determined by MRI [466, 467], [$H^2 \text{ }^{15}\text{O}$] PET [468], [^{133}Xe] [469] and [$^{11}\text{CH}_3$] PET [470] for similar measurement stimuli, i.e. 21% – 60%. Mean oxy-, deoxy- and total-hemoglobin changes agree quantitatively with increases reported by BOLD of 2 – 4% [466, 471]. The increase in CMRO₂ is within the range of values (9% to 29%) from hybrid MRI measurements [466]. The ratio of rCBF to rCMRO₂ is also agreement with data reported by hybrid MRI techniques [466, 472] which range from two to four.

Overall, these results demonstrate the ability of NIRS/DOS and DCS to probe local changes in cerebral hemodynamics.

4.2.2. Diffuse Optics versus fMRI—Since NIRS/DOS and DCS both employ fiber-optics to deliver and detect light, they are readily adaptable for use concurrently in the MRI-magnet using MRI compatible probes and long optical fibers. This permits cross-validation studies, as well as utilization of MRI derived spatial information for diffuse optical data analysis. In a series of papers, Boas and coworkers have compared NIRS/DOS with BOLD and ASL MRI; in so doing, they have also developed models to describe the physiological origin of the BOLD signal, to account for partial volume effects in NIRS/DOS signals and to derive composite models to estimate $rCMRO_2$ [473–478].

Here we highlight one study [474] that compares the temporal properties of NIRS/DOS signals with BOLD and ASL-MRI. As shown in Figure 14, the temporal evolution of NIRS/DOS determined ΔHbO_2 and ΔHb agree with ASL-MRI and ΔHb agrees with BOLD. Notice how ASL-MRI derived CBF, ΔHbO_2 and ΔHb maxima arise earlier than BOLD and ΔHb maxima. ΔHb and BOLD are strongly correlated while ΔHbO_2 and BOLD exhibit a weaker correlation, in agreement with biophysical models for the BOLD signals. It has long been assumed that NIRS/DOS measures of ΔHbO_2 (or blood volume) would correlate with CBF under many circumstances. These results explicitly demonstrate strong correlation between these signals.

4.2.3. Longitudinal Bed-Side Monitoring—One of the most promising applications of diffuse optics is at the bed-side for longitudinal monitoring of cerebral hemodynamics. To demonstrate this idea and to test the feasibility of hybrid NIRS/DOS-DCS measurements on a critically ill population of acute, ischemic stroke patients, we have induced orthostatic stress by changes in head-of-bed positioning as shown in Figure 15 [80]. Our hypothesis was that in response to this challenge, the impaired cerebral autoregulation would lead to larger changes in cerebral hemodynamics in the infarcted hemisphere by comparison to the “healthy”, contralateral hemisphere.

To this end, diffuse optical measurements were obtained from patients with acute hemispheric ischemic stroke ($n=17$, mean age 65 years) with probes placed on the forehead near the frontal poles (Figure 15 (Top, right)). CBF and hemoglobin concentrations were measured sequentially for 5 min each at HOB positions: 30, 15, 0, –5 and 0 degrees and normalized to their values at 30 degrees. Figure 15(bottom) shows continuous CBF data taken over 25 minutes from a representative subject with acute ischemic stroke. A clear differentiation is observed between two hemispheres; this differentiation was statistically significant over the whole population. In contrast, when an age-matched group with “vascular risk factors” was studied, i.e. risk factors such as cigarette smoking, high blood pressure etc, we did not observe any hemispherical differentiation. Interestingly, in ~25% of subjects, we have observed that CBF was *not* maximized at –5 degrees; rather it was *minimized* at this HOB angle. This paradoxical response was observed in traumatic brain injury patients [479]. The effect was likely a result of a substantial increase in intra-cranial pressure, a parameter that is not routinely monitored in ischemic stroke patients.

This example illustrates that diffuse optical instrumentation can be deployed at the bed-side of critically ill-patients, and that it may be promising for use as a tool to optimize patient care based on cerebral hemodynamic measurements in *real-time*.

4.2.4. Full Head, 3D tomography in Neonates—Amongst numerous applications of NIRS/DOS to neonatal studies, few groups have reported three-dimensional, tomographic imaging of the whole head [460, 480–484]. As discussed in previous sections, 3D tomography with NIRS/DOS has mostly been limited to less absorbing tissues such as the breast. New results, while still very preliminary, demonstrate the feasibility of whole-head imaging in neonates by taking advantage of their smaller head circumferences and thinner skulls. When combined with other modalities such as Ultrasound, MRI or CT, this approach could provide valuable physiologic information in addition to the mostly morphological information available via other modalities. Figure 16 (from Ref [480]) shows a photo of the probe on a subject and coronal sections of images of blood volume and blood oxygen saturation as it compares to an ultrasound image from a 34-week gestational age infant. In general, 3D scans such as this one show a left/right symmetry between hemispheres, except in the presence of a condition such as a hemorrhage. The images shown are from an infant who was diagnosed with a left-sided intraventricular hemorrhage which is also visible on the ultrasound image. A clear increase in blood volume is evident on the left hemisphere, consistent with the presence of the hemorrhage. In the blood oxygen saturation image, a small region of significantly low oxygen saturation (10% vs 62% on the contralateral side) that is apparent; it is more lateral and superficial than both the ultrasound and blood volume images. This observation may be attributed to the presence of an ischemic penumbra surrounding hemorrhagic lesions, or it may be due to issues with optical image reconstruction. Nevertheless, the authors reported data from ~40 infants showing the feasibility of 3D tomography in neonates. This type of approach may become more common in the future with improved probe designs, detectors and newer reconstruction algorithms.

5. Other Applications

Due to space constraints, we have chosen to focus on breast and brain applications. Other applications include, but are not limited to, imaging and monitoring in preclinical and clinical oncology [485], monitoring of muscle diseases and physiology [435, 486], photodynamic therapy planning [487, 488], in-surgery monitoring [458] and guidance [273, 489], dermatology [490] and tomography of finger joint physiology and disease [491, 492]. The biomedical optics field has, more broadly, also been branching into many other clinically exciting directions with tools ranging from optical coherence tomography to photo-acoustic tomography and microscopy to optical projection tomography. Interested readers will find more information about these subjects in references [493–497].

6. Conclusion

In this review, we have outlined the physical and algorithmic foundations of near-infrared (NIRS) or diffuse optical (DOS) spectroscopy, diffuse correlation spectroscopy (DCS), and diffuse optical tomography (DOT). We have showcased their applications in two sub-fields: optical mammography and cerebral hemodynamics. These subfields were chosen because

they are, arguably, the two areas with the largest amount of diffuse optics research activity. The field has now evolved to a point wherein substantial effort is oriented towards clinical application. In the near future, improved understanding of photon propagation in tissues, better access to algorithms and computational resources, new developments in laser and detector technologies, and increasing amounts of clinical data will enable these developments.

Acknowledgments

This work was partially funded by NIH-grants HL-57835, NS-60653, RR-02305, EB-07610, NS-45839, CA-126187, Thrasher Research Fund (NR 0016) and Fundació Cellex Barcelona. The authors gratefully acknowledge many fruitful discussions and interactions over the years with colleagues from the biomedical optics community at the University of Pennsylvania and, indeed, throughout the world. At UPenn, much of the research in this review was facilitated by sustained collaborations over many years with Britton Chance, Mitchell Schnall, Joel Greenberg, John Detre, Daniel Licht, Theresa Busch, Mark Rosen, Joseph Culver, Guoqiang Yu, and David Boas.

Glossary

α	Fraction of dynamic photon scattering events in medium
g	Scattering anisotropy factor
G_0	Homogeneous Green's Function
c_i	Concentration of the i^{th} chromophore
g_1	Normalized electric field temporal auto-correlation function, $g_1(\mathbf{r}, \tau, t) = G_1(\mathbf{r}, \tau, t) / \langle E(\mathbf{r}, t) E^*(\mathbf{r}, t) \rangle$
g_2	Normalized intensity auto-correlation function, $g_2(\mathbf{r}, \tau, t) = G_2(\mathbf{r}, \tau, t) / \langle I(t) \rangle^2$
G_1	Electric field temporal auto-correlation function, $G_1(\mathbf{r}, \tau, t) = \langle E^*(\mathbf{r}, t) E(\mathbf{r}, t + \tau) \rangle$
G_2	Intensity auto-correlation function, $G_2(\mathbf{r}, \tau, t) = \langle I(\mathbf{r}, t) I(\mathbf{r}, t + \tau) \rangle$
D	Photon Diffusion Coefficient, $D = v \ell_{tr} / 3$
D_b	Brownian Diffusion Coefficient
ϵ	Extinction coefficient
λ	Wavelength of Light (nm)
$L(\mathbf{r}, \Omega, \hat{t})$	Radiance; power per unit area per unit angle traveling in $\hat{\Omega}$ direction at position $\mathbf{r}$ and time t
$E(\mathbf{r}, \Omega, \hat{t})$	Light electric field traveling in $\hat{\Omega}$ direction at position $\mathbf{r}$ and time t
ℓ_{tr}	Transport mean free path, $\ell_{tr} \approx 1 / \mu'_s$
$E(\mathbf{r}, t)$	Total light electric field at position $\mathbf{r}$ and time t
$I(\mathbf{r}, t)$	Light field intensity (i.e., $ E(\mathbf{r}, t) ^2$) at position $\mathbf{r}$ and time t
μ'_s	Reduced Scattering Coefficient, $\mu'_s = \mu_s (1 - g)$

μ_a	Absorption Coefficient
μ_s	Scattering Coefficient
v	Speed of light in tissue
$\langle r^2(\tau) \rangle$	The mean-square displacement in time τ of the scattering particles (e.g. red blood cells)
$\Phi(\mathbf{r}, t)$	Photon-Fluence Rate at position $\mathbf{r}$ and time t
$U(\mathbf{r})$	Photon-Fluence Rate; expressed in the frequency domain, $\Phi(\mathbf{r}, t) = U(\mathbf{r})e^{-i\omega t}$
ω	Laser/Source Modulation Frequency
BFI	Blood Flow Index estimated by DCS (i.e., αD_b)
CBF	Cerebral Blood Flow
CMRO₂	Cerebral Metabolic Rate of Oxygen
CT	Computed Tomography
CW	Continuous Wave
DCS	Diffuse Correlation Spectroscopy
DOS	Diffuse Optical Spectroscopy
DOT	Diffuse Optical Tomography
FD	Frequency Domain
HbO₂	Oxy-Hemoglobin Concentration
Hbr/Hb	De-oxy Hemoglobin Concentration
ICG	Indocyanine Green
MRI	Magnetic Resonance Imaging
NIRS	Near Infrared Spectroscopy
PET	Positron Emission Tomography
RBCs	Red Blood Cells
StO₂	Tissue Blood Oxygen Saturation
THC	Total Hemoglobin Concentration
TRS	Time Domain Spectroscopy

References

1. Cutler M. Transillumination of the breast. *Surg Gynecol Obstet.* 1929; 48:721–727.
2. Jobsis FF. Noninvasive infrared monitoring of cerebral and myocardial sufficiency and circulatory parameters. *Science.* 1977; 198:1264–1267. [PubMed: 929199]
3. Jobsis-vanderVliet FF, Jobsis PD. Biochemical and physiological basis of medical near-infrared spectroscopy. *Journal of Biomedical Optics.* 1999; 4:397. [PubMed: 23014611]

4. Jöbsis-vanderVliet FF. Discovery of the near-infrared window into the body and the early development of near-infrared spectroscopy. *Journal of Biomedical Optics*. 1999; 4:392. [PubMed: 23014610]
5. Yodh A, Chance B. Spectroscopy and imaging with diffusing light. *Physics Today*. 1995; 48(3):34–40.
6. Chance, B.; Alfano, R. *Proceedings of Optical Tomography, Photon Migration, and Spectroscopy of Tissue and Model Media: Theory, Human Studies, and Instrumentation*. SPIE; 1995. p. 2389
7. Patterson MS, Moulton JD, Wilson BC, Berndt KW, Lakowicz JR. Frequency-Domain reflectance for the determination of the scattering and absorption properties of tissue. *Appl Opt*. 1991; 30(31): 4474–4476. [PubMed: 20717230]
8. Patterson MS, Chance B, Wilson BC. Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. *Appl Opt*. 1989; 28:2331–2336. [PubMed: 20555520]
9. Gratton, E.; Mantulin, W.; Ven, MJ.; van de Ven, M.; Fishkin, J.; Maris, M.; Chance, B. The possibility of a near-infrared imaging system using frequency-domain methods. *Japan: Hamamatsu*; 1990. p. 183-189.
10. Delpy DT, Cope M, van der Zee P, Arridge S, Wray S, Wyatt J. Estimation of optical pathlength through tissue from direct time of flight measurement. *Phys Med Biol*. 1988; 33:1433–1442. [PubMed: 3237772]
11. Jacques SL. Time resolved propagation of ultrashort laser pulses within turbid tissues. *Appl Opt*. 1989; 28:2223–2229. [PubMed: 20555503]
12. Benaron DA, Stevenson DK. Optical time-of-flight and absorbance imaging of biologic media. *Science*. 1993; 259(5100):1463–1466. [PubMed: 8451643]
13. O’Leary MA, Boas DA, Chance B, Yodh AG. Refraction of diffuse photon density waves. *Phy Rev Lett*. 1992; 69(18):2658–2661.
14. Boas DA, O’Leary MA, Chance B, Yodh AG. Scattering and wavelength transduction of diffuse photon density waves. *Phys Rev E*. 1993; 47(5):R2999–R3002.
15. Fishkin JB, Gratton E. Propagation of photon density waves in strongly scattering media containing an absorbing ‘semi-infinite’ plane bounded by a straight edge. *J Opt. Soc. Am. A*. 1993; 10:127–140. [PubMed: 8478741]
16. Schmitt JM, Knuttel A, Knutson JR. Interference of diffusive light waves. *J Opt. Soc. Am. A*. 1992; 9:1832. [PubMed: 1403242]
17. Tromberg BJ, Svaasand LO, Tsay T, Haskell RC. Properties of photon density waves in multiple-scattering media. *Appl Opt*. 1993; 32:607–616. [PubMed: 20802732]
18. Sevick EM, Lakowicz JR, Szmecinski H, Nowaczyk K, Johnson ML. Frequency domain imaging of absorbers obscured by scattering. *J.Photochem.Photobiol.B: Biol*. 1992; 16:169–185.
19. Johnson CC. Optical diffusion in blood. *IEEE Transactions on Biomedical Engineering*. 1970; BME17:129–133. [PubMed: 5463589]
20. Ishimaru, A. *Wave Propagation and Scattering in Random Media*. San Diego: Academic Press, Inc.; 1978.
21. Furutsu K. On the diffusion equation derived from the space-time transport equation. *J Opt. Soc. Am. A*. 1980; 70:360.
22. Groenhuis RAJ, Ferwerda HA, Bosch TJJ. Scattering and absorption of turbid materials determined from reflection measurements, I. theory. *Appl Opt*. 1983; 22:2456–2462. [PubMed: 18196156]
23. Yodh, AG.; Boas, DA. chapter *Functional Imaging with Diffusing Light*. CRC Press; 2003. *Biomedical Photonics*; p. 21p. 1-45.
24. Ntziachristos V, Chance B. Probing physiology and molecular function using optical imaging: applications to breast cancer. *Breast Cancer Res*. 2001; 3(1):41–46. [PubMed: 11250744]
25. Hawrysz DJ, Sevick-Muraca EM. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. *Neoplasia*. 2000; 2(5):388–417. [PubMed: 11191107]

26. Corlu A, Choe R, Durduran T, Rosen MA, Schweiger M, Arridge SR, Schnall MD, Yodh AG. Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. *Optics Express*. 2007; 15(11):6696–6716. [PubMed: 19546980]
27. Ferrari M, Hanley DF, Wilson DA, Traystman RJ. Redox changes in cat brain cytochrome-c oxidase after blood-fluorocarbon exchange. *American Journal of Physiology-Heart and Circulatory Physiology*. 1990; 258(6):1706–1713.
28. Gratton G, Corballis PM, Cho E, Fabiani M, Hood DC. Shades of gray matter: noninvasive optical images of human brain responses during visual stimulation. *Psychophysiology*. 1995; 32:505–509. [PubMed: 7568645]
29. Gratton G, Fabiani M, Friedman D, Franceschini MA, Fantini S, Corballis PM, Gratton E. Rapid changes of optical parameters in the human brain during a tapping task. *J Cogn Neuroscience*. 1995; 7:446–456.
30. Arridge SR, Schotland JC. Optical tomography: forward and inverse problems. *Inverse Problems*. 2009; 25(12):123010.
31. Boas DA, Brooks DH, Miller EL, DiMarzio CA, Kilmer M, Gaudette RJ, Zhang Q. Imaging the body with diffuse optical tomography. *IEEE Signal Processing Magazine*. 2001; 18:57–75.
32. Hebden JC, Arridge SR, Delpy DT. Optical imaging in medicine: I. experimental techniques. *Phys Med Biol*. 1997; 42:825–840. [PubMed: 9172262]
33. Hebden JC, Delpy DT. Diagnostic imaging with light. *Br J Radiol*. 1997; 70 Spec No:S206–S214. [PubMed: 9534736]
34. Arridge SR, Hebden JC. Optical imaging in medicine: II. modelling and reconstruction. *Phys. Med. Biol*. 1997; 42(5):841–854. [PubMed: 9172263]
35. Villringer A, Chance B. Non-invasive optical spectroscopy and imaging of human brain function. *Trends Neurosci*. 1997; 20:435–442. [PubMed: 9347608]
36. Clark NA, Lunacek JH, Benedek GB. A study of brownian motion using light scattering. *Am J Phys*. 1970; 38:575–585.
37. Fuller GG, Rallison JM, Schmidt RL, Leal LG. The measurement of velocity gradients in laminar flow by homodyne light-scattering spectroscopy. *J.Fluid Mech*. 1980; 100:555–575.
38. Tong P, Goldburg WI, Chan CK, Sirivat A. Turbulent transition by photon-correlation spectroscopy. *Phys. Rev. A*. 1988; 37:2125–2133. [PubMed: 9899906]
39. Bertolotti M, Crosignani B, Di Porto P, Sette D. Light scattering by particles suspended in a turbulent fluid. *J Phys. A*. 1969; 2:126–128.
40. Bourke PJ, Butterworth J, Drain LE, Egelstaff PA, Jakeman E, Pike ER. A study of the spatial structure of turbulent flow by intensity-fluctuation spectroscopy. *J.Phys.A*. 1970; 3:216–228.
41. Tanaka T, Riva C, Ben-Sira I. Blood velocity measurements in human retinal vessels. *Science*. 1974; 186:830–831. [PubMed: 4469681]
42. Stern MD. In vivo evaluation of microcirculation by coherent light scattering. *Nature*. 1975; 254:56–58. [PubMed: 1113878]
43. Bonner, RF.; Nossal, R. chapter Principles of laser-Doppler flowmetry. Vol. 107. Boston: Kluwer Academic Publishers; 1990. Laser-Doppler blood flowmetry; p. 17-45.
44. Pusey, PN.; Vaughan, JM. chapter Light Scattering and Intensity Fluctuation Spectroscopy. Vol. 2. London: The Chemical Society; 1975. Dielectric and Related Molecular Processes X - Ed. M. D. Specialist Periodical Report.
45. Berne, BJ.; Pecora, R. Dynamic Light Scattering with Applications to Chemistry, Biology, and Physics. Malabar, FL: Krieger; 1990.
46. Brown, W. Dynamic Light Scattering: The Method and Some Applications. New York: Clarendon; 1993.
47. Cummings, HZ.; Pike, ER. Photon Correlation and Light-Beating Spectroscopy. New York: Plenum; 1974. Vol. 3 of NATO Advanced Study Institute Series B: Physics.
48. Cummings HZ, Swinney HL. Light beating spectroscopy. *Prog. Opt*. 1970; 8:133–200.
49. Valkov AY, Romanov VP. Characteristics of propagation and scattering of light in nematic liquid crystals. *Sov. Phys. JETP*. 1986; 63:737–743.

50. Briers JD. Laser doppler, speckle and related techniques for blood perfusion mapping and imaging. *Physiol. Meas.* 2001; 22:R35–R66. [PubMed: 11761081]
51. Riva CE, Ross B, Benedek GB. Laser doppler measurements of blood flow in capillary tubes and retinal arteries. *Invest. Ophthalmol.* 1972; 11:936–944. [PubMed: 4634958]
52. Tanaka T, Benedek GB. Measurement of the velocity of blood flow (in vivo) using a fiber optic catheter and optical mixing spectroscopy. *Appl Opt.* 1975; 14:189–196. [PubMed: 20134853]
53. Stern MD, Bowen PD, Parma R, Osgood RW, Bowman RL, Stein JH. Measurements of renal cortical and medullary blood flow by laser-doppler spectroscopy in the rat. *Am. J. Physiol.* 1979; 236:F80–F87. [PubMed: 434156]
54. Stern MD, Lappe DL, Bowen PD, Chimosky JE. Continuous measurements of tissue blood flow by laser-doppler spectroscopy. *Am. J. Physiol.* 1977; 232:H441–H448. [PubMed: 556582]
55. Oberg PA, Nilsson GE, Tenland T, Holmstrom A, Lewis DH. Use of a new laser doppler flowmeter for measurements of capillary blood flow in skeletal muscle after bullet wounding. *Acta Chir Scand Suppl.* 1979; 489:145–150. [PubMed: 158931]
56. Kiel JW, Riedel GL, DiResta GR, Shepherd AP. Gastric mucosal blood flow measured by laser-doppler velocimetry. *Am. J. Physiol.* 1985; 249:G539–G545. [PubMed: 2931996]
57. Hellem S, Jacobsson LS, Nilsson GE, Lewis DH. Measurements of microvascular blood flow in cancellous bone using laser doppler flowmetry and ¹³³Xe-clearance. *Int. J. Oral Surg.* 1983; 12:165–177. [PubMed: 6224749]
58. Williams PC, Stern MD, Bowen PD, Brooks RA, Hammock MK, Bowman RL, Chiro G. Mapping of cerebral cortical strokes in rhesus monkeys by laser doppler spectroscopy. *Med. Res. Eng.* 1980; 13:3–5. [PubMed: 6772916]
59. Shepherd AP, Riedel GL. Continuous measurements of intestinal mucosal blood flow by laser-doppler velocimetry. *Am. J. Physiol.* 1982; 242:G668–G672. [PubMed: 7091339]
60. Boas DA, Campbell LE, Yodh AG. Scattering and imaging with diffusing temporal field correlations. *Phys Rev Lett.* 1995; 75(9):1855–1858. [PubMed: 10060408]
61. Boas DA, Yodh AG. Spatially varying dynamical properties of turbid media probed with diffusing temporal light correlation. *J Opt. Soc. Am. A.* 1997; 14(1):192–215.
62. Pine DJ, Weitz DA, Chaikin PM, Herbolzheimer. Diffusing-wave spectroscopy. *Phys. Rev. Lett.* 1988; 60:1134–1137. [PubMed: 10037950]
63. Maret G, Wolf PE. Multiple light scattering from disordered media. the effect of brownian motion of scatterers. *Z Phys. B.* 1987; 65:409–413.
64. Stephen MJ. Temporal fluctuations in wave propagation in random media. *Phys. Rev. B.* 1988; 37:1–5.
65. Durduran, T. Ph.D. Dissertation. University of Pennsylvania; 2004. Non-Invasive Measurements of Tissue Hemodynamics with Hybrid Diffuse Optical Methods.
66. Durduran T, Yu G, Burnett MG, Detre JA, Greenberg JH, Wang J, Zhou C, Yodh AG. Diffuse optical measurements of blood flow, blood oxygenation and metabolism in human brain during sensorimotor cortex activation. *Opt Lett.* 2004; 29:1766–1768. [PubMed: 15352363]
67. Li J, Dietsche G, Iftime D, Skipetrov SE, Maret G, Elbert T, Rockstroh B, Gisler T. Noninvasive detection of functional brain activity with near-infrared diffusing-wave spectroscopy. *J Biomed Opt.* 2005 Jul-Aug;10(4):044002–1–044002–12.
68. Yu G, Durduran T, Zhou C, Wang HW, Putt ME, Saunders M, Seghal CM, Glatstein E, Yodh AG, Busch TM. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. *Clin. Cancer Res.* 2005; 11:3543–3552. [PubMed: 15867258]
69. Buckley EM, Cook NM, Durduran T, Kim MN, Zhou C, Choe R, Yu Guoqiang, Shultz S, Seghal CM, Licht DJ, Arger PH, Putt ME, Hurt HH, Yodh AG. Cerebral hemodynamics in preterm infants during positional intervention measured with diffuse correlation spectroscopy and transcranial doppler ultrasound. *Optics Express.* 2009; 17:12571–12581. [PubMed: 19654660]
70. Menon C, Polin GM, Prabakaran I, Hs A, Cheung C, Culver JP, Pingpank J, Sehgal CS, Yodh AG, Buerk DG, Fraker DL. An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model. *Cancer Res.* 2003; 63:7232–7240. [PubMed: 14612518]

71. Roche-Labarbe N, Carp SA, Surova A, Patel M, Boas DA, Grant PE, Franceschini MA. Noninvasive optical measures of cbv, sto2, cbf index, and rcmro2 in human premature neonates' brains in the first six weeks of life (p na). *Human Brain Mapping*. 2009 advance online.
72. Durduran T, Zhou C, Buckley EM, Kim MN, Yu G, Choe R, Gaynor WJ, Spray TL, Durning SM, Mason SE, Montenegro LM, Nicolson SC, Zimmerman RA, Putt ME, Wang JJ, Greenberg JH, Detre JA, Yodh AG, Licht DJ. Optical measurement of cerebral hemodynamics and oxygen metabolism in neonates with congenital heart defects. *J Biomed Opt*. 2009 accepted.
73. Yu G, Floyd T, Durduran T, Zhou C, Wang JJ, Detre JA, Yodh AG. Validation of diffuse correlation spectroscopy for muscle blood flow with concurrent arterial-spin-labeling perfusion. *Opt Exp*. 2007; 15:1064–1075.
74. Kim MN, Durduran T, Frangos S, Edlow BL, Buckley EM, Heather EM, Zhou C, Yu G, Choe R, Maloney-Wilensky E, Wolf RL, Woo JH, Grady MS, Greenberg JH, Levine JM, Yodh AG, Detre JA, Kofke WA. Noninvasive measurement of cerebral blood flow and blood oxygenation using near-infrared and diffuse correlation spectroscopies in critically brain-injured adults. *Neurocritical Care*. 2009 advance online.
75. Zhou C, Eucker S, Durduran T, Yu G, Ralston J, Friess SH, Ichord RN, Margulies SS, Yodh AG. Diffuse optical monitoring of hemodynamic changes in piglet brain with closed head injury. *Journal of Biomedical Optics*. 2009; 14:034015. [PubMed: 19566308]
76. Culver JP, Durduran T, Furuya D, Cheung C, Greenberg JH, Yodh AG. Diffuse optical tomography of cerebral blood flow, oxygenation and metabolism in rat during focal ischemia. *J Cereb. Blood Flow Metab*. 2003; 23:911–924. [PubMed: 12902835]
77. Cheung C, Culver JP, Takahashi K, Greenberg JH, Yodh AG. In vivo cerebrovascular measurement combining diffuse near-infrared absorption and correlation spectroscopies. *Phys. Med. and Biol*. 2001; 46(8):2053–2065. [PubMed: 11512610]
78. Zhou C, Yu G, Furuya D, Greenberg JH, Yodh AG, Durduran T. Diffuse optical correlation tomography of cerebral blood flow during cortical spreading depression in rat brain. *Opt. Exp*. 2006; 14:1125–1144.
79. Durduran, T.; Zhou, C.; Yu, G.; Edlow, B.; Choe, R.; Shah, Q.; Kasner, SE.; Cucchiara, BL.; Yodh, AG.; Greenberg, JH.; Detre, JA. International Stroke Conference. Vol. P37. American Heart Association; 2007. Bed-side monitoring of cerebral blood flow (CBF) in acute stroke patients during changes in head of bed position.
80. Durduran T, Zhou C, Edlow BL, Yu G, Choe R, Kim MN, Cucchiara BL, Putt ME, Shah Q, Kasner SE, Greenberg JH, Yodh AG, Detre JA. Transcranial optical monitoring of cerebrovascular hemodynamics in acute stroke patients. *Optics Express*. 2009; 17(5):3884–3902. [PubMed: 19259230]
81. Yu G, Durduran T, Lech G, Zhou C, Chance B, Mohler ER, Yodh AG. Time-dependent blood flow and oxygenation in human skeletal muscle measured with noninvasive near-infrared diffuse optical spectroscopies. *J Biomed Opt*. 2005; 10(3):024027–1–024027–12. [PubMed: 15910100]
82. Yu G, Durduran T, Zhou C, Zhu TC, Finlay JC, Busch TM, Malkowicz SB, Hahn SM, Yodh AG. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. *Photochem Photobiol*. 2006; 82:1279–1284. [PubMed: 16696593]
83. Sunar U, Quon H, Durduran T, Zhang J, Du J, Zhou C, Yu G, Choe R, Kilger A, Lustig R, Loevner L, Nioka S, Chance B, Yodh AG. Non-invasive diffuse optical measurement of blood flow and blood oxygenation for monitoring radiation therapy in patients with head and neck tumors: a pilot study. *J Biomed Opt*. 2006; 11:064021. [PubMed: 17212544]
84. Zhou C, Choe R, Shah N, Durduran T, Yu Guoqiang, Durkin A, Hsiang D, Mehta R, Butler J, Cerussi A, Tromberg BJ, Yodh AG. Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. *J Biomed Opt*. 2007 Oct-Sep;12(5):051903. [PubMed: 17994886]
85. Sunar U, Makonnen S, Zhou C, Durduran T, Yu Guoqiang, Wang HW, Lee WM, Yodh AG. Hemodynamic responses to antivascular therapy and ionizing radiation assessed by diffuse optical spectroscopies. *Opt. Express*. 2007 Nov; 15(23):15507–15516. [PubMed: 19550836]
86. Durduran T, Choe R, Yu G, Zhou C, Tchou JC, Czerniecki BJ, Yodh AG. Diffuse optical measurement of blood flow in breast tumors. *Opt Lett*. 2005 Nov.30:2915–2917. [PubMed: 16279468]

87. Li J, Ninck M, Koban L, Elbert T, Kissler J, Gisler T. Transient functional blood flow change in the human brain measured noninvasively by diffusing-wave spectroscopy. *Optics Letters*. 2008; 33(19):2233–2235. [PubMed: 18830362]
88. Dietsche G, Ninck M, Ortolfo C, Li J, Jaillon F, Gisler T. Fiber-based multispeckle detection for time-resolved diffusing-wave spectroscopy: characterization and application to blood flow detection in deep tissue. *Applied Optics*. 2007; 46(35):8506–8514. [PubMed: 18071383]
89. Jaillon F, Li J, Dietsche G, Elbert T, Gisler T. Activity of the human visual cortex measured non-invasively by diffusing-wave spectroscopy. *Optics Express*. 2007; 15(11):6643–6650. [PubMed: 19546974]
90. Jaillon F, Skipetrov SE, Li J, Dietsche G, Maret G, Gisler T. Diffusing-wave spectroscopy from head-like tissue phantoms : influence of a non-scattering layer. *Optics Express*. 2006; 14(22): 10181–10194. [PubMed: 19529414]
91. Case, KM.; Zweifel, PF. *Linear Transport Theory*. Boston: Addison-Wesley; 1967.
92. Davidson, B. *Neutron Transport Theory*. Oxford: Clarendon; 1957.
93. Glasstone, S.; Edlund, MC. *The Elements of Nuclear Reactor Theory*. New York: Van Nostrand; 1952.
94. Chandrasekhar, S. *Radiative Transfer*. Dover: 1960.
95. Cheong WF, Prahl SA, Welch AJ. A review of the optical properties of biological tissues. *IEEE J. Quantum Electron*. 1990; QE-26:2166–2185.
96. Ripoll, J. Ph.D. Dissertation. Universidad Autonoma de Madrid; 2000. *Ligth Diffusion in Turbid Media With Biomedical Applications*.
97. Farrell TJ, Patterson MS, Wilson B. A diffusion theory model of spatially resolved, steady-state diffuse reflectance for the noninvasive determination of tissue optical properties in vivo. *Medical Physics*. 1992; 19(4):879–888. [PubMed: 1518476]
98. Jacques SL, Pogue BW. Tutorial on diffuse light transport. *J Biomed. Opt*. 2008; 13(4):041302. [PubMed: 19021310]
99. Heino J, Arridge S, Sikora J, Somersalo E. Anisotropic effects in highly scattering media. *Phys. Rev. E*. 2003; 68:031908.
100. Custo A, Wells WM III, Barnett AH, Hillman EMC, Boas DA. Effective scattering coefficient of the cerebral spinal fluid in adult head models for diffuse optical imaging. *Appl. Opt*. 2006; 45(19):4747–4755. [PubMed: 16799690]
101. Okada E, Delpy DT. Near-infrared light propagation in an adult head model. I. modeling of low-level scattering in the cerebrospinal fluid layer. *Appl. Opt*. 2003; 42:2906–2914. [PubMed: 12790439]
102. Kaplan PD, Kao MH, Yodh AG, Pine DJ. Geometric constraints for the design of diffusing-wave spectroscopy experiments. *Appl Opt*. 1993; 32(21):3828–3836. [PubMed: 20830013]
103. Siegel AM, Marota JA, Boas DA. Design and evaluation of a continuous-wave diffuse optical tomography system. *Optics Express*. 1999; 4:287–298. [PubMed: 19396285]
104. Nioka S, Luo Q, Chance B. Human brain functional imaging with reflectance CWS. *Oxygen Transport to Tissue XIX*. 1997; 428:237–242.
105. Colier W, van der Sluijs MC, Menssen J, Oeseburg B. A new and highly sensitive optical brain imager with 50 Hz sample rate. *NeuroImage*. 2000; 11:542.
106. Culver JP, Choe R, Holboke MJ, Zubkov L, Durduran T, Slemph A, Ntziachristos V, Pattanayak DN, Chance B, Yodh AG. Three-dimensional diffuse optical tomography in the plane parallel transmission geometry: Evaluation of a hybrid frequency domain/continuous wave clinical system for breast imaging. *Med Phys*. 2003; 30:235–247. [PubMed: 12607841]
107. Chance B, Cope M, Gratton E, Ramanujam N, Tromberg B. Phase measurement of light absorption and scattering in human tissues. *Rev. Sci. Instru*. 1998; 689:3457–3481.
108. Pogue BW, Patterson MS. Frequency-domain optical-absorption spectroscopy of finite tissue volumes using diffusion-theory. *Phys. Med. Biol*. 1994; 39:1157–1180. [PubMed: 15552104]
109. Andersson-Engels S, Berg R, Svanberg S, Jarlman O. Time-resolved transillumination for medical diagnostics. *Optics Letters*. 1990; 15(21):1179–1181. [PubMed: 19771033]

110. Jacques SL. Time-resolved reflectance spectroscopy in turbid tissues. *IEEE Transactions on Biomedical Engineering*. 1989; 36:1155–1161. [PubMed: 2606489]
111. Schmidt FEW, Fry ME, Hillman EMC, Hebden JC, Delpy DT. A 32-channel time-resolved instrument for medical optical tomography. *Rev. Sci. Instrum.* 2000; 71:256–265.
112. Ntziachristos V, Ma XH, Chance B. Time-correlated single photon counting imager for simultaneous magnetic resonance and near-infrared mammography. *Rev. Sci. Instrum.* 1998; 69:4221–4233.
113. Selb J, Stott JJ, Franceschini MA, Sorensen AG, Boas DA. Improved sensitivity to cerebral hemodynamics during brain activation with a time-gated optical system: analytical model and experimental validation. *J Biomed. Opt.* 2005; 10(1):011013.
114. Liebert A, Wabnitz H, Steinbrink J, Obrig H, Moller M, Macdonald R, Villringer A, Rinneberg H. Time-resolved multidistance near-infrared spectroscopy of the adult head: intracerebral and extracerebral absorption changes from moments of distribution of times of flight of photons. *Appl Opt.* 2004; 43:3037–3047. [PubMed: 15176190]
115. Haskell RC, Svaasand LO, Tsay T, Feng T, McAdams MS, Tromberg BJ. Boundary conditions for the diffusion equation in radiative transfer. *J Opt Soc Am A.* 1994; 11:2727–2741.
116. Aronson R. Boundary conditions for diffusion of light. *J. Opt. Soc. of Am. A.* 1995; 12:2532–2539.
117. Dehghani H, Eames ME, Yalavarthy PK, Davis SC, Srinivasan S, Carpenter CM, Pogue BW, Paulsen KD. Near infrared optical tomography using nirfast: algorithm for numerical model and image reconstruction. *Commun. Numer. Meth. Engng.* 2008
118. Arfken, G. *Mathematical Methods for Physicists*. second edition. Academic; 1970.
119. Barton, G. *Elements of Green's Functions and Propagation: Potentials, Diffusion, and Waves*. Vol. 7. USA: Oxford University Press; 1989.
120. Arridge SR, Cope M, Delpy DT. The theoretical basis for the determination of optical pathlengths in tissue: temporal and frequency analysis. *Phys Med Biol.* 1992; 37(7):1531–1560. [PubMed: 1631197]
121. Carslaw, HS.; Jaeger, J. *Conduction of heat in solids*. New York: Oxford University Press; 1986.
122. Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, Pathak S, Czerniecki BJ, Tchou J, Fraker DL, DeMichele A, Chance B, Arridge SR, Schweiger M, Culver JP, Schnall MD, Putt ME, Rosen MA, Yodh AG. Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. *J Biomed. Opt.* 2009; 14(2):024020. [PubMed: 19405750]
123. Boas DA, O'Leary MA, Chance B, Yodh AG. Scattering of diffuse photon density waves by spherical inhomogeneities within turbid media - analytic solution and applications. *Proceedings of the National Academy of Sciences of the United States of America.* 1994; 91(11):4887–4891. [PubMed: 8197151]
124. Walker SA, Boas DA, Gratton E. Photon density waves scattered from cylindrical inhomogeneities: Theory and experiments. *Appl Opt.* 1998; 37:1935–1944. [PubMed: 18273113]
125. Ripoll J, Ntziachristos V, Culver JP, Pattanayak DN, Yodh AG, Nieto-Vesperinas M. Recovery of optical parameters in multiple-layered diffusive media: theory and experiments. *J Opt. Soc. A.* 2001; 18(4):821–830.
126. Farrell TJ, Patterson MS, Essenpreis M. Influence of layered tissue architecture on estimates of tissue optical properties obtained from spatially resolved diffuse reflectometry. *Appl Opt.* 1998; 37(10):1958–1972. [PubMed: 18273116]
127. Hielscher AH, Liu HL, Chance B, Tittel FK, Jacques SL. Time-resolved photon emission from layered turbid media. *Appl Opt.* 1996; 35(4):719–728. [PubMed: 21069062]
128. Alexandrakis G, Busch DR, Faris GW, Patterson MS. Determination of the optical properties of two-layer turbid media by use of a frequency-domain hybrid monte carlo diffusion model. *Appl Opt.* 2001; 40(22):3810–3821. [PubMed: 18360415]
129. Alexandrakis G, Farrell TJ, Patterson MS. Accuracy of the diffusion approximation in determining the optical properties of a two-layer turbid medium. *Appl Opt.* 1998; 37(31):7401–7409. [PubMed: 18301574]
130. Schweiger M, Nissilä I, Boas DA, Arridge SR. Image reconstruction in optical tomography in the presence of coupling errors. *Applied optics.* 2007; 46(14):2743–2756. [PubMed: 17446924]

131. Hueber DM, Franceschini MA, Ma HY, Zhang Q, Ballesteros JR, Fantini S, Wallace D, Ntziachristos V, Chance B. Non-invasive and quantitative near-infrared haemoglobin spectrometry in the piglet brain during hypoxic stress, using a frequency-domain multidistance instrument. *Phys Med Biol.* 2001; 46(1):41–62. [PubMed: 11197678]
132. Nissilä I, Noponen T, Kotilahti K, Katila T, Lipiainen L, Tarvainen T, Schweiger S, Arridge S. Instrumentation and calibration methods for the multichannel measurement of phase and amplitude in optical tomography. *Review of Scientific Instruments.* 2005; 76(4):044302.
133. Yamashita Y, Maki A, Koizumi H. Wavelength dependence of the precision of noninvasive optical measurement of oxy-, deoxy-, and total-hemoglobin concentration. *Med Phys.* 2001; 28(6):1108–1114. [PubMed: 11439480]
134. Strangman G, Franceschini MA, Boas DA. Factors affecting the accuracy of near-infrared spectroscopy concentration calculations for focal changes in oxygenation parameters. *NeuroImage.* 2003; 18:865–879. [PubMed: 12725763]
135. Boas DA, Dale AM, Franceschini MA. Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy. *Neuroimage.* 2004; 23:275–288.
136. Corlu A, Durduran T, Choe R, Schweiger M, Hillman EMC, Arridge SR, Yodh AG. Uniqueness and wavelength optimization in continuous-wave multispectral diffuse optical tomography. *Opt. Lett.* 2003; 28:2339–2341. [PubMed: 14680175]
137. Corlu A, Choe R, Durduran T, Lee K, Schweiger M, Hillman EMC, Arridge SR, Yodh AG. Diffuse optical tomography with spectral constraints and wavelength optimization. *Appl Opt.* 2005; 44:2082–2093. [PubMed: 15835357]
138. Arridge SR, Lionheart WRB. Nonuniqueness in diffusion-based optical tomography. *Opt Lett.* 1998; 23:882–884. [PubMed: 18087373]
139. Srinivasan S, Pogue BW, Jiang S, Dehghani H, Paulsen KD. Spectrally constrained chromophore and scattering near-infrared tomography provides quantitative and robust reconstruction. *Appl. Opt.* 2005; 44(10):1858–1869. [PubMed: 15813523]
140. Brendel B, Nielsen T. Selection of optimal wavelengths for spectral reconstruction in diffuse optical tomography. *J Biomed. Opt.* 2009; 14(3):034041. [PubMed: 19566333]
141. Eames ME, Wange J, Pogue BW, Dehghani H. Wavelength band optimization in spectral near-infrared optical tomography improves accuracy while reducing data acquisition and computational burden. *J Biomed. Opt.* 2008; 13(5):054037. [PubMed: 19021417]
142. van der Zee P, Cope M, Arridge SR, Essenpreis M, Potter LA, Edwards AD, Wyatt JS, McCormick DC, Toth SC, Reynolds EOR, Delpy DT. Experimentally measured optical pathlengths for the adult's head, calf and forearm and the head of the newborn infant as a function of interoptode spacing. *Adv. Exp. Med. Biol.* 1992; 316:143–153. [PubMed: 1288074]
143. Duncan A, Meek JH, Clemence M, Elwell CE, Tysczuk L, Cope M, Delpy DT. Optical pathlength measurements on adult head, calf and forearm and the head of the newborn infant using phase resolved optical spectroscopy. *Phys. Med. Biol.* 1995; 40(2):295–304. [PubMed: 7708855]
144. Cope M, Delpy DT. System for long-term measurement of cerebral blood flow and tissue oxygenation on newborn infants by infra-red transillumination. *Med Biol Eng Comput.* 1988; 26:289–294. [PubMed: 2855531]
145. Boas DA, Gaudette T, Strangman G, Cheng X, Marota JJA, Mandeville JB. The accuracy of near infrared spectroscopy and imaging during focal changes in cerebral hemodynamics. *NeuroImage.* 2001; 13:76–90. [PubMed: 11133311]
146. Kohl M, Lindauer U, Royl G, Kuhl M, Gold L, Villringer A, Dirnagl U. Physical model for the spectroscopic analysis of cortical intrinsic optical signals. *Phys. Med. Biol.* 2000; 45:3749–3764. [PubMed: 11131197]
147. Franceschini MA, Toronov V, Filiaci ME, Gratton E, Fantini S. On-line optical imaging of the human brain with 160-ms temporal resolution. *Optics Express.* 2000; 6(3):49–57. [PubMed: 19401744]
148. Tamura M, Hoshi Y, Okada F. Localized near-infrared spectroscopy and functional optical imaging of brain activity. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* 1997; 352:737–742. [PubMed: 9232862]

149. Nollert G, Jonas RA, Reichart B. Optimizing cerebral oxygenation during cardiac surgery: a review of experimental and clinical investigations with near infrared spectrophotometry. *Thorac. Cardiovasc. Surg.* 2000; 48:247–253. [PubMed: 11005605]
150. Fantini S, Hueber D, Franceschini MA, Gratton E, Rosenfeld W, Stubblefield PG, Maulik D, Stankovic MR. Non-invasive optical monitoring of the newborn piglet brain using continuous-wave and frequency-domain spectroscopy. *Phys Med Biol.* 1999; 44(6):1543–1563. [PubMed: 10498522]
151. Chu, B. *Laser Light Scattering, Basic Principles and Practice.* New York: Academic; 1991.
152. Lemieux PA, Durian DJ. Investigating non-gaussian scattering processes by using nth-order intensity correlation functions. *J Opt. Soc. Am. A.* 1999; 16(7):1651–1664.
153. Bonner R, Nossal R. Model for laser doppler measurements of blood flow in tissue. *Appl Opt.* 1981; 20:2097–2107. [PubMed: 20332893]
154. Ackerson BJ, Dougherty RL, Reguigui NM, Nobbman U. Correlation transfer: Application of radiative transfer solution methods to photon correlation problems. *J. Thermophys. and Heat Trans.* 1992; 6:577–588.
155. Dougherty RL, Ackerson BJ, Reguigui NM, Dorri-Nowkooorani F, Nobbmann U. Correlation transfer: Development and application. *J Quant Spectrosc Radiat Transfer.* 1994; 52:713–727.
156. Weitz, DA.; Pine, DJ. chapter Diffusing-wave Spectroscopy. Oxford Science Publications; 1993. *Dynamic Light Scattering The Method and Some Applications.*
157. Xue JZ, Pine DJ, Milner ST, Wu XL, Chaikin PM. Nonergodicity and light scattering from polymer gels. *Phys. Rev. A.* 1992; 46:6550–6563. [PubMed: 9907964]
158. Schatzel K. Accuracy of photon correlation measurements on nonergodic samples. *Appl Opt.* 1993; 32:3880–3885. [PubMed: 20830020]
159. Pusey PN, Van Megen W. Dynamic light scattering by non-ergodic media. *Physica A.* 1989; 157:705–742.
160. Einstein A. On the motion of small particles suspended in liquids at rest required by the molecular-kinetic theory of heat. *Annalen der Physik.* 1905; 17:549–560.
161. Bishop JJ, Popel AS, Intaglietta M, Johnson PC. Effect of aggregation and shear rate on the dispersion of red blood cells flowing in venules. *Am J Physiol Heart Circ Physiol.* 2002 Nov; 283(5):1985–1996.
162. Boryczko K, Dzwinel W, Yuen DA. Dynamical clustering of red blood cells in capillary vessels. *J Mol Model (Online).* 2003 Feb; 9(1):16–33.
163. Binzoni T, Leung TS, Seghier ML, Delpy DT. Translational and brownian motion in laser-doppler flowmetry of large tissue volumes. *Phys Med Biol.* 2004 Dec; 49(24):5445–5458. [PubMed: 15724535]
164. Abbot NC, Beck JS. Biological zero in laser doppler measurements in normal ischemic and inflamed human skin. *International Journal of Microcirculation - Clinical and Experimental.* 1993; 12:89–98.
165. Kernick DP, Tooke JE, Shore AC. The biological zero signal in laser doppler fluximetry - origins and practical implications. *Pflugers Arch.* 1999 Mar; 437(4):624–631. [PubMed: 10089577]
166. Caspary L, Creutzig A, Alexander K. Biological zero in laser doppler fluximetry. *Int J Microcirc Clin Exp.* 1988 Nov; 7(4):367–371. [PubMed: 3220682]
167. Liebert A, Leahy M, Maniewski R. A calibration standard for laser-doppler perfusion measurements. *Review of Scientific Instruments.* 1995; 66(11):5169–5173.
168. Katayama K, Nishimura G, Kinjo M, Tamura M. Absorbance measurements in turbid media by the photon correlation method. *Appl.Optics.* 1995; 34:7419–7427.
169. Arridge, SR.; Schweiger, M. Inverse methods for optical tomography. *Information Processing in Medical Imaging (IPMI'93 Proceedings), Lecture Notes in Computer Science;* Springer-Verlag; 1993. p. 259–277.
170. Arridge SR, Schweiger M. Image reconstruction in optical tomography. *Philosophical Transactions of the Royal Society of London Series B-Biological Sciences.* 1997; 352(1354): 717– 726.
171. Arridge SR. Optical tomography in medical imaging. *Inverse Problems.* 1999; 15:R41–R93.

172. Walker SA, Fantini S, Gratton E. Image reconstruction by backprojection from frequency-domain optical measurements in highly scattering media. *Appl. Opt.* 1997; 36(1):170–179. [PubMed: 18250659]
173. Colak SB, Papaioannou DG, W't Hooft G, van der Mark MB, Schomberg H, Paasschens JCJ, Melissen JBM, van Asten NAAJ. Tomographic image reconstruction from optical projections in light-diffusing media. *Appl. Opt.* 1997; 36(1):180–213. [PubMed: 18250660]
174. Schotland JC. Continuous-wave diffusion imaging. *J. Opt. Soc. Am. A.* 1997; 14(1):275–279.
175. Li XD, Durduran T, Chance B, Yodh AG, Pattanayak DN. Diffraction tomography for biochemical imaging with diffuse-photon density waves. *Opt Lett.* 1997; 22(8):573–575. errata: p 1198. [PubMed: 18183271]
176. Cheng X, Boas DA. Diffuse optical reflectance tomography with continuous-wave illumination. *Opt. Express.* 1998; 3:118–123. [PubMed: 19381247]
177. Matson CL, Liu HL. Analysis of the forward problem with diffuse photon density waves in turbid media by use of a diffraction tomography model. *J. Opt. Soc. Am. A.* 1999; 16:455–466.
178. Schotland JC, Haselgrove JC, Leigh JS. Photon hitting density. *Appl. Opt.* 1993; 32:448–453. [PubMed: 20802710]
179. O'Leary MA, Boas DA, Chance B, Yodh AG. Experimental images of heterogeneous turbid media by frequency-domain diffusing-photon tomography. *Opt Lett.* 1995; 20(5):426–428. [PubMed: 19859209]
180. Arridge SR. Photon-measurement density functions. Part 1: Analytical forms. *Appl. Opt.* 1995; 34(31):7395–7409. [PubMed: 21060614]
181. Arridge SR, Schweiger M. Photon-measurement density functions. Part 2: Finite-element-method calculations. *Appl. Opt.* 1995; 34(34):8026–8036. [PubMed: 21068901]
182. Yao Y, Wang Y, Pei Y, Zhu W, Barbour RL. Frequency-domain optical imaging of absorption and scattering distributions using a born iterative method. *J. Opt. Soc. Am. A.* 1997; 14:325–342.
183. Paulsen KD, Jiang H. Spatially varying optical property reconstruction using a finite element diffusion equation approximation. *Med. Phys.* 1995; 22(6):691–701. [PubMed: 7565358]
184. Jiang H, Paulsen KD, Osterberg UL. Optical image reconstruction using DC data: simulations and experiments. *Phys. Med. Biol.* 1996; 41:1483–1498. [PubMed: 8858732]
185. Paulsen KD, Jiang H. Enhanced frequency-domain optical image reconstruction in tissues through total variation minimization. *Appl. Opt.* 1996; 35:3447–3458. [PubMed: 21102734]
186. Jiang H, Paulsen KD, Osterberg UL, Patterson MS. Frequency-domain optical image reconstruction in turbid media: an experimental study of single-target detectability. *Appl. Opt.* 1997; 36(1):52–63. [PubMed: 18250647]
187. Jiang H, Paulsen KD, Osterberg UL, Patterson MS. Improved continuous light diffusion imaging in single- and multi-target tissue-like phantoms. *Phys. Med. Biol.* 1998; 43(3):675–693. [PubMed: 9533145]
188. Pogue BW, McBride TO, Prewitt J, Osterberg UL, Paulsen KD. Spatially variant regularization improves diffuse optical tomography. *Appl Opt.* 1999; 38(13):2950–2961. [PubMed: 18319877]
189. Arridge SR, Schweiger M. A gradient-based optimisation scheme for optical tomography. *Optics Express.* 1998; 2(6):213–226. [PubMed: 19377605]
190. Hielscher AH, Klose AD, Hanson KM. Gradient-based iterative image reconstruction scheme for time-resolved optical tomography. *IEEE Trans. Med. Imaging.* 1999; 18:262–271. [PubMed: 10363704]
191. Klivanov MV, Lucas TR, Frank RM. A fast and accurate imaging algorithm in optical /diffusion tomography. *Inverse Problems.* 1997; 13:1341–1361.
192. Gryazin YA, Klivanov MV, Lucas TR. Imaging the diffusion coefficient in a parabolic inverse problem in optical tomography. *Inverse Problems.* 1999; 1:373–397.
193. Roy R, Sevick-Muraca EM. Truncated newton's optimization scheme for absorption and fluorescence optical tomography: Part I Theory and formulation. *Opt. Express.* 1999; 4:353–371. [PubMed: 19396292]

194. Roy R, Sevick-Muraca EM. Truncated newton's optimization scheme for absorption and fluorescence optical tomography: Part II Reconstruction from synthetic measurements. *Opt. Express*. 1999; 4:372–382. [PubMed: 19396293]
195. Roy R, Sevick-Muraca EM. Active constrained truncated newton method for simple-bound optical tomography. *J. Opt. Soc. Am. A*. 2000; 17:1627–1641.
196. Roy R, Sevick-Muraca EM. Three-dimensional unconstrained and constrained image-reconstruction techniques applied to fluorescence, frequency-domain photon migration. *Appl. Opt.* 2001; 40:2206–2215. [PubMed: 18357229]
197. Oh S, Milstein AB, Bouman CA, Webb KJ. A general framework for nonlinear multigrid inversion. *IEEE Trans. Image Processing*. 2005; 14:125–140.
198. Eppstein MJ, Dougherty DE, Troy TL, Sevick-Muraca EM. Biomedical optical tomography using dynamic parameterization and Bayesian conditioning on photon migration measurements. *Appl. Opt.* 1999; 38:2138–2150. [PubMed: 18319774]
199. Eppstein MJ, Dougherty DE, Hawrysz DJ, Sevick-Muraca EM. Three-dimensional Bayesian optical image reconstruction with domain decomposition. *IEEE Trans. Med. Imaging*. 2001; 20:147–163. [PubMed: 11341706]
200. Eppstein MJ, Hawrysz DJ, Godavarty A, Sevick-Muraca EM. Three-dimensional, Bayesian image reconstruction from sparse and noisy data sets: Near-infrared fluorescence tomography. *Proc. Natl. Acad. Sci. U. S. A.* 2002; 99:9619–9624. [PubMed: 12105269]
201. Ye JC, Webb KJ, Bouman CA, Millane RP. Optical diffusion tomography using iterative coordinate descent optimization in a Bayesian framework. *J. Opt. Soc. Am. A*. 1999; 16:2400–2412.
202. Ye JC, Bouman CA, Webb KJ, Millane RP. Nonlinear multigrid algorithms for Bayesian optical diffusion tomography. *IEEE Trans. Image Processing*. 2001; 10:909–922.
203. Milstein AB, Oh S, Reynolds JS, Webb KJ, Bouman CA, Millane RP. Three-dimensional Bayesian optical diffusion imaging using experimental data. *Opt. Lett.* 2002; 27:95–97. [PubMed: 18007723]
204. Milstein AB, Oh S, Webb KJ, Bouman CA, Zhang Q, Boas DA, Millane RP. Fluorescence optical diffusion tomography. *Appl. Opt.* 2003; 42:3081–3094. [PubMed: 12790460]
205. Milstein AB, Stott JJ, Oh S, Boas DA, Millane RP, Bouman CA, Webb KJ. Fluorescence optical diffusion tomography using multiple frequency data. *J. Opt. Soc. Am. A*. 2004; 21:1035–1049.
206. Markel VA, Schotland JC. Inverse problem in optical diffusion tomography: I. Fourier-Laplace inversion formulas. *J. Opt. Soc. Am. A*. 2001; 18:1336–1347.
207. Markel VA, Schotland JC. Inverse problem in optical diffusion tomography. II. role of boundary conditions. *J. Opt. Soc. Am. A*. 2002; 19:558–66.
208. Markel VA, Mital V, Schotland JC. Inverse problem in optical diffusion tomography. III. inversion formulas and singular-value decomposition. *J. Opt. Soc. Am. A*. 2003; 20:890–902.
209. Markel VA, O'Sullivan JA, Schotland JC. Inverse problem in optical diffusion tomography. iv. nonlinear inversion formulas. *J. Opt. Soc. Am. A*. 2003; 20:903–912.
210. Pei Y, Graber HL, Barbour RL. Influence of systematic error in reference states on image quality and on stability of derived information for DC optical imaging. *Appl. Opt.* 2001; 40:5755–5769. [PubMed: 18364867]
211. Ntziachristos V, Chance B, Yodanis AG. Differential diffuse optical tomography. *Opt. Express*. 1999; 5:230–242. [PubMed: 19401727]
212. Kilmer ME, Miller EL, Barbaro A, Boas D. Three-dimensional shape-based imaging of absorption perturbation for diffuse optical tomography. *Appl. Opt.* 2003; 42:3129–3144. [PubMed: 12790464]
213. Li A, Miller EL, Kilmer ME, Brukilacchio TJ, Chaves T, Stott J, Zhang Q, Wu T, Chortlton M, Moore RH, Kopans DB, Boas DA. Tomographic optical breast imaging guided by three-dimensional mammography. *Appl. Opt.* 2003; 42:5181–5190. [PubMed: 12962399]
214. Cuccia DJ, Bevilacqua F, Durkin AJ, Tromberg BJ. Modulated imaging: quantitative analysis and tomography of turbid media in the spatial-frequency domain. *Optics letters*. 2005; 30(11):1354–1356. [PubMed: 15981531]

215. Joshi A, Bangerth W, Hwang K, Rasmussen JC, Sevick-Muraca EM. Fully adaptive fem based fluorescence optical tomography from time-dependent measurements with area illumination and detection. *Medical Physics*. 2006; 33:1299. [PubMed: 16752565]
216. Bassi A, D'Andrea C, Valentini G, Cubeddu R, Arridge S. Temporal propagation of spatial information in turbid media. *Optics Letters*. 2008; 33(23):2836–2838. [PubMed: 19037443]
217. Knuttel A, Schmitt JM, Knutson JR. Spatial localization of absorbing bodies by interfering diffusive photon density waves. *Appl Opt*. 1993; 32:381–389. [PubMed: 20802701]
218. Chance B, Kang K, He L, Weng J, Sevick EM. Highly sensitive object location in tissue models with linear in-phase and anti-phase multi-element optical arrays in one and two dimensions. *Proc. Natl. Acad. Sci. USA*. 1993; 90:3423–3427. [PubMed: 8475092]
219. Gibson A, Dehghani H. Diffuse optical imaging. *Phil. Trans. R. Soc. A*. 2009; 367:3055–3072. [PubMed: 19581255]
220. Gibson AB, Hebden JC, Arridge SR. Recent advances in diffuse optical imaging. *Phys Med Biol*. 2005; 50:R1–R43. [PubMed: 15773619]
221. Dunsby C, French PMW. Techniques for depth-resolved imaging through turbid media including coherence gated imaging. *J. Phys. D: Appl. Phys.* 2003; 36:R207–R227.
222. Schulz RB, Ripoll J, Ntziachristos V. Noncontact optical tomography of turbid media. *Opt. Lett*. 2003; 28(18):1701–1703. [PubMed: 13677542]
223. Ripoll J, Ntziachristos V. Iterative boundary method for diffuse optical tomography. *J. Opt. Soc. Am. A*. 2003; 20(6):1103–1110.
224. Ripoll J, Schulz RB, Ntziachristos V. Free-space propagation of diffuse light: Theory and experiments. *Phys. Rev. Lett*. 2003; 91(10):1039011–1039014.
225. Klose AD, Hielscher AH. Optical tomography with the equation of radiative transfer. *Methods for Heat and Fluid Flow*. 2008; 18:443–464.
226. Hielscher AH, Klose AD, Scheel AK, Moa-Anderson B, Backhaus M, Netz U, Beuthan J. Sagittal laser optical tomography for imaging of rheumatoid finger joints. *Phys. Med. Biol*. 2004; 49:1147–1163. [PubMed: 15128195]
227. Wright S, Schweiger M, Arridge SR. Reconstruction in optical tomography using the p_n approximations. *Meas. Sci. Technol*. 2007; 18:79–86.
228. Aydin ED, de Oliveira CRE, Goddard AJH. A comparison between transport and diffusion calculations using a finite element-spherical harmonics radiation transport method. *Med. Phys*. 2002; 29:2013–2023. 2003. [PubMed: 12349922]
229. Boas DA. Ph.D. Dissertation. University of Pennsylvania; 1996. Diffuse Photon Probes of Structural and Dynamical Properties of Turbid Media: Theory and Biomedical Applications.
230. Hull EL, Foster TH. Steady-state reflectance spectroscopy in the P_3 approximation. *J. Opt. Soc. Am. A*. 2001; 18(3):584–599.
231. Firbank M, Arridge SR, Schweiger M, Delpy DT. An investigation of light transport through scattering bodies with non-scattering regions. *Phys Med Biol*. 1996; 41(4):767–783. [PubMed: 8730669]
232. Arridge SR, Dehghani H, Schweiger M, Okada E. The finite element model for the propagation of light in scattering media: A direct method for domains with nonscattering regions. *Med Phys*. 2000; 27(1):252–264. [PubMed: 10659765]
233. Riley J, Dehghani H, Schweiger M, Arridge SR, Ripoll J, Nieto-Vesperinas M. 3d optical tomography in the presence of void regions. *Optics Express*. 2000; 7(13):462–467. [PubMed: 19407898]
234. Hayashi T, Kashio Y, Okada E. Hybrid monte carlo-diffusion method for light propagation in tissue with a low-scattering region. *Appl. Opt*. 2003; 42(16):2888–2896. [PubMed: 12790437]
235. Dehghani H, Srinivasan S, Pogue BW, Gibson A. Numerical modelling and image reconstruction in diffuse optical tomography. *Phil. Trans. R. Soc. A*. 2009; 367:3073–3093. [PubMed: 19581256]
236. Srinivasan S, Pogue BW, Carpenter C, Yalavarthy PK, Paulsen K. A boundary element approach for image-guided near-infrared absorption and scatter estimation. *Med. Phys*. 2007; 34:4545–4557. [PubMed: 18072520]

237. Wang LV, Jacques SL. Hybrid model of Monte Carlo simulation diffusion theory for light reflectance by turbid media. *J. Opt. Soc. Am. A*. 1993; 10:1746–1752.
238. Kak, AC.; Slaney, M. Principles of Computerized Tomographic Imaging. New York: IEEE Press; 1988.
239. O'Leary, MA. Ph.D. Dissertation. University of Pennsylvania; 1996. Imaging with diffuse photon density waves.
240. Lagendijk, A.; Biemond, J. Iterative Identification and Restoration of Images. Kluwer Academic Publishers; 1991.
241. Hansen, Per Christian. Rank-Deficient and Discrete Ill-Posed Problems. SIAM, Philadelphia; 1998.
242. Tikhonov AN. Regularization of mathematically incorrectly posed problems. *Sov. Math.* 1963; 4:1624.
243. Douiri A, Schweiger M, Riley J, Arridge S. Local diffusion regularization method for optical tomography reconstruction by using robust statistics. *Opt Lett*. 2005; 30:2439–2441. [PubMed: 16196345]
244. Hansen P, O'Leary D. The use of the L-curve in the regularization of discrete ill-posed problems. *SIAM J. Sci. Comput.* 1993; 14:1487–1503.
245. Hansen P. Analysis of discrete ill-power problems by means of the L-curve. *SIAM Rev.* 1992; 34:561–580.
246. Boas DA. A fundamental limitation of linearized algorithms for diffuse optical tomography. *Opt. Expr.* 1997; 1:404–413.
247. Li XD, Pattanayak DN, Durduran T, Culver JP, Chance B, Yodh AG. Near-field diffraction tomography with diffuse photon density waves. *Phys Rev E*. 2000; 61(4):4295–4309.
248. Schotland JC, Markel VA. Inverse scattering with diffusing waves. *J. Opt. Soc. Am. A*. 2001; 18(11):2767–2777.
249. Matson CL. A diffraction tomographic model of the forward problem using diffuse photon density waves. *Optics Express*. 1997; 1:6–11. [PubMed: 19373373]
250. Konecky SD, Panasyuk GY, Lee K, Markel VA, Yodh AG, Schotland JC. Imaging complex structures with diffuse light. *Opt Expr*. 2008; 16(7):5048–5060.
251. Moskow S, Schotland JC. Convergence and stability of the inverse scattering series for diffuse waves. *Inverse Problems*. 2008; 24(6):065005.
252. O'Leary MA, Boas DA, Chance B, Yodh AG. Reradiation and imaging of diffuse photon density waves using fluorescent inhomogeneities. *Journal of Luminescence*. 1994; 60-1:281–286.
253. O'Leary MA, Boas DA, Li XD, Chance B, Yodh AG. Fluorescence lifetime imaging in turbid media. *Opt Lett*. 1996; 21(2):158–160. [PubMed: 19865337]
254. Li XD, O'Leary MA, Boas DA, Chance B, Yodh AG. Fluorescent diffuse photon: Density waves in homogeneous and heterogeneous turbid media: Analytic solutions and applications. *Appl Opt*. 1996; 35(19):3746–3758. [PubMed: 21102772]
255. Li XD, Chance B, Yodh AG. Fluorescent heterogeneities in turbid media: limits for detection, characterization, and comparison with absorption. *Appl Opt*. 1998; 37(28):6833–6844. [PubMed: 18301500]
256. Patterson MS, Pogue BW. Mathematical-model for time-resolved and frequency-domain fluorescence spectroscopy in biological tissue. *Appl Opt*. 1994; 33(10):1963–1974. [PubMed: 20885531]
257. Seavick-Muraca EM, Burch CL. The origin of phosphorescence signals re-emitted from tissues. *Opt Lett*. 1994; 19:1928–1930. [PubMed: 19855698]
258. Reynolds JS, Troy TL, Mayer RH, Thompson AB, Waters DJ, Cornell KK, Snyder PW, Seavick-Muraca EM. Imaging of spontaneous canine mammary tumors using fluorescent contrast agents. *Photochem Photobiol*. 1999; 70(1):87–94. [PubMed: 10420847]
259. Seavick-Muraca EM, Lopez G, Reynolds JS, Troy TL, Hutchinson CL. fluorescence and absorption contrast mechanisms for biomedical optical imaging using frequency-domain techniques. *Photochemistry and Photobiology*. 1997; 66(1):55–64. [PubMed: 9230705]

260. Wu J, Feld MS, Rava RP. Analytical model for extracting intrinsic fluorescence in turbid media. *Appl Opt.* 1993; 32:3585–3595. [PubMed: 20829983]
261. Wu J, Wang Y, Perelman L, Itzkan I, Dasari RR, Feld MS. Time-resolved multichannel imaging of fluorescent objects embedded in turbid media. 1995; 20:489–491. 1997.
262. Durkin AJ, Jaikumar S, Ramanujam N, Richards-Kortum R. Relation between fluorescence spectra of dilute and turbid samples. *Applied Optics.* 1994; 33(3):414–423. [PubMed: 20862033]
263. Chang JW, Graber HL, Barbour RL. Luminescence optical tomography of dense scattering media. *J. Opt. Soc. Am. A.* 1997; 14(1):288–299.
264. Paithankar DY, Chen AU, Pogue BW, Patterson MS, Sevick-Muraca EM. Imaging of fluorescent yield and lifetime from multiply scattered light reemitted from random media. *Appl Opt.* 1997; 36(10):2260–2272. [PubMed: 18253202]
265. Jiang H. Frequency-domain fluorescent diffusion tomography: a finite-element-based algorithm and simulations. *Applied optics.* 1998; 37:5337–5343. [PubMed: 18286015]
266. Ntziachristos V, Weissleder R. Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized born approximation. *Optics Letters.* 2001; 26(12):893–895. [PubMed: 18040483]
267. Milstein AB, Oh S, Webb KJ, Bouman CA, Zhang Q, Boas DA, Millane RP. Fluorescence optical diffusion tomography. *Applied Optics.* 2003; 42(16):3081–3094. [PubMed: 12790460]
268. Wilson BC, Patterson MS, Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. *Las. Med. Sci.* 1997; 12:182–192.
269. Cottrell WJ, Oseroff AR, Foster TH. A portable instrument that integrates irradiation with fluorescence and reflectance spectroscopies during clinical photodynamic therapy of cutaneous disease. *Rev. Sci. Instrum.* 2006; 77:064302.
270. Ntziachristos V, Bremer C, Graves EE, Ripoll J, Weissleder R. In vivo tomographic imaging of near-infrared fluorescent probes. *Mol. Imaging.* 2002; 1(2):82–88. [PubMed: 12920848]
271. Weissleder R, Ntziachristos V. Shredding light onto live molecular targets. *Nat. Med.* 2003; 9(1):123–128. [PubMed: 12514725]
272. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. *Nature Biotechnology.* 2005; 23(3):313–320.
273. Tanaka E, Choi HS, Fujii H, Bawendi MG, Frangioni JV. Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. *Annals of Surgical Oncology.* 2006; 13:1671–1681. [PubMed: 17009138]
274. Sevick-Muraca EM, Sharma R, Rasmussen JC, Marshall MV, Wendt JA, Pham HQ, Bonefas E, Houston JP, Sampath L, Adams KE, Blanchard DK, Fisher RE, Chiang SB, Elledge R, Mawad ME. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study. *Radiology.* 2008; 246:734–741. [PubMed: 18223125]
275. Hagen, AJ.; Grosenick, D.; Pöllinger, A.; Burock, S.; Warnick, P.; Macdonald, R.; Rinneberg, HH.; Schlag, PM. SPIE Photonics West. San Jose, CA: 2009. In-vivo fluorescence imaging of breast cancer; p. 7174-7138.
276. Leproux, A.; van der Voort, M.; Harberts, R.; Verhaegh, W.; Bakker, L.; Nielsen, T.; Brendel, BJ.; van der Mark, MB. SPIE Photonics West. San Jose, CA: 2009. Optical mammography: improved sensitivity by combined absorption and fluorescence analysis; p. 7174-7137.
277. Kuebler WM. How NIR is the future in blood flow monitoring? *J Appl Physiol.* 2008; 104(4):905–906. [PubMed: 18239080]
278. Terborg C, Bramer S, Harscher S, Simon M, Witte OW. Bedside assessment of cerebral perfusion reductions in patients with acute ischaemic stroke by near-infrared spectroscopy and indocyanine green. *J Neurol Neurosurg Psychiatry.* 2004; 75(1):38–42. [PubMed: 14707304]
279. Liebert A, Wabnitz H, Steinbrink J, Moller M, Macdonald R, Rinneberg H, Villringer A, Obrig H. Bed-side assessment of cerebral perfusion in stroke patients based on optical monitoring of a dye bolus by time-resolved diffuse reflectance. *Neuroimage.* 2005; 24:426–435. [PubMed: 15627584]
280. Keller E, Wietasch G, Ringleb P, Scholz M, Schwarz S, Stinge R, Schwab S, Hanley D, Hacke W. Bedside monitoring of cerebral blood flow in patients with acute hemispheric stroke. *Crit Care Med.* 2000; 28(2):511–516. [PubMed: 10708192]

281. Apreleva SV, Wilson DF, Vinogradov SA. Tomographic imaging of oxygen by phosphorescence lifetime. *Appl. Opt.* 2006; 45:8547–8559. [PubMed: 17086268]
282. Vinogradov SA, Lo LW, Jenkins WT, Evans SM, Koch C, Wilson DF. Noninvasive imaging of the distribution of oxygen in tissue in vivo using infrared phosphors. *Biophys J.* 1996; 70:1609. [PubMed: 8785320]
283. Sakadzi S, Yuan S, Dilekoz E, Ruvinskaya S, Vinogradov SA, Ayata C, Boas DA. Simultaneous imaging of cerebral partial pressure of oxygen and blood flow during functional activation and cortical spreading depression. *Applied Optics.* 2009; 48(10):169–177.
284. Wang G, Cong W, Durairaj K, Qian X, Shen H, Sinn P, Hoffman E, McLennan G, Henry M. In vivo mouse studies with bioluminescence tomography. *Biomed. Eng.* 2002; 4:235–260.
285. Quistorff B, Haselgrove JC, Chance B. High spatial resolution readout of 3-D metabolic organ structure: An automated, low-temperature redox ratio-scanning instrument. *Analytical Biochemistry.* 1985; 148:389–400. [PubMed: 4061818]
286. Ramanujam, N. *Encyclopedia of Analytical Chemistry.* Wiley; 2000. Fluorescence spectroscopy in vivo; p. 20-56.
287. Bigio, IJ.; Mourant, JR. *Encyclopedia of Optical Engineering.* Marcel Dekker Press; 2003. Optical biopsy.
288. Bigio IJ, Bown SG. Spectroscopic sensing of cancer and cancer chemotherapy, current status of translational research. *Cancer Biology and Therapy.* 2004; 3:259–267. [PubMed: 15107613]
289. Ji S, Chance B, Stuart BH, Nathan R. Two-dimensional analysis of the redox state of the rat cerebral cortex in vivo by NADH fluorescence photography. *Brain Research.* 1977; 119:357–373. [PubMed: 187281]
290. Siesjo, BK. *Brain Energy Metabolism.* Vol. 4. John Wiley & Sons Ltd; 1978.
291. Buxton RB, Frank LR. A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. *J. Cereb. Blood Flow Metab.* 1997; 17:64–72. [PubMed: 8978388]
292. Friston KJ, Mechelli A, Turner R, Price CJ. Nonlinear responses in fMRI: the balloon model, volterra kernels, and other hemodynamics. *NeuroImage.* 2000; 12(4):466–477. [PubMed: 10988040]
293. Gjedde, A. Cerebrovascular disease, chapter on The relation between brain function and cerebral blood flow and metabolism. Philadelphia: Lippincott-Raven; 1997. p. 23-40.
294. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man; theory, procedure and normal values. *J Clin Invest.* 1948 Jul; 27(4):476–483. [PubMed: 16695568]
295. Gesztelyi G, Finnegan W, DeMaro JA, Wang JY, Chen JL. Parenchymal microvascular systems and cerebral atrophy in spontaneously hypertensive rats. *Brain Research.* 1993; 611:249–257. [PubMed: 8334518]
296. Boas DA, Strangman G, Culver JP, Hoge RD, Jaszewski G, Poldrack RA, Rosen BR, Mandeville JB. Can the cerebral metabolic rate of oxygen be estimated with near-infrared spectroscopy? *Phys Med Biol.* 2003; 48:2405–2418. [PubMed: 12953906]
297. American cancer society, statistics for 2007 : Cancer facts & figures 2007. http://www.cancer.org/docroot/STT/stt_0.asp.
298. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. *J. Natl. Cancer Inst.* 1997; 89(1):76–82. [PubMed: 8978410]
299. Goergen SK, Evans J, Cohen GPB, MacMillan JH. Characteristics of breast carcinomas missed by screening radiologists. *Radiology.* 1997; 204:131–135. [PubMed: 9205234]
300. Birdwell RL, Ikeda DM, O'Shaughnessy KF, Sickles EA. Mammographic characteristics of 115 missed cancers later detected with screening mammography and the potential utility of computer-aided detection. *Radiology.* 2001; 219(1):192–202. [PubMed: 11274556]
301. Wang J, Shih TT, Hsu JC, Li YW. The evaluation of false negative mammography from malignant and benign breast lesions. *J. Clin. Imaging.* 2000; 24:96–103.
302. Fletcher SW. Breast cancer screening among women in their forties: an overview of the issues. *J. Natl. Cancer Inst. Monogr.* 1997; 22:5–9. [PubMed: 9709267]

303. Elmore JG, Barton MB, Moceris VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. *New Engl. J. Med.* 1998; 338:1089–1096. [PubMed: 9545356]
304. Bevilacqua F, Berger AJ, Cerussi AE, Jakubowski D, Tromberg BJ. Broadband absorption spectroscopy in turbid media by combined frequency-domain and steady-state methods. *Appl. Opt.* 2000; 39:6498–6507. [PubMed: 18354663]
305. Cheng X, Mao J, Bush R, Kopans DB, Moore RH, Chorlton M. Breast cancer detection by mapping hemoglobin concentration and oxygen saturation. *Appl. Opt.* 2003; 42:6412–6421. [PubMed: 14649285]
306. Chance B, Nioka S, Zhang J, Conant EF, Hwang E, Briest S, Orel SG, Schnall MD, Czerniecki BJ. Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: A six-year, two-site study. *Acad. Radiol.* 2005; 12:925–933. [PubMed: 16023383]
307. Simick MK, Jong R, Wilson B, Lilge L. Non-ionizing near-infrared radiation transillumination spectroscopy for breast tissue density and assessment of breast cancer risk. *J. Biomed. Opt.* 2004; 9:794–803. [PubMed: 15250768]
308. Xu RX, Quang B, Mao JJ, Povoski SP. Development of a handheld near-infrared imager for dynamic characterization of in vivo biological tissue systems. *Appl. Opt.* 2007; 46:7442–7451. [PubMed: 17952180]
309. Chen NG, Guo PY, Yan SK, Piao DQ, Zhu Q. Simultaneous near-infrared diffusive light and ultrasound imaging. *Appl. Opt.* 2001; 40:6367–6380. [PubMed: 18364946]
310. Franceschini MA, Moesta KT, Fantini S, Gaida G, Gratton E, Jess H, Mantulin WW, Seeber M, Schlag PM, Kaschke M. Frequency-domain techniques enhance optical mammography: Initial clinical results. *Proc. Natl. Acad. Sci. U. S. A.* 1997; 94:6468–6473. [PubMed: 9177241]
311. Pera VE, Heffer EL, Siebold H, Schutz O, Heywang-Kobrunner S, Gotz L, Heinig A, Fantini S. Spatial second-derivative image processing: an application to optical mammography to enhance the detection of breast tumors. *J. Biomed. Opt.* 2003; 8:517–524. [PubMed: 12880359]
312. Torricelli A, Spinelli L, Pifferi A, Taroni P, Cubeddu R, Danesini GM. Use of a nonlinear perturbation approach for in vivo breast lesion characterization by multi-wavelength time-resolved optical mammography. *Opt Express.* 2003; 11:853–867. [PubMed: 19461799]
313. Bassi A, Spinelli L, D'Andrea C, Guisto A, Swartling J, Pifferi A, Torricelli A, Cubeddu R. Feasibility of white-light time-resolved optical mammography. *J. Biomed. Opt.* 2006; 11:054035. [PubMed: 17092184]
314. Grosenick D, Moesta KT, Möller M, Mucke J, Wabnitz H, Gebauer B, Stroszczyński C, Wassermann B, Schlag PM, Rinneberg H. Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients. *Phys. Med. Biol.* 2005; 50(11): 2429–2450. [PubMed: 15901947]
315. Dierkes T, Grosenick D, Moesta KT, Möller M, Schlag PM, Rinneberg H, Arridge S. Reconstruction of optical properties of phantom and breast lesion in vivo from paraxial scanning data. *Phys. Med. Biol.* 2005; 50(11):2519–2542. [PubMed: 15901952]
316. Colak SB, van der Mark MB, Hooft GW, Hoogenraad JH, van der Linden ES, Kuipers FA. Clinical optical tomography and NIR spectroscopy for breast cancer detection. *IEEE J. Quantum Electron.* 1999; 5(4):1143–1158.
317. Iftimia N, Gu XJ, Xu Y, Jiang HB. A compact, parallel-detection diffuse optical mammography system. *Rev. Sci. Instrum.* 2003; 74:2836–2842.
318. Li C, Zhao H, Anderson B, Jiang H. Multispectral breast imaging using a ten-wavelength 64×64 source/detector channels silicon photodiode-based diffuse optical tomography system. *Med. Phys.* 2006; 33:627–636. [PubMed: 16878566]
319. Schmitz CH, Klemer DP, Hardin R, Katz MS, Pei Y, Graber HL, Levin MB, Levina RD, Fraco NA, Solomon WB, Barbour RL. Design and implementation of dynamic near-infrared optical tomographic imaging instrumentation for simultaneous dual-breast measurements. *Appl. Opt.* 2005; 44:2140–2153. [PubMed: 15835360]

320. McBride TO, Pogue BW, Jiang S, Osterberg UL, Paulsen KD. A parallel-detection frequency-domain near-infrared tomography system for hemoglobin imaging of the breast in vivo. *Rev. Sci. Instrum.* 2001; 72:1817–1824.
321. Intes X, Djéziri S, Ichalalene Z, Mincu N, Wang Y, St-Jean P, Lesage F, Hall D, Boas D, Polyzos M, Fleiszer D, Mesurrolle B. Time-domain optical mammography SoftScan: Initial results. *Acad. Radiol.* 2005; 12:934–947. [PubMed: 16023382]
322. Durduran T, Choe R, Culver JP, Zubkov L, Holboke MJ, Giammarco J, Chance B, Yodh AG. Bulk optical properties of healthy female breast tissue. *Phys. Med. Biol.* 2002; 47:2847–2861. [PubMed: 12222850]
323. Jiang SD, Pogue BW, Paulsen KD, Kogel C, Poplack SP. In vivo near-infrared spectral detection of pressure-induced changes in breast tissue. *Opt. Lett.* 2003; 28:1212–1214. [PubMed: 12885024]
324. Srinivasan S, Pogue BW, Jiang SD, Dehghani H, Kogel C, Soho S, Gibson JJ, Tosteson TD, Poplack SP, Paulsen KD. Interpreting hemoglobin and water concentration, oxygen saturation, and scattering measured in vivo by near-infrared breast tomography. *Proc. Natl. Acad. Sci. U. S. A.* 2003; 100:12349–12354. [PubMed: 14514888]
325. Jakubowski DB, Cerussi AE, Bevilacqua F, Shah N, Hsiang D, Butler J, Tromberg BJ. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study. *J. Biomed. Opt.* 2004; 9:230–238. [PubMed: 14715078]
326. Tromberg BJ, Shah N, Lanning R, Cerussi A, Espinoza J, Pham T, Svaasand L, Butler J. Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. *Neoplasia.* 2000; 2:26–40. [PubMed: 10933066]
327. Painchaud Y, Mailloux A, Harvey E, Verreault S, Frechette J, Gilbert C, Vernon ML, Beaudry P. Multi-port time-domain laser mammography: results on solid phantom and volunteers. *International Symposium of Biomedical Optics.* 1999; 3597:548–555.
328. Chance B. Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation. *Ann. N. Y. Acad. Sci.* 1998; 838:19–45.
329. Suzuki K, Yamashita Y, Ohta K, Kaneko M, Yoshida M, Chance B. Quantitative measurement of optical parameters in normal breasts using time-resolved spectroscopy: In vivo results of 30 Japanese women. *J. Biomed. Opt.* 1996; 1:330–334. [PubMed: 23014733]
330. Thomsen S, Tatman D. Physiological and pathological factors of human breast disease that can influence optical diagnosis. *Ann. N. Y. Acad. Sci.* 1998; 838:171–193. [PubMed: 9511805]
331. Spinelli L, Torricelli A, Pifferi A, Taroni P, Danesini GM, Cubeddu R. Bulk optical properties and tissue components in the female breast from multiwavelength time-resolved optical mammography. *J. Biomed. Opt.* 2004; 9:1137–1142. [PubMed: 15568933]
332. Boyd NF, Lockwood GA, Byng JW, Trichler DL, Yaffe MJ. Mammographic densities and breast cancer risk. *Cancer Epidemiol. Biomarkers Prevent.* 1998; 7:1133–1144.
333. Blyschak K, Simick M, Jong R, Lilge L. Classification of breast tissue density by optical transillumination spectroscopy: Optical and physiological effects governing predictive value. *Med. Phys.* 2004; 31:1398–1414. [PubMed: 15259643]
334. Blackmore KM, Knight JA, Jong R, Lilge L. Assessing breast tissue density by transillumination breast spectroscopy (tibs): an intermediate indicator of cancer risk. *British Journal Of Radiology.* 2007; 80:545–556. [PubMed: 17537757]
335. Blackmore KM, Knight JA, Lilge L. Association between transillumination breast spectroscopy and quantitative mammographic features of the breast. *Cancer Epidemiology Biomarkers & Prevention.* 2008; 17:1043–1050.
336. Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. *Proc. Natl. Acad. Sci. U. S. A.* 2000; 97:2767–2772. [PubMed: 10706610]
337. Pogue BW, Poplack SP, McBride TO, Wells WA, Osterman KS, Osterberg UL, Paulsen KD. Quantitative hemoglobin tomography with diffuse near-infrared spectroscopy: Pilot results in the breast. *Radiology.* 2001; 218:261–266. [PubMed: 11152812]

338. Jiang H, Xu Y, Ifitimia N, Eggert J, Klove K, Baron L, Fajardo L. Three-dimensional optical tomographic imaging of breast in a human subject. *IEEE Trans. Med. imaging.* 2001; 20:1334–1340. [PubMed: 11811833]
339. Dehghani H, Pogue BW, Jiang SD, Brooksby B, Paulsen KD. Three-dimensional optical tomography: resolution in small-object imaging. *Appl. Opt.* 2003; 42:3117–3128. [PubMed: 12790463]
340. Zhu QI, Huang MM, Chen NG, Zarfes K, Jagjivan B, Kane M, Hedge P, Kurtzman SH. Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: Initial clinical results of 19 cases. *Neoplasia.* 2003; 5:379–388. [PubMed: 14670175]
341. Choe R, Corlu A, Lee K, Durduran T, Konecky SD, Grosicka-Koptyra M, Arridge SR, Czerniecki BJ, Fraker DL, DeMichele A, Chance B, Rosen MA, Yodh AG. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. *Med. Phys.* 2005; 32(4):1128–1139. [PubMed: 15895597]
342. Grosenick D, Wabnitz H, Moesta KT, Mucke J, Schlag PM, Rinneberg H. Time-domain scanning optical mammography: II. Optical properties and tissue parameters of 87 carcinomas. *Phys. Med. Biol.* 2005; 50(11):2451–2468. [PubMed: 15901948]
343. Spinelli L, Torricelli A, Pifferi A, Taroni P, Danesini G, Cubeddu R. Characterization of female breast lesions from multi-wavelength time-resolved optical mammography. *Phys. Med. Biol.* 2005; 50(11):2489–2502. [PubMed: 15901950]
344. Enfield LC, Gibson AP, Everdell NL, Delpy DT, Schweiger M, Arridge SR, Richardson C, Keshtgar M, Douek M, Hebden JC. Three-dimensional time-resolved optical mammography of the uncompressed breast. *Appl. Opt.* 2007; 46:3628–3638. [PubMed: 17514325]
345. Dehghani H, Pogue BW, Poplack SP, Paulsen KD. Multiwavelength three-dimensional near-infrared tomography of the breast: initial simulation, phantom, and clinical results. *Appl. Opt.* 2003; 42:135–145. [PubMed: 12518832]
346. Jiang HB, Ifitimia NV, Xu Y, Eggert JA, Fajardo LL, Klove KL. Near-infrared optical imaging of the breast with model-based reconstruction. *Acad. Radiol.* 2002; 9:186–194. [PubMed: 11918371]
347. Zhu Q, Chen N, Kurtzman SH. Imaging tumor angiogenesis by use of combined near-infrared diffusive light and ultrasound. *Opt. Lett.* 2003; 28:337–339. [PubMed: 12659436]
348. Srinivasan S, Pogue BW, Brooksby B, Jiang S, Dehghani H, Kogel C, Wells WA, Poplack SP, Paulsen KD. Near-infrared characterization of breast tumors in vivo using spectrally-constrained reconstruction. *Tech. Cancer Res. Treat.* 2005; 4:513–526.
349. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000; 100:57–70. [PubMed: 10647931]
350. Zhu Q, Kurtzman SH, Hegde P, Tannenbaum S, Kane M, Huang M, Chen NG, Jagjivan B, Zarfes K. Utilizing optical tomography with ultrasound localization to image heterogeneous hemoglobin distribution in large breast cancers. *Neoplasia.* 2005; 7(3):263–270. [PubMed: 15799826]
351. Li C, Grobmyer SR, Massol N, Liang X, Zhang Q, Chen L, Fajardo LL, Jiang H. Noninvasive in vivo tomographic optical imaging of cellular morphology in the breast: Possible convergence of microscopic pathology and macroscopic radiology. *Med. Phys.* 2008; 35:2493–2501. [PubMed: 18649482]
352. Brown JM. Tumor hypoxia in cancer therapy. *Methods Enzymol.* 2007; 435:297–321. [PubMed: 17998060]
353. Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. *J. Natl. Cancer Inst.* 2001; 93:266–276. [PubMed: 11181773]
354. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. *Cancer Lett.* 2003; 195:1–16. [PubMed: 12767506]
355. Fantini S, Walker SA, Franceschini MA, Kaschke M, Schlag PM, Moesta KT. Assessment of the size, position, and optical properties of breast tumors in vivo by noninvasive optical methods. *Appl. Opt.* 1998; 37:1982–1989. [PubMed: 18273118]
356. Chernomordik V, Hattery DW, Grosenick D, Wabnitz H, Rinneberg H, Moesta KT, Schlag PM, Gandjbakhche A. Quantification of optical properties of a breast tumor using random walk theory. *J. Biomed. Opt.* 2002; 7:80–87. [PubMed: 11818015]

357. Heffer E, Pera V, Schutz O, Siebold H, Fantini S. Near-infrared imaging of the human breast: complementing hemoglobin concentration maps with oxygenation images. *J. Biomed. Opt.* 2004; 9:1152–1160. [PubMed: 15568935]
358. Srinivasan S, Pogue BW, Carpenter C, Jiang S, Wells WA, Poplack SP, Kaufman PA, Paulsen KD. Developments in quantitative oxygen-saturation imaging of breast tissue in vivo using multispectral near-infrared tomography. *Antioxidants & Redox Signaling.* 2007; 9:1143–1156. [PubMed: 17627478]
359. McBride TO, Pogue BW, Poplack S, Soho S, Wells WA, Jiang SD, Osterberg UL, Paulsen KD. Multispectral near-infrared tomography: a case study in compensating for water and lipid content in hemoglobin imaging of the breast. *J. Biomed. Opt.* 2002; 7:72–79. [PubMed: 11818014]
360. Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ. In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. *J. Biomed. Opt.* 2006; 11:044005. [PubMed: 16965162]
361. Gu XJ, Zhang QZ, Bartlett M, Schutz L, Fajardo LL, Jiang HB. Differentiation of cysts from solid tumors in the breast with diffuse optical tomography. *Acad. Radiol.* 2004; 11:53–60. [PubMed: 14746402]
362. Taroni P, Torricelli A, Spinelli L, Pifferi A, Arpaia F, Danesini G, Cubeddu R. Time-resolved optical mammography between 637 and 985 nm: clinical study on the detection and identification of breast lesions. *Phys. Med. Biol.* 2005; 50(11):2469–2488. [PubMed: 15901949]
363. Yates T, Hebden JC, Gibson A, Everdell N, Arridge SR, Douek M. Optical tomography of the breast using a multi-channel time-resolved imager. *Phys. Med. Biol.* 2005; 50(11):2503–2518. [PubMed: 15901951]
364. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. *J. Biomed. Opt.* 2005; 10:051503. [PubMed: 16292947]
365. Tromberg, BJ.; Cerussi, AE.; Shah, N.; Hsiang, D.; Butler, JA.; Du, T.; Compton, M.; Fedyk, A. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. In: Chance, B.; Alfano, RR.; Tromberg, BJ.; Tamura, M.; Sevick-Muraca, EM., editors. *Optical Tomography and Spectroscopy of Tissue VI.* Vol. 5693. Bellingham, WA: SPIE; 2005.
366. Azar FS, Lee K, Khamene A, Choe R, Corlu A, Konecky SD, Sauer F, Yodh AG. Standardized platform for coregistration of non-concurrent diffuse optical and magnetic resonance breast images obtained in different geometries. *J. Biomed. Opt.* 2007; 12:051902. [PubMed: 17994885]
367. Konecky SD, Choe R, Corlu A, Lee K, Wiener R, Srinivas SM, Saffer JR, Freifelder R, Karp JS, Hajjioui N, Azar F, Yodh AG. Comparison of diffuse optical tomography of human breast with whole-body and breast-only positron emission tomography. *Med. Phys.* 2008; 35:446–455. [PubMed: 18383664]
368. Breslow, NE.; Day, NE.; Davis, W. *Statistical methods in cancer research.* International Agency for Research on Cancer; 1980.
369. Pepe, MS. *The Statistical Evaluation of Medical Tests for Classification and Prediction.* Oxford University Press; 2003.
370. Poplack SP, Tosteson TD, Wells WA, Pogue BW, Meaney PM, Hartov A, Kogel CA, Soho SK, Gibson JJ, Paulsen KD. Electromagnetic breast imaging: Results of a pilot study in women with abnormal mammograms. *Radiology.* 2007; 243(2):350–359. [PubMed: 17400760]
371. Ntzachristos V, Yodh AG, Schnall MD, Chance B. MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. *Neoplasia.* 2002; 4:347–354. [PubMed: 12082551]
372. Intes X, Ripoll J, Chen Y, Nioka S, Yodh AG, Chance B. In vivo continuous-wave optical breast imaging enhanced with indocyanine green. *Med. Phys.* 2003; 30:1039–1047. [PubMed: 12852527]
373. Bastiaens PI, Squire A. Fluorescence lifetime imaging microscopy: spatial resolution of biochemical processes in the cell. *Trends Cell Biol.* 1999; 9:48–52. [PubMed: 10087617]
374. Kuwana E, Sevick-Muraca EM. Fluorescence lifetime spectroscopy for pH sensing in scattering media. *Anal. Chem.* 2003; 75:4325–4329. [PubMed: 14632153]

375. Reynolds JS, Troy TL, Mayer RH, Thompson AB, Waters DJ, Cornell KK, Snyder PW, Sevick-Muraca EM. Imaging of spontaneous canine mammary tumors using fluorescent contrast agents. *Photochem. Photobiol.* 1999; 70:87–94. [PubMed: 10420847]
376. Godavarty A, Eppstein MJ, Zhang CY, Theru S, Thompson AB, Gurfinkel M, Sevick-Muraca EM. Fluorescence-enhanced optical imaging in large tissue volumes using a gain-modulated iccd camera. *Phys. Med. Biol.* 2003; 48:1701–1720. [PubMed: 12870578]
377. Knopp MV, Brix G, Zeger SL. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. *Magn. Reson. Imaging Clin. N. Am.* 1994; 2(4):633–658. [PubMed: 7489314]
378. Tsuboi N, Ogawa Y, Inomata T, Yoshida D, Yoshida S, Moriki T, Kumon M. Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III: pathologic correlation. *Oncol. Rep.* 1999; 6(4):727–732. [PubMed: 10373646]
379. Drew PJ, Kerin MJ, Mahapatra T, Malone C, Monson JRT, Turnbull LW, Fox JN. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. *Eur. J. Surg. Oncol.* 2001; 27:617–620. [PubMed: 11669587]
380. Wahl RL. Overview of the current status of PET in breast cancer imaging. *Q. J. Nucl. Med.* 1998; 42:1–7. [PubMed: 9646639]
381. Tiling R, Linke R, Untch M, Richter A, Fieber S, Brinkbaumer K, Tatsch K, Hahn K. F-18-FDG PET and tc-99m-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. *Eur. J. Nucl. Med.* 2001; 28:711–720. [PubMed: 11440031]
382. Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA, Forero JA, Muffly LS, Schwartz GN, Paulsen KD, Kaufman PA. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: Case studies of tumor region-of-interest changes. *Radiology.* 2009; 252:551–560. [PubMed: 19508985]
383. Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. *Neoplasia.* 2008; 10:1028–1040. [PubMed: 18813360]
384. Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, Tromberg BJ. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. *Proc. Natl. Acad. Sci. U. S. A.* 2007; 104:4014–4019. [PubMed: 17360469]
385. Chung SH, Cerussi AE, Klifa C, Baek HM, Birgul O, Gulsen G, Merritt SI, Hsiang D, Tromberg BJ. In vivo water state measurements in breast cancer using broadband diffuse optical spectroscopy. *Phys. Med. Biol.* 2008; 53:6713–6727. [PubMed: 18997265]
386. Taroni P, Comelli D, Pifferi A, Torricelli A, Cubeddu R. Absorption of collagen: effects on the estimate of breast composition and related diagnostic implications. *J. Biomed. Opt.* 2007; 12:014021. [PubMed: 17343496]
387. Liang X, Zhang Q, Li C, Grobmyer SR, Fajardo LL, Jiang H. Phase-contrast diffuse optical tomography: Pilot results in the breast. *Acad. Radiol.* 2008; 15:859–866. [PubMed: 18572121]
388. Brooksby B, Jiang SD, Dehghani H, Pogue BW, Paulsen KD, Kogel C, Doyley M, Weaver JB, Poplack SP. Magnetic resonance-guided near-infrared tomography of the breast. *Rev. Sci. Instrum.* 2004; 75(12):5262–5270.
389. Brooksby B, Jiang S, Dehghani H, Pogue BW, Paulsen KD, Weaver J, Kogel C, Poplack SP. Combining near-infrared tomography and magnetic resonance imaging to study in vivo breast tissue: implementation of a Laplacian-type regularization to incorporate magnetic resonance structure. *J. Biomed. Opt.* 2005; 10:051504. [PubMed: 16292948]
390. Boverman G, Miller EL, Li A, Zhang Q, Chaves T, Brooks DH, Boas DA. Quantitative spectroscopic diffuse optical tomography of the breast guided by imperfect *a priori* structural information. *Phys. Med. Biol.* 2005; 50:3941–3956. [PubMed: 16177522]
391. Carpenter CM, Pogue BW, Jiang S, Dehghani H, Wang X, Paulsen KD, Wells WA, Forero J, Kogel C, Weaver JB, Poplack SP, Kaufman PA. Image-guided optical spectroscopy provides molecular-specific information in vivo: MRI-guided spectroscopy of breast cancer hemoglobin, water, and scatterer size. *Optics Letters.* 2007; 32(8):933–935. [PubMed: 17375158]

392. Carpenter CM, Srinivasan S, Pogue BW, Paulsen KD. Methodology development for three-dimensional MR-guided near infrared spectroscopy of breast tumors. *Opt. Express*. 2008; 16:17903–17914. [PubMed: 18958072]
393. Zhang Q, Brukilacchio TJ, Li A, Stott JJ, Chaves T, Hillman E, Wu T, Chorlton A, Rafferty E, Moore RH, Kopans DB, Boas DA. Coregistered tomographic x-ray and optical breast imaging: initial results. *J. Biomed. Opt.* 2005; 10(2):024033. [PubMed: 15910106]
394. Fang Q, Carp SA, Selb J, Boverman G, Zhang Q, Kopans DB, Moore RH, Miller EL, Brooks DH, Boas DA. Combined optical imaging and mammography of the healthy breast: optical contrast derived from breast structure and compression. *IEEE Trans. Med. Imaging*. 2009; 28:30–42. [PubMed: 19116186]
395. Zhu Q, Durduran T, Ntziachristos V, Holboke M, Yodh AG. Imager that combines near-infrared diffusive light and ultrasound. *Opt. Lett.* 1999; 24:1050–1052. [PubMed: 18073937]
396. Holboke MJ, Tromberg BJ, Li X, Shah N, Fishkin J, Kidney D, Butler J, Chance B, Yodh AG. Three-dimensional diffuse optical mammography with ultrasound localization in a human subject. *J. Biomed. Opt.* 2000; 5:237–247. [PubMed: 10938789]
397. Zhu Q, Conant E, Chance B. Optical imaging as an adjunct to sonograph in differentiating benign from malignant breast lesions. *J. Biomed. Opt.* 2000; 5:229–236. [PubMed: 10938788]
398. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. *Nat Med*. 2003; 9:123–128. [PubMed: 12514725]
399. Ermilov SA, Khamapirad T, Conjusteau A, Leonard MH, Lacewell R, Megta K, Miller T, Oraevsky AA. Laser optoacoustic imaging system for detection of breast cancer. *J. Biomed. Opt.* 2009; 14:024007. [PubMed: 19405737]
400. Roy CS, Sherrington CS. On the regulation of the blood-supply of the brain. *The Journal of Physiology*. 1890; 11(1–2):85.
401. Mosso, A. Ueber den Kreislauf des Blutes im menschlichen Gehirn. Veit, Leipzig: 1881.
402. Lou HC, Edvinsson L, Mackenzie ET. The concept of coupling blood-flow to brain-function - revision required. *An. of Neurol.* 1987; 22(3):289–297.
403. Villringer A, Dirnagl U. Coupling of brain activity and cerebral blood flow: basis of functional neuroimaging. *Cereb. Brain. Metab. Rev.* 1995; 7:240–276.
404. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. *Cerebrovasc Brain Metab Rev.* 1990; 2(2):161–192. [PubMed: 2201348]
405. Smith M. Monitoring intracranial pressure in traumatic brain injury. *Anesth Analg.* 2008; 106(1): 240–248. [PubMed: 18165584]
406. Wintermark M, Sesay M, Barbier E, Borbely K, Dillon WP, Eastwood JD, Glenn TC, Grandin CB, Pedraza S, Soustiel JF, Nariai T, Zaharchuk G, Caille JM, Dousset V, Yonas H. Comparative overview of brain perfusion imaging techniques. *Stroke*. 2005; 36(9):83–99.
407. Rosenblum BR, Bonner RF, Oldfield EH. Intraoperative measurement of cortical blood flow adjacent to cerebral AVM using laser doppler velocimetry. *Journal of neurosurgery*. 1987; 66(3): 396–399. [PubMed: 2950213]
408. Fasano VA, Urciuoli R, Bolognese P, Mostert. Intraoperative use of laser doppler in the study of cerebral microvascular circulation. *Acta neurochirurgica*. 1988; 95(1):40–48. [PubMed: 3146212]
409. Prakash N, Uhleman F, Sheth SA, Bookheimer S, Martin N, Toga AW. Current trends in intraoperative optical imaging for functional brain mapping and delineation of lesions of language cortex. *NeuroImage*. 2008; 47:T116–T126. [PubMed: 18786643]
410. Binzoni T, Leung TS, Boggett D, Delpy DT. Non-invasive laser Doppler perfusion measurements of large tissue volumes and human skeletal muscle blood RMS velocity. *Phys Med Biol*. 2003; 48:2527–2549. [PubMed: 12953913]
411. Dunn AK, Bolay T, Moskowitz MA, Boas DA. Dynamic imaging of cerebral blood flow using laser speckle. *J. Cereb. Blood Flow Metab.* 2001; 21(3):195–201. [PubMed: 11295873]
412. Durduran T, Burnett MG, Yu G, Zhou C, Furuya D, Yodh AG, Detre JA, Greenberg JH. Spatio-temporal quantification of cerebral blood flow during functional activation in rat somatosensory cortex using laser speckle flowmetry. *J. Cereb. Blood Flow Metab.* 2004; 24:518–525. [PubMed: 15129183]

413. Kirkham FJ, Padayachee TS, Parsons S, Seargeant LS, House FR, Gosling RG. Transcranial measurement of blood velocities in the basal cerebral arteries using pulsed doppler ultrasound: velocity as an index of flow. *Ultrasound Med Biol.* 1986; 12:15–21. [PubMed: 3083551]
414. Bishop CC, Powell S, Rutt D, Browne NL. Transcranial doppler measurement of middle cerebral artery blood flow velocity: a validation study. *Stroke.* 1986; 17:913–915. [PubMed: 3764963]
415. Pindzola RR, Balzer JR, Nemoto EM, Goldstein S, Yonas H. Cerebrovascular reserve in patients with carotid occlusive disease assessed by stable xenon-enhanced ct cerebral blood flow and transcranial Doppler. *Stroke.* 2001 Aug; 32(8):1811–1817. [PubMed: 11486110]
416. Alexandrov AV, Demchuk AM, Wein TH, Grotta JC. Yield of transcranial Doppler in acute cerebral ischemia. *Stroke.* 1999 Aug; 30(8):1604–1609. [PubMed: 10436108]
417. Detre JA, Alsop DC. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. *Euro J Rad.* 1999; 30(2):115–124.
418. Barbier EL, Silva AC, Kim SG, Koretsky AP. Perfusion imaging using dynamic arterial spin labeling (DASL). *Mag Res Med.* 2001; 45:1021–1029.
419. Detre JA, Zhang W, Roberts DA, Silva AC, Williams DS, Grandis DJ, Koretsky AP, Leigh JS. Tissue specific perfusion imaging using arterial spin labeling. *NMR in Biomedicine.* 1994; 7:75–82. [PubMed: 8068529]
420. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. *Mag. Res. Med.* 1995; 34:293–301.
421. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R, Cheng H-M, Brady TJ, Rosen BR. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. *Proc. Natl. Acad. Sci. USA.* 1992; 89(12):5675–5679. [PubMed: 1608978]
422. Pindzola RR, Yonas H. The xenon-enhanced computed tomography cerebral blood flow method. *Neurosurgery.* 1998; 43:1488–1492. [PubMed: 9848867]
423. Yonas RP, Pindzola H, Johnson DW. Xenon/computed tomography cerebral blood flow and its use in clinical management. *Neurosurg Clin N Am.* 1996; 7:605–616. [PubMed: 8905775]
424. Frackowiak RS, Lenzi GL, Jones T, Heather JD. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. *J. Comput. Assit. Tomogr.* 1980; 4:727–736.
425. Reivich M, Kuhl D, Wolf A, Greenberg JH, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. The [18F] fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. *Circ Res.* 1979; 44:127–137. [PubMed: 363301]
426. Phelps ME, Mazziotta JC, Schelbert HR, Hawkins RA, Engel J. Clinical PET - what are the issues. *J Nucl Med.* 1985; 26(12):1353–1358.
427. Brazy JE, Lewis DV, Mitnick MH, Jobsis FF. Noninvasive monitoring of cerebral oxygenation in preterm infants: preliminary observations. *Pediatrics.* 1985; 75:217–225. [PubMed: 2982128]
428. Brazy JE, Lewis DV. Changes in cerebral blood volume and cytochrome AA3 during hypertensive peaks in preterm infants. *J Pediatr.* 1986; 108:983–987. [PubMed: 3012056]
429. Bucher HU, Edwards AD, Lipp AE, Duc G. Comparison between near infrared spectroscopy and 133xenon clearance for estimation of cerebral blood flow in critically ill preterm infants. *Pediatric Research.* 1993; 33:56–59. [PubMed: 8433862]
430. Cope, M. The Development of a Near-Infrared Spectroscopy System and Its Application for Noninvasive Monitoring of Cerebral Blood and Tissue Oxygenation in the Newborn Infant. London: University College London; 1991.
431. Delpy DT, Cope MC, Cady EB, Wyatt JS, Hamilton PA, Hope PL, Wray S, Reynolds EO. Cerebral monitoring in newborn infants by magnetic resonance and near infrared spectroscopy. *Scand. J. Clin. Lab. Invest. Suppl.* 1987; 188:9–17. [PubMed: 2835812]
432. Hintz SR, Benaron DA, Siegel AM, Stevenson DK, Boas DA. Bedside functional imaging of the premature infant brain during passive motor activation. *Journal of Investigative Medicine.* 1999; 47(2):60a–60a.

433. Hebden JC. Advances in optical imaging of the newborn infant brain. *Psychophysiol.* 2003; 40:501–510.
434. Hillman EMC. Optical brain imaging in vivo: techniques and applications from animal to man. *Journal of Biomedical Optics.* 2007; 12(5)
435. Wolf M, Ferrari M, Quaresima V. Progress of near-infrared spectroscopy and topography for brain and muscle clinical applications. *Journal of Biomedical Optics.* 2007; 12(6):062104. [PubMed: 18163807]
436. Dehghani H, White BR, Zeff BW, Tizzard A, Culver JP. Depth sensitivity and image reconstruction analysis of dense imaging arrays for mapping brain function with diffuse optical tomography. *Applied Optics.* 2009; 48(10):137–143.
437. Gomersall CD, Joynt GM, Gin T, Freebairn RC, Stewart IE. Failure of the INVOS3100 cerebral oximeter to detect complete absence of cerebral blood flow. *Crit. Care. Med.* 1997; 25:1252–1254. [PubMed: 9233756]
438. Schwarz G, Litscher G, Kleinert R, Jobstmann R. Cerebral oximetry in dead subjects. *J Neurosurg. Anesthesiol.* 1996; 8:189–193. [PubMed: 8803829]
439. Nicklin SE, Hassan IAA, Wickramasinghe YA, Spencer SA. The light still shines, but not that brightly? the current status of perinatal near infrared spectroscopy. *Archives of Disease in Childhood Fetal & Neonatal Edition.* 2003; 88(4):F263. [PubMed: 12819155]
440. Al-Rawi PG. Near infrared spectroscopy in brain injury: today's perspective. *Acta Neurochirurgica-Supplementum.* 2005; 95:453.
441. Kirkpatrick PJ, Smielewski P, Czosnyka M, Menon DK, Pickard JD. Near-infrared spectroscopy use in patients with head injury. *Journal of Neurosurgery.* 1995; 83(6):963–970. [PubMed: 7490639]
442. Gopinath SP, Robertson CS, Contant CF, Narayan RK, Grossman RG, Chance B. Early detection of delayed traumatic intracranial hematomas using near-infrared spectroscopy. *J Neurosurg.* 1995; 83:438–444. [PubMed: 7666220]
443. Gopinath SP, Robertson CS, Grossman RG, Chance B. Near-infrared spectroscopic localization of intracranial hematomas. *J Neurosurg.* 1993; 79:43–47. [PubMed: 8315468]
444. Lewis SB, Myburgh JA, Thornton EL, Reilly PL. Cerebral oxygenation monitoring by near-infrared spectroscopy is not clinically useful in patients with severe closed-head injury: A comparison with jugular venous bulb oximetry. *Crit. Care. Med.* 1996; 24:1334–1338. [PubMed: 8706488]
445. Keller E, Nadler A, Imhof HG, Niederer P, Roth P, Yonekawa Y. New methods for monitoring cerebral oxygenation and hemodynamics in patients with subarachnoid hemorrhage. *Acta neurochirurgica. Supplement.* 2002; 82:87. [PubMed: 12378997]
446. Carandang R, Krieger DW. Near infrared spectroscopy: finding utility in malignant hemispheric stroke. *Neurocritical Care.* 2007; 6(3):161–164. [PubMed: 17572858]
447. Bönöczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial doppler study. *European Journal of Ultrasound.* 2002; 15(1–2):85–91. [PubMed: 12044859]
448. Sakatani K, Xie Y, Lichty W, Li S, Zuo H. Language-activated cerebral blood oxygenation and hemodynamic changes of the left prefrontal cortex in poststroke aphasic patients : A near-infrared spectroscopy study. *Stroke.* 1998; 29(7):1299–1304. [PubMed: 9660376]
449. Kato H, Izumiyama M, Koizumi H, Takahashi A, Itoyama Y. Near-infrared spectroscopic topography as a tool to monitor motor reorganization after hemiparetic stroke: A comparison with functional MRI. *Stroke.* 2002; 33(8):2032–2036. [PubMed: 12154258]
450. Miyai I, Yagura H, Hatakenaka M, Oda I, Konishi I, Kubota K. Longitudinal optical imaging study for locomotor recovery after stroke. *Stroke.* 2003; 34(12):2866–2870. [PubMed: 14615624]
451. Damian MS, Schlosser R. Bilateral near infrared spectroscopy in space-occupying middle cerebral artery stroke. *Neurocritical Care.* 2007; 6(3):165–173. [PubMed: 17572859]
452. Vernieri F, Rosato N, Pauri F, Tibuzzi F, Passarelli F, Rossini PM. Near infrared spectroscopy and transcranial doppler in monohemispheric stroke. *Eur Neurol.* 1999; 41(3):159–162. [PubMed: 10202248]

453. Hargroves D, Tallis R, Pomeroy V, Bhalla A. The influence of positioning upon cerebral oxygenation after acute stroke: a pilot study. *Age Ageing*. 2008; 37(5):581–585. [PubMed: 18755785]
454. Hayakawa T, Terashima M, Kayukawa Y, Ohta T, Okada T. Changes in cerebral oxygenation and hemodynamics during obstructive sleep apnea. *Chest*. 1996; 109(4):916–921. [PubMed: 8635370]
455. McGown AD, Makker H, Elwell C, Al Rawi PG, Valipour A, Spiro SG. Measurement of changes in cytochrome oxidase redox state during obstructive sleep apnea using near-infrared spectroscopy. *Sleep*. 2003; 26(6):710–716. [PubMed: 14572124]
456. Spielman AJ, Zhang G, Yang CM, D'Ambrosio P, Serizawa S, Nagata M, von Gizycki H, Alfano RR. Intracerebral hemodynamics probed by near infrared spectroscopy in the transition between wakefulness and sleep. *Brain research*. 2000; 866(1–2):313–325. [PubMed: 10825508]
457. Michalos A, Safonova LP, Wolf U, Wolf M, Choi JH, Gupta R, Mantulin WW, Hueber DM, Barbieri B, Gratton E. Obstructive sleep apnea: Evaluation of brain oxygenation and hemodynamics by near-infrared spectroscopy. *Sleep*. 2002; 25:547.
458. Taillefer MC, Denault AY. Cerebral near-infrared spectroscopy in adult heart surgery: systematic review of its clinical efficacy. *Canadian Journal of Anesthesia*. 2005; 52(1):79–87. [PubMed: 15625262]
459. Al-Rawi PG, Kirkpatrick PJ. Tissue oxygen index: Thresholds for cerebral ischemia using near-infrared spectroscopy. *Stroke*. 2006; 37(11):2720. [PubMed: 17008623]
460. Benaron DA, Hintz SR, Villringer A, Boas D, Kleinschmidt A, Frahm J, Hirth C, Obrig H, van Houten JC, Kermit EL, Cheong WF, Stevenson DK. Noninvasive functional imaging of human brain using light. *J Cereb Blood Flow Metab*. 2000; 20(3):469–477. [PubMed: 10724111]
461. Wolfberg AJ, du Plessis AJ. Near-infrared spectroscopy in the fetus and neonate. *Clinics in Perinatology*. 2006; 33(3):707–728. [PubMed: 16950321]
462. Minagawa-Kawai Y, Mori K, Hebden J, Dupoux E. Optical imaging of infants' neurocognitive development: Recent advances and perspectives. *Developmental Neurobiology*. 2008; 68(6): 712–728. [PubMed: 18383545]
463. Yang Y, Liu HL, Li XD, Chance B. Low cost frequency-domain photon migration instrument for tissue spectroscopy, oximetry, and imaging. *Opt. Eng.* 1997; 36950:1562–1569.
464. Sokoloff L. The effects of carbon dioxide on the cerebral circulation. *Anesthesiology*. 1960; 21:664–673.
465. Jasper H. Report of the committee on methods of clinical examination in electroencephalography. *Clin. Neurophysiol*. 1958; 10:370–375.
466. Kastrup A, Kruger G, Neumann-Haefelin T, Glover GH, Moseley ME. Changes of cerebral blood flow, oxygenation, and oxidative metabolism during graded motor activation. *NeuroImage*. 2002; 74–82. [PubMed: 11771975]
467. Ye FQ, Smith AM, Yang Y, Duyn J, Mattay VS, Ruttimann UE, Frank JA, Weinberger DR, McLaughlin AC. Quantitation of regional cerebral blood flow increases during motor activation: A steady-state arterial spin tagging study. *Mag Res Med*. 1999; 42:404–407.
468. Colebatch JG, Deiber MP, Passingham RE, Friston KJ, Frackowiak RS. Regional cerebral blood flow during voluntary arm and hand movements in human subjects. *J Neurophysiol*. 1991; 65:1392–1401. [PubMed: 1875248]
469. Roland PE, Larsen B, Lassen NA, Skinhoj E. Supplementary motor area and other cortical areas in organization of voluntary movements in man. *J. Neurophysiol*. 1980; 43:118–136. [PubMed: 7351547]
470. Seitz RJ, Roland PE. Learning of sequential finger movements in man: a combined kinematic and positron emission tomography (pet) study. *Eur. J. Neurosci*. 1992; 4:154–165. [PubMed: 12106378]
471. Mehagnoul-Schipper DJ, van der Kallen BFW, Colier WJNM, van der Sluijs MC, van Erning LJTO, Thijssen HOM, Oeseburg B, Hoefnagels WHL, Jansen RWMM. Simultaneous measurements of cerebral oxygenation changes during brain activation by near-infrared spectroscopy and functional magnetic resonance imaging in healthy young and elderly subjects. *Human Brain Mapping*. 2002; 16:14–23. [PubMed: 11870923]

472. Hoge RD, Atkinson J, Gill B, Crelier GR, Marrett S, Pike GB. Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex. *Proc Natl Acad Sci U S A*. 1999; 96(16):9403–9408. [PubMed: 10430955]
473. Hoge RD, Franceschini MA, Covolan RJM, Huppert T, Mandeville JB, Boas DA. Simultaneous recording of task-induced changes in blood oxygenation, volume, and flow using diffuse optical imaging and arterial spin-labeling MRI. *Neuroimage*. 2005; 25(3):701–707. [PubMed: 15808971]
474. Huppert TJ, Hoge RD, Diamond SG, Franceschini MA, Boas DA. A temporal comparison of BOLD, ASL, and NIRS hemodynamic responses to motor stimuli in adult humans. *Neuroimage*. 2006 Jan; 29(2):368–382. [PubMed: 16303317]
475. Diamond SG, Huppert TJ, Kolehmainen V, Franceschini MA, Kaipio JP, Arridge SR, Boas DA. Dynamic physiological modeling for functional diffuse optical tomography. *Neuroimage*. 2006; 30(1):88–101. [PubMed: 16242967]
476. Joseph DK, Huppert TJ, Franceschini MA, Boas DA. Diffuse optical tomography system to image brain activation with improved spatial resolution and validation with functional magnetic resonance imaging. *Applied optics*. 2006; 45(31):8142–8151. [PubMed: 17068557]
477. Huppert TJ, Hoge RD, Dale AM, Franceschini MA, Boas DA. Quantitative spatial comparison of diffuse optical imaging with blood oxygen level-dependent and arterial spin labeling-based functional magnetic resonance imaging. *Journal of biomedical optics*. 2006; 11:064018. [PubMed: 17212541]
478. Huppert TJ, Allen MS, Diamond SG, Boas DA. Estimating cerebral oxygen metabolism from fmri with a dynamic multi-compartment windkessel model. *Human brain mapping*. 2009; 30(5): 1548. [PubMed: 18649348]
479. Kim, MN.; Durduran, T.; Frangos, S.; Buckley, EM.; Zhou, C.; Yu, G.; Moss, H.; Edlow, BL.; Maloney-Wilensky, E.; Detre, JA.; Greenberg, JH.; Kofke, WA.; Yodh, AG.; Grady, MS.; Woo, JH.; Wolf, RL.; Levine, J. SPIE Photonics West. San Jose, CA: 2009. Diffuse optical measurements of cerebral blood flow and oxygenation in patients after traumatic brain injury or subarachnoid hemorrhage.
480. Hebden JC, Austin T. Optical tomography of the neonatal brain. *European Radiology*. 2007; 17(11):2926–2933. [PubMed: 17473923]
481. Hintz SR, Benaron DA, Houten JP, Duckworth JL, Liu FWH, Spilman SD, Stevenson DK, Cheong WF. Stationary headband for clinical time-of-flight optical imaging at the bedside. *Photochemistry and photobiology*. 1998; 68(3):361–369. [PubMed: 9747590]
482. Hintz SR, Cheong WF, van Houten JP, Stevenson DK, Benaron DA. Bedside imaging of intracranial hemorrhage in the neonate using light: Comparison with ultrasound, computed tomography, and magnetic resonance imaging. *Pediatric research*. 1999; 45(1):54. [PubMed: 9890608]
483. Hebden JC, Gibson A, Yusof RM, Everdell N, Hillman EMC, Delpy DT, Arridge SR, Austin T, Meek JH, Wyatt JS. Three-dimensional optical tomography of the premature infant brain. *Physics in Medicine and Biology*. 2002; 47(23):4155–4166. [PubMed: 12502040]
484. Hebden JC, Gibson A, Austin T, Yusof RM, Everdell N, Delpy DT, Arridge SR, Meek JH, Wyatt JS. Imaging changes in blood volume and oxygenation in the newborn infant brain using three-dimensional optical tomography. *Physics in Medicine and Biology*. 2004; 49(7):1117–1130. [PubMed: 15128193]
485. Kondepoti VR, Heise HM, Backhaus J. Recent applications of near-infrared spectroscopy in cancer diagnosis and therapy. *Analytical and Bioanalytical Chemistry*. 2008; 390(1):125–139. [PubMed: 17955220]
486. Vardi M, Nini A. Near-infrared spectroscopy for evaluation of peripheral vascular disease. a systematic review of literature. *Eur J Vasc Endovasc Surg*. 2008; 35:68–74. [PubMed: 17919945]
487. Luksiene Z. Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment. *Medicina (Kaunas)*. 2003; 39:1137–1150. [PubMed: 14704501]
488. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbek M, Moan J, Peng Q. Photodynamic therapy. *J. Nat. Cancer Inst*. 1998; 90:889–905. [PubMed: 9637138]

489. De Grand AM, Frangioni JV. An operational near-infrared fluorescence imaging system prototype for large animal surgery. *Tech Cancer Res & Treat*. 2003; 2(6):553–562.
490. Marghoob AA, Swindle LD, Moricz CZM, Negron FAS, Slue B, Halpern ACH, Kopf AW. Instruments and new technologies for the in vivo diagnosis of melanoma. *Journal of the American Academy of Dermatology*. 2003; 49(5):777–797. [PubMed: 14576657]
491. Xu Y, Iftimia N, Jiang HB, Key LL, Bolster MB. Imaging of in vitro and in vivo bones and joints with continuous-wave diffuse optical tomography. *Optics Express*. 2001; 8(7):447–451. [PubMed: 19417840]
492. Lasker JM, Fong CJ, Ginat DT, Dwyer E, Hielscher AH. Dynamic optical imaging of vascular and metabolic reactivity in rheumatoid joints. *Journal of Biomedical Optics*. 2007; 12:052001. [PubMed: 17994887]
493. Wang, LV.; Wu, HI. *Biomedical Optics: Principles and Imaging*. 1 edition. Wiley-Interscience; 2007. p. 5
494. Vo-Dinh, T., editor. *Biomedical Photonics Handbook*. CRC Press; 2003.
495. Bouma, BE.; Tearney, GJ. *Handbook of Optical Coherence Tomography*. 1st edition. Informa HealthCare; 2001. p. 11
496. Sharpe J. Optical projection tomography. *Annual Review of Biomedical Engineering*. 2004; 6(1): 209–228.
497. Johansson A, Katharina K, Ronald S, Herbert S. Clinical optical diagnostics - status and perspectives. *Medical Laser Application*. 2008; 23(4):155–174.
498. Patterson MS, Andersson-Engels S, Wilson BC, Osei EK. Absorption spectroscopy in tissue-simulating materials: a theoretical and experimental study of photon paths. *Appl. Opt*. 1995; 34(1):22–30. [PubMed: 20963080]
499. Zhou, C. Ph.D. Dissertation. University of Pennsylvania; 2007. *In-Vivo Optical Imaging and Spectroscopy of Cerebral Hemodynamics*.

Figure 1.

Absorption (μ_a) spectra of main tissue chromophores over a large wavelength range. The inset shows the so-called “physiological window” in the near-infrared where water and hemoglobin absorption are relatively low. In this part of the spectrum, light can penetrate several centimeters into tissue. Furthermore, there are clear features in the spectra which enable estimation of chromophore concentration from diffuse optical measurements at several wavelengths.

Figure 2.

Three common types of sources are employed. On the far left are schematic “banana patterns” showing the sampled volumes in the reflection and transmission geometries. As a rough rule of thumb, the mean light penetration depth in the reflection geometry is $\rho/2$ (for a more precise relation, see [498]). For continuous wave (CW), intensity modulated (FD) and time-resolved (TR) sources, the detected light intensity over time resembles (1), (2), and (3) respectively.

Figure 3.

Constant phase contours shown as a function of position for homogeneous, 0.5% Intralipid solution filling a large aquarium ($30 \times 30 \times 60$ cm). At the origin (roughly the middle of the aquarium) is the source (3-mW laser diode operating at 816 nm and modulated at 200 MHz), resulting in a geometry that very well approximates a homogeneous infinite medium. The contours are shown in 20° intervals. Inset: The measured phase shift (squares) and $\ln|rU(\mathbf{r})|$ (circles) are plotted as a function of radial distance from the source. The slopes reveal $-k_i$

and k_r , from which μ_a and D can be calculated using Equation (15) and Equation (14).
Figure taken from O'Leary *et al.* [13, Fig. 2].

Figure 4.

Common geometry used to model tissue. In the semi-infinite geometry, w , h , and d all go to infinity, while in the infinite slab geometry, w and h are infinite but d is finite. Both geometries have azimuthal symmetry about the z -axis, meaning the photon fluence rate only depends on the radial and axial cylindrical coordinates ρ and z . The unit vector $\hat{n}$ points from inside the tissue to outside. On the left, a single source-detector pair (with separation ρ) in the reflection geometry is shown. Note that for the slab geometry, detectors can also be used for transmission measurements by being placed on the $z = d$ plane. On the right is a cross-section showing that the radiance moving into the turbid medium at the boundary is due to the Fresnel reflection of the radiance incident on the boundary.

Figure 5.

The fluence rate curve is approximated by its tangent line at $z = 0$, and the $\Phi = 0$ intercept of this curve is found to occur $z = -z_b$ (z_b is defined exactly in Table 1).

Figure 6.

Illustration of a single scattering DLS experiment (Top) and of multiple scattering (Bottom) along a single photon path in turbid media. $\mathbf{k}_j$ and $\mathbf{k}_{j+1}$ are the wavevectors before and after the j^{th} scattering event, respectively. $\mathbf{q}_j = \mathbf{k}_{j+1} - \mathbf{k}_j$ is the momentum transfer and θ_j is the scattering angle of the j^{th} scattering event. The solid line represents the photon path at time t , while the dotted line represents the photon path at time $t + \tau$. During the delay time τ , the j^{th} scatterer moves $\mathbf{r}_j(\tau)$. Courtesy of C Zhou [499].

Figure 7.

The measured intensity auto-correlation curves from two experiments on isolated limb preparations on rats; (Left) Shows the electric field correlation functions during healthy circulation and under artificial perfusion with a pump. (Right) Shows the electric field auto-correlation functions from a rat before/after death.

Figure 8.

Data from a mouse tumor, a piglet brain, a human calf muscle and adult human brain. Dots show the experimental data, the dashed line is a fit with $\langle r^2 \rangle \sim \tau^2$ (random flow), and the solid line is a fit with $\langle r^2 \rangle \sim \tau^2$ (Brownian motion). Note how the accuracy of the fits vary depending on the delay time (τ) and the longer delays tend to deviate further from the fits for brain measurements. This is mainly because later delays correspond to photons that probe more superficial tissues and presence of the skull alters this part of the curves. Note, r in the figure titles is the source-detector separation on the tissue surface.

Figure 9.

Slices from three dimensional image reconstructions of the relative absorption coefficient ($\delta\mu_a/\mu_a^{(0)}$) for targets suspended in a 6 cm thick slab filled with highly scattering fluid. The Rytov linearized analytic inversion was used for this reconstruction. The three slices shown for each reconstruction correspond to depths of 1 cm (left), 3 cm (middle), and 5 cm (right) from the source plane. (a) Schematics of the positions of the letters during the experiments. Left: The target consists of letters "DOT" and "PENN" suspended 1 cm and 5 cm from the source plane, respectively. Right: The target consists only of the letters "DOT" suspended 3 cm from the source plane. (b) Reconstructed image of the letters "DOT" and "PENN" (c)

Reconstructed image of the letters “DOT”. This figure is reproduced from Konecky *et al.* [250, Figure 1].

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 10.

Flow chart of Born and Distorted Born iterative methods. A linear inverse problem of the form $J\hat{x} = y$ is solved for each iteration. Both the fluence rate and Green's function are updated in the Distorted Born method, but only the fluence rate is updated in the Born iterative method (see text for details). The iterations continue until χ^2 has reached the desired tolerance.

Figure 11.

(a) Tumor-to-normal ratio of total hemoglobin concentration ($rTHC$) of 10 benign and 41 malignant lesions. (b) Receiver-operating-characteristic curve for $rTHC$ showing true positive rate for malignant lesions versus false positive rate for benign lesions. (Reprinted with permission from Ref. [122].)

Figure 12.

A case of 3D optical tomography of breast with malignant cancer is shown with both endogenous (relative total hemoglobin, relative blood oxygen saturation and relative tissue scattering) and exogenous contrast images (relative Indocyanine Green concentration measured from fluorescence) (left). On the top right, a parallel-plane DOT instrument and measurement geometry is illustrated. The isosurface diagram on the bottom right shows the volumetric extent of the observed tumor for each optically derived parameter. (Reprinted with permission from Ref. [26].)

Figure 13.

(a) Schematic showing placement of probes used for hypercapnia (frontal) and sensorimotor (side) studies. For the frontal probe, a laser Doppler flowmetry (LDF) probe was placed mid-way the source and detector fibers to record scalp blood flow. (b) Increased CO₂ breathing (hypercapnia) results in significant increases in end-tidal CO₂ (EtCO₂) and blood-flow in brain (rCBF(DCS)) but only a negligible amount in scalp blood-flow (rCBF(LDF)). (c-d) Hemodynamic response to finger-tapping when the probe is placed (c) away from the contralateral sensorimotor cortex and (d) when its placed on the contralateral sensorimotor cortex.

Figure 14.

(a–b) Morphological MRI scans showing location of fiducial markers indicating the location of NIRS/DOS probe which is then overlaid onto BOLD and ASL scans to define ROIs. As shown in (c), an MRI compatible NIRS/DOS probe was used for simultaneous data acquisition. (d) Group averaged responses from simultaneous ASL, BOLD and NIRS/DOS studies. Temporal evolution of NIRS/DOS measures of THC and HbO_2 agree with ASL and Hb agrees with BOLD. Notice how ASL, THC and HbO_2 maxima are earlier than BOLD and Hb maxima. Hb curve is shown inverted. Figure courtesy of D. A. Boas [474]).

Figure 15.

(Top) Cerebral autoregulation implies a range of cerebral perfusion pressure (CPP) values where CBF is kept constant. As shown in the inset, impairment causes CBF to depend passively on CPP. Head-of-bed positioning was used to induce orthostatic changes in CPP. Schematic showing placement of probes where one is placed on the infarcted hemisphere and the other on contralateral, 'healthy' hemisphere. (Bottom) Changes in THC and rCBF are significantly larger on the infarcted hemisphere (right) which is presumably due to impaired cerebral autoregulation.

Figure 16.

(Left) Placement of probes on an infant. (Right) Coronal sections showing (a) blood volume, (b) blood oxygen saturation and (c) the corresponding ultrasound image. Figure courtesy of J. C. Hebden [480].

Table 1

Frequency-domain Green's functions for Equation (12) in several homogeneous geometries subject to the extrapolated-zero boundary condition (Equation (19)). $\mathbf{r}_s$ is the position of a normalized isotropic point source. With the exception of the infinite case, cylindrical coordinates are used explicitly to specify position, i.e. $\mathbf{r} = (\rho, z)$. Notation is defined in the lower part of the Table. In practice, the infinite sums are truncated after a desired accuracy has been reached.

Case	Green's function (frequency-domain)
Infinite	$G_0(\mathbf{r}, \mathbf{r}_s) = \frac{1}{4\pi \mathbf{r} - \mathbf{r}_s } \exp(-k \mathbf{r} - \mathbf{r}_s)$
Semi-infinite	$G_0([\rho, z], [\rho_s=0, z_s=\ell_{tr}]) = \frac{1}{4\pi} \left[\frac{\exp(-kr_1)}{r_1} - \frac{\exp(-kr_b)}{r_b} \right]$
Infinite Slab	$G_0([\rho, z], [\rho_s=0, z_s=\ell_{tr}]) = \frac{1}{4\pi} \sum_{m=-\infty}^{\infty} \left(\frac{\exp[-kr_{+,m}]}{r_{+,m}} - \frac{\exp[-kr_{-,m}]}{r_{-,m}} \right)$
Infinite Cylindrical	$G_0([\rho, z], [\rho_s, z_s]) = \frac{1}{2\pi a_b^2} \sum_{m=-\infty}^{\infty} \cos m\varphi \sum_{\beta_m} \frac{e^{- z-z_s /\sqrt{k^2+\beta_m^2}} J_m(\beta_m \rho) J_m(\beta_m \rho_s)}{\sqrt{k^2+\beta_m^2} [J'_m(\beta_m a_b)]^2}$
$k \equiv \sqrt{(\mu_a v - i\omega)/D}$	$J_m(z)$ m^{th} order Bessel function, 1 st kind
$r_{\pm,m} \equiv \sqrt{\rho^2 + (z - z_{\pm,m})^2}$	a , cylinder radius
$z_{+,m} \equiv 2m(d + 2z_b) + \ell_{tr}$	$a_b = a + z_b$, i.e. extrapolated-zero boundary (cylinder)
$z_{-,m} \equiv 2m(d + 2z_b) - 2z_b - \ell_{tr}$	β_m , a positive root of $J_m(\beta_m a_b) = 0$
$k_m \equiv \sqrt{k^2 + m^2 \pi^2 / h_b^2}$	ρ , radial cylindrical coordinate
$r_1 \equiv \sqrt{(z - \ell_{tr})^2 + \rho^2}$	$r_b \equiv \sqrt{(z + 2z_b + \ell_{tr})^2 + \rho^2}$
$R_{eff} \equiv \frac{R_\phi + R_J}{2 - R_\phi + R_J}$	$z_b = 2\ell_{tr} \frac{1 + R_{eff}}{3(1 - R_{eff})}$
$R_\phi \equiv \int_0^{\pi/2} \text{Sin}(2\vartheta) R_{\text{Fresnel}}(\vartheta) d\vartheta$	$R_J \equiv \int_0^{\pi/2} 3\text{Sin}\vartheta \cos^2\vartheta R_{\text{Fresnel}}(\vartheta) d\vartheta$
m , an integer	d , slab thickness (Figure 4)
$\cos \vartheta = \hat{\Omega} \cdot \hat{n}$ (Figure 4)	$R_{\text{Fresnel}}(\vartheta)$, Fresnel reflection coefficient
ϑ , angle of incidence in $R_{\text{Fresnel}}(\vartheta)$	ϕ , angle between input/output light beams (cylinder)